Arthritis & Rheumatism

Official Journal of the American College of Rheumatology

VOLUME 32	JANUARY	NO. 1
	ms of Action of Nonsteroidal Antiinflammatory Drugs	
Treatment of Chronic Knee Syn	derald Weissmann	
	se, and Jacques Sanyumatoid Arthritis: Identification of Susceptibility Alle	
David Stage, and Barbara Immunohistologic Analysis of the	Byers, Christine Seyfried, Louis A. Healey, Kenneth S. Nepom	
Kay H. Singer, and Barton 1,25-Dihydroxyvitamin D ₃ Potenti	F. Haynes	22
	mor, and Catherine FournierScale to Measure Perceived Self-Efficacy in People w	
Kate Lorig, Robert L. Cha.	stain, Elaine Ung, Stanford Shoor, and Halsted R. Hophosphamide Treatment for Vasculitis	
John D. Bradley, Kenneth . Racial Differences in Antinuclear	D. Brandt, and Barry P. Katz	eroderma
Increased α-Adrenergic Responsive	n Youngchaiyud, and Senga Whittinghamveness in Idiopathic Raynaud's Disease	
Insulin-Like Growth Factor Stimu Joost Schalkwijk, Leo A. B	ash C. Sabharwal, Nagaraj Desai, Paul Wenig, and Alation of Chondrocyte Proteoglycan Synthesis by Hur B. Joosten, Wim B. van den Berg, Judson J. van Wyk,	man Synovial Fluid , and
Levinus B. A. van de Putte Brief Reports	······································	60
Characterization of Two In Factors	mmunoglobulin V _H Genes that are Homologous to H	
Pojen P. Chen, Ming-Fei L Dennis A. Carson	iu, Charles A. Glass, Suman Sinha, Thomas J. Kipps	s, and 72
Ankylosing Spondylitis	and Environmental Factors in Disease Expression: S	Sib Pair Analysis in
	d Predictive Value of Abrominal Fat Aspiration for	
Margaret A. Duston, Mart.	ha Skinner, Robert F. Meenan, and Alan S. Cohen	
Edward V. Lally, Bernard	ion in Nodal Osteoarthritis: Clinical and Roentgenogra Zimmermann, George Ho, Jr., and Stephen R. Kaplaf the Arthritis Self-Management Course are Not Adequate the Not Adequate the Arthritis Self-Management Course are Not Adequate the Not Adequ	an 8
Kate Lorig, Mitchel Selezn	nick, Deborah Lubeck, Elaine Ung, Robert L. Chasta	

Arthritis & Rheumatism

Official Journal of the American College of Rheumatology

VOLUME 32	JANUARY	NO. 1
	ms of Action of Nonsteroidal Antiinflammatory Drugs	
Treatment of Chronic Knee Syn	derald Weissmann	
	se, and Jacques Sanyumatoid Arthritis: Identification of Susceptibility Alle	
David Stage, and Barbara Immunohistologic Analysis of the	Byers, Christine Seyfried, Louis A. Healey, Kenneth S. Nepom	
Kay H. Singer, and Barton 1,25-Dihydroxyvitamin D ₃ Potenti	F. Haynes	22
	mor, and Catherine FournierScale to Measure Perceived Self-Efficacy in People w	
Kate Lorig, Robert L. Cha.	stain, Elaine Ung, Stanford Shoor, and Halsted R. Hophosphamide Treatment for Vasculitis	
John D. Bradley, Kenneth . Racial Differences in Antinuclear	D. Brandt, and Barry P. Katz	eroderma
Increased α-Adrenergic Responsive	n Youngchaiyud, and Senga Whittinghamveness in Idiopathic Raynaud's Disease	
Insulin-Like Growth Factor Stimu Joost Schalkwijk, Leo A. B	ash C. Sabharwal, Nagaraj Desai, Paul Wenig, and Alation of Chondrocyte Proteoglycan Synthesis by Hur B. Joosten, Wim B. van den Berg, Judson J. van Wyk,	man Synovial Fluid , and
Levinus B. A. van de Putte Brief Reports	······································	60
Characterization of Two In Factors	mmunoglobulin V _H Genes that are Homologous to H	
Pojen P. Chen, Ming-Fei L Dennis A. Carson	iu, Charles A. Glass, Suman Sinha, Thomas J. Kipps	s, and 72
Ankylosing Spondylitis	and Environmental Factors in Disease Expression: S	Sib Pair Analysis in
	d Predictive Value of Abrominal Fat Aspiration for	
Margaret A. Duston, Mart.	ha Skinner, Robert F. Meenan, and Alan S. Cohen	
Edward V. Lally, Bernard	ion in Nodal Osteoarthritis: Clinical and Roentgenogra Zimmermann, George Ho, Jr., and Stephen R. Kaplaf the Arthritis Self-Management Course are Not Adequate the Not Adequate the Arthritis Self-Management Course are Not Adequate the Not Adequ	an 8
Kate Lorig, Mitchel Selezn	nick, Deborah Lubeck, Elaine Ung, Robert L. Chasta	

Eosinophilic Fasciitis in Glen T. D. Thomson, B.	a Pair of Siblings Trendan MacDougall, Peter H. Watson, and Ian M. Chalmers	. 96
The Effect of Chemonus Joel A. Block, Thomas	cleolysis on Serum Keratan Sulfate Levels in Humans J. Schnitzer, Gunnar B. J. Andersson, Mary Ellen Lenz, Rosemarie Jeffery nd Eugene J-M. A. Thonar	
Editorials	u Eugene J-M. A. Inonar	. 100
T Cell Receptor Genes	and Disease Susceptibility	
Arthroscopic Synovecto	omy by Rheumatologists: Time for a New Look	
William J. Arnold and I	Kenneth Kalunian	. 108
In Memoriam: Donald M. Mite Letters	chell	. 112
	in Methotrexate-Treated Rheumatoid Arthritis Patients: Comment on the	e
,	hony Saway, and Graciela S. Alarcón	. 113
Comment on the Article	e by Furst and Kremer	
	H. Mackenzie, Allen M. Segal, Daniel J. Mazanec, Anna P. Koo,	
	Constance S. White, Leonard H. Calabrese, John D. Clough, and	
		. 114
Reply	JM V	116
	el M. Kremer	. 115
Comment on the Article	e by weinblatt et al	. 115
Reply	***************************************	. 113
	nd Barbara N. Weissmane by Lasky et al	. 116
	brielle H. Kingsley, Dorian O. Haskard, and G. S. Panayi	116
Reply		
	Paul Lasky, and Kenneth Bauer	
Valerie E. Jones and R	R. K. Jacoby	117
Multiple Autoimmune I	Diseases in a Predisposed Patient	
	d David G. Borenstein	
ACR Announcements		A1:
VOLUME 32	JANUARY SUPPLEMENT	NO. 1
1988 Regional Meetings of the	American College of Rheumatology	. RI
WOLLING AS	PERRITARY	10 2
VOLUME 32	FEBRUARY	NO. 2
Study with Baseline and Sequen	Arthritis Patients Receiving Long-Term Methotrexate Therapy: A Prospective ntial Biopsy Samples all G. Lee, and Keith G. Tolman	
Lack of Correlation Between Status of Individuals with Rhe	the Steinbrocker Staging of Hand Radiographs and the Functional Health sumatoid Arthritis	n
Martha G. Regan-Smith	h, Gerald T. O'Connor, C. Kent Kwoh, Lin A. Brown, Elaine M. Olmstead	. 128
Demonstration of a Cross-Read Arthritis but Not in Rheumato	ctive Idiotype (IdRQ) in Rheumatoid Factors from Patients with Rheumatoid oid Factors from Healthy, Aged Subjects	
A Longitudinal Study of Antic	es and Miguel Presno-Bernal collagen Antibodies in Patients with Rheumatoid Arthritis	. 134
Keith Morgan, Roy B.	Clague, Ian Collins, Shirley Ayad, Shirley D. Phinn, and P. J. Lennox Holt	. 139
Tumor Necrosis Factor in the	Serum of Patients with Systemic Lupus Erythematosus	
	M. Teppo	. 146

Pregnancy in Women with Systemic Sclerosis	
Virginia D. Steen, Claudia Conte, Nancy Day, Rosalind Ramsey-Goldman, and Thomas A. Medsger, Jr.	151
A Double-Blind Placebo-Controlled Study of Auranofin in Patients with Psoriatic Arthritis Simon Carette, Andrei Calin, Jim P. McCafferty, Bruce A. Wallin, and The Auranofin Cooperation	
Group Does Smoking Protect Against Osteoarthritis?	
David T. Felson, Jennifer J. Anderson, Allan Naimark, Marian T. Hannan, William B. Kannel, an Robert F. Meenan	
Some Recombinant Human Cytokines Stimulate Glycosaminoglycan Synthesis in Human Synovial Fibrobla Cultures and Inhibit It in Human Articular Cartilage Cultures	
Ilana Yaron, Frank A. Meyer, Jean-Michel Dayer, Ilan Bleiberg, and Michael Yaron	
Jean-Pierre Pelletier and Johanne Martel-Pelletier	181
Reversal of Neutropenia with Methotrexate Treatment in Patients with Felty's Syndrome: Correlation Response with Neutrophil-Reactive IgG	
Justus J. Fiechtner, Donald R. Miller, and Gordon Starkebaum Brief Reports	
Correlation of Anti-Ro Antibody with Photosensitivity Rash in Systemic Lupus Erythematosi Patients	
Chaim B. Mond, Margaret G. E. Peterson, and Naomi F. Rothfield	
David M. Nordstrom, Sterling G. West, and Robert L. Rubin The "Neck Sign" in Scleroderma	
A. J. Barnett Home Central Venous Hyperalimentation in Fifteen Patients with Severe Scleroderma Bowel Disea	se
Swee Cheng Ng, Philip J. Clements, William E. Berquist, Daniel E. Furst, and Harold E. Paulus Central Nervous System Vasculitis in Behçet's Syndrome: Angiographic Improvement after Thera with Cytotoxic Agents	ру
Jane D. Zelenski, Judith A. Capraro, Daniel Holden, and Leonard H. Calabrese	
John T. Sharp Editorial: The Coexistence of Acute Rheumatic Fever and Acute Glomerulonephritis	
Alan L. Bisno In Memoriam: William Dodd Robinson	
Letters	
Favorable Results Using Methotrexate in the Treatment of Patients with Ankylosing Spondylitis Richard P. Handler Thrombocytopenia in Patients with Sjögren's Syndrome	234
Susumu Sugai, Junko Tachibana, Shiro Shimuzu, and Susumu Konda	234
J. S. Axford, Katherine Bodman, F. C. Hay, D. A. Isenberg, P. M. Lydyard, Lorna Mackenz I. M. Roitt, Nazira Sumar, G. Rook, R. A. Dwek, R. B. Parekh, and T. W. Rademacher	
Milan Tomana, Ralph E. Schrohenloher, William J. Koopman, Graciela S. Alarcón, and William A. Paul	236
Rheumatic Fever and Poststreptococcal Glomerulonephritis: A Case Report Gregory A. Kujala, Himanshu Doshi, and James E. Brick	236
Chronic Fungal Olecranon Bursitis Caused by Penicillium Robert G. Berger	239
ACR Announcements	A15
VOLUME 32 MARCH	NO. 3
Current Comment: Cartilage Collagens: What is Their Function, and Are They Involved in Articular Disease?	
Richard Mayne	241

Mutant Fibronectin Gene in Skin Fibroblasts of Sclerotic Lesions from Patients with Progressive	
Systemic Sclerosis Yasuhiro Deguchi, Shigeru Negoro, and Susumu Kishimoto	247
Class II Major Histocompatibility Complex Gene Sequences in Rheumatoid Arthritis: The Third Diversity	241
Regions of Both $DR\beta_i$ Genes in Two DR1, DRw10-Positive Individuals Specify the Same Inferred Amino	
Acid Sequence as the $DR\beta_1$ and $DR\beta_2$ Genes of a $DR4$ ($Dw/4$) Haplotype	
Parvin F. Merryman, Richard M. Crapper, Sicy Lee, Peter K. Gregersen, and	
Robert J. Winchester	251
Reduced Numbers of Complement Receptor Type 1 on Erythrocytes are Associated with Increased Levels	
of Anticardiolipin Antibodies: Findings in Patients with Systemic Lupus Erythematosus and the	
Antiphospholipid Syndrome	
Anthony Hammond, Andrew C. Rudge, Sozos Loizou, Stella J. Bowcock, and Mark J. Walport	259
Expression of the Major Rheumatoid Factor Cross-Reactive Idiotype in Juvenile Rheumatoid Arthritis	266
Norman T. Ilowite, Josiah F. Wedgwood, and Vincent R. Bonagura	265
Ghaly Kerolus, Gilda Clayburne, and H. Ralph Schumacher, Jr	271
Interleukin-1 Induces Interleukin-1α and Interleukin-1β Gene Expression in Synovial Fibroblasts and	2/1
Peripheral Blood Monocytes	
Barbara J. Dalton, Janice R. Connor, and William J. Johnson	279
Independent Effects of Interleukin-1 on Proteoglycan Breakdown, Proteoglycan Synthesis, and	
Prostaglandin E ₂ Release from Cartilage in Organ Culture	
Elizabeth C. Arner and Michael A. Pratta	288
Binding of Double-Stranded DNA to Glomeruli of Rats In Vivo	
Carol Horgan, Richard J. Johnson, V. Joyce Gauthier, Mart Mannik, and Woodruff Emlen	298
Elevated Levels of Serum Hyaluronate and Correlation with Disease Activity in Experimental Models of	
Arthritis J. Björk, S. Kleinau, A. Tengblad, and G. Smedegård	306
Canine Serum Keratan Sulfate and Hyaluronate Concentrations: Relationship to Age and Osteoarthritis	300
Harry R. Leipold, Ronald L. Goldberg, and George Lust	312
Expression of an Endogenous Retroviral Transcript is Associated with Murine Lupus	212
Arthur M. Krieg, Arifa S. Khan, and Alfred D. Steinberg	322
Requirements for Flare Reactions of Joint Inflammation Induced in Mice by Clones MT4+, Lyt-2- T	
Cells	
Ina S. Klasen, Renée M. T. Ladestein, Wim B. van den Berg, and Robbert Benner	330
Radiologic Vignettes	
The Significance of Calcaneal Spurs in Rheumatic Diseases Jeno I. Sebes	220
Panner's Disease	338
William W. Daniel	341
	541
Brief Reports	
Subacute Cutaneous Lupus Erythematosus During PUVA Therapy for Psoriasis: Case Report and	
Review of the Literature	343
Marcia J. Dowdy, Thomas P. Nigra, and Werner F. Barth	343
Patients with Rheumatoid Arthritis	
Tomasz Pawlowski, Stefan H. Mackiewicz, and Andrzej Mackiewicz	347
Factitious Septic Arthritis	
T. G. Elliott, D. Burdge, and G. D. Reid	352
Letters	
Large Granular Lymphocytes and Neutropenia in a Patient with Ankylosing Spondylitis	
Slim Lassoued, Francis Roubinet, Mohamed Hamidou, Emilienne Kuhlein, Georges Cassar,	
Bernard Fournie, and Antoine Fournie	
Alpha-Methyldopa-Induced Systemic Vasculitis Confused with Wegener's Granulomatosis	
Eric L. Matteson and Thomas D. Pallela	356
Participation of Synovial Mast Cells in Intermittent Hydrarthrosis	
Daniel G. Malone and Ronald L. Wilder	35
The Role of Cholesterol-Lowering Agents in Drug-Induced Rhabdomyolysis and Polymyositis	250
John A. Goldman, Alan R. Fishman, John F. Lee, and R. Julian Johnson.	351

Comment on the Article by Downey et al Bruce W. Kirkham and T. Gibson Standard Abbreviations for Antiphospholipid Antibodies		359
Ronald A. Asherson		359
Book Review		360
ACR Announcements		A29
VOLUME 32 APRIL	NO). 4
Changes in Lymphocyte Infiltration of the Synovial Membrane and the Clinical Course of Rheur Arthritis		
Madeleine Rooney, Alex Whelan, Conleth Feighery, and Barry Bresnihan The Effects of Methotrexate on the Production and Activity of Interleukin-1		361
Rafael Segal, Edna Mozes, Michael Yaron, and Boris Tartakovsky		370
Nancy J. Olsen and Lisa M. Murray		378
Very Late Activation Antigen on Synovial Fluid T Cells from Patients with Rheumatoid Arthritis and Rheumatic Diseases		
A. Laffon, F. Sánchez-Madrid, M. Ortíz de Landázuri, A. Jiménez Cuesta, A. Ariza, C. Ossori P. Sabando		386
Genetic Analysis of CR1 Expression on Erythrocytes of Patients with Systemic Lupus Erythematosi Jacques H. M. Cohen, Valérie Caudwell, Matthieu Levi-Strauss, Pierre Bourgeois, and	us	
Michel D. Kazatchkine Antilymphocyte Antibodies Against CD4+2H4+ Cell Populations in Patients with Systemic Lupus Erythematosus		393
Shinsuke Tanaka, Takami Matsuyama, Alfred D. Steinberg, Stuart F. Schlossman, and Chikao Morimoto		398
DNA-Anti-DNA Complexes Account for Part of the Antihistone Activity Found in Patients with Systemic Erythematosus	Lupus	
J. L. Subiza, A. Caturla, D. Pascual-Salcedo, M. J. Chamorro, E. Gazapo, M. A. Figueredo E. G. de la Concha	, and	406
Genetic Studies of Ro (SS-A) and La (SS-B) Autoantibodies in Families with Systemic Lupus Erythematos Primary Sjögren's Syndrome	us and	
Frank C. Arnett, Robert G. Hamilton, John D. Reveille, Wilma B. Bias, John B. Harley, and		413
The Expression and Function of CD3 and CD5 in Patients with Primary Sjögren's Syndrome		
Michael J. Dauphinée, Zair Tovar, Ana Ballester, and Norman Talal		420
Alice Kahan, Jacqueline Gerfaux, André Kahan, Anne-Marie Joret, Charles J. Menkès, and Bernard Amor		430
Cross-Reactive Epitope with Klebsiella pneumoniae Nitrogenase in Articular Tissue of HLA-B27+ Patien Ankylosing Spondylitis Gunnar Husby, Naoyuki Tsuchiya, Peter L. Schwimmbeck, Andrew Keat, Jon A. Pahle,	is with	
Michael B. A. Oldstone, and Ralph C. Williams, Jr		437
Proliferative Response of Peripheral Blood Mononuclear Cells to Autologous and Allogeneic Mus Patients with Polymyositis/Dermatomyositis		
Apostolos E. Kalovidouris, Rachman Pourmand, Murray H. Passo, and Zoya Plotkin		446
Robert M. Bennett, Sharon R. Clark, Linn Goldberg, Donna Nelson, R. Peter Bonafede, John Porto David Specht	er, and	454
Changes in the Viscosity of Hyaluronic Acid after Exposure to a Myeloperoxidase-Derived Oxidant Mark S. Baker, Simon P. Green, and Denis A. Lowther		461
Suppression of Glycosaminoglycan Synthesis by Articular Cartilage, But Not of Hyaluronic Acid Synthesynovium, after Exposure to Radiation	esis by	401
Steven T. Hugenberg, Stephen L. Myers, and Kenneth D. Brandt		468

David M. Nordstrom, Ange	nd Acquired Immunodeficiency Syndrome elo A. Petropolis, Ralph Giorno, Robert H. Gates, and Vishnu B. Reddy cal Features of Childhood Reflex Neurovascular Dystrophy: Comparison	475
Donald P. Goldsmith, Free Sydney Heyman	derick B. Vivino, Andrew H. Eichenfield, Balu H. Athreya, and	480
Unilateral Anterior Cruciat	te Ligament Transection , Marjorie E. Albrecht, and Kenneth D. Brandt	486
F. Mor, Y. Beigel, A. Inba	tient with the Lupus Anticoagulant	491
	aplicating Rheumatoid Arthritis and Other Chronic Rheumatic Disorders	
Special Article: Winners of the 19 Collection on the Rheumatic Disc	988 ACR Slide Competition and Future Plans for the Revised Clinical Slide	496
	the ACR Audiovisual Aids Subcommittee	503
Letters		
Comment on the Article by	y Laxer et al	
Correlation of Rheumatoid Rheumatoid Arthritis Patie	Pidrman, and Petr Bradna	505
Articular Presentation of F	rochier, and J. Sany	505
Lawrence J. Leventhal and	d John S. Bomalaski	506
Kenneth Fremont-Smith	Gold Dermatitis as "Treatment Failures"	507
The Relationship of "Shar	Egger, James C. Reading, and H. James Williams red Epitopes" of Major Histocompatibility Complex Molecules to	508
Leg Claudication and Peripulation View Djin Tan, John D. Ma	ey, and B. D. Tait	
	ot Predict Joint Erosion in Early Rheumatoid Arthritis annonen, Jaakko Rautiainen, Ilmari Jokinen, Martii Oka, and	
	amonen, Jaakko Raanamen, imani Jokinen, marin Oka, ana	511
ACR Announcements		A23
VOLUME 32	APRIL SUPPLEMENT N	0.4
53rd Annual Meeting of the Ame	rican College of Rheumatology	SI
VOLUME 32	MAY	10. 5
Antibodies Deposited in Glomer Kenneth C. Kalunian, Niv	nunoglobulins Associated with Systemic Lupus Erythematosus: Studies of uli of Humans ver Panosian-Sahakian, Fanny M. Ebling, Arthur H. Cohen, Kaine, and Bevra H. Hahn	
Lymphoid Irradiation in Intractal Rads or 2,000 Rads	ble Rheumatoid Arthritis: Long-Term Followup of Patients Treated with 750	1
Muriel Soden, Jaythoon I	Hassan, David L. Scott, John G. Hanly, Michael Moriarty, Alex Whelan,	
A Simplified Twenty-Eight-Joint	t Quantitative Articular Index in Rheumatoid Arthritis	
	H. Brooks, Leigh F. Callahan, and Theodore Pincus with Rheumatoid Arthritis: The Relative Importance of Disease, Social,	
	en E. Grady, Carol Goodenow, and Judith Fifield	538

Antibodies to the Collagen-Like Region of C1q in Sera of Patients with Autoimmune Rheumatic Diseases Mark H. Wener, Shu Uwatoko, and Mart Mannik	544
Decreased Expression of Interleukin-2 Binding Molecules (p70/75) in T Cells from Patients with Systemic Lupus Erythematosus Table Targets Occurs Scibi Shicery Necess Targets I Targets Visitable Head	
Toshio Tanaka, Osamu Saiki, Shigeru Negoro, Tsuyoshi Igarashi, Taro Kuritani, Hideki Hara, Masaki Suemura, and Susumu Kishimoto	552
Synovial Fluid Characteristics and the Lupus Erythematosus Cell Phenomenon in Drug-Induced Lupus: Findings in Three Patients and Review of Pertinent Literature	
Frederick B. Vivino and H. Ralph Schumacher, Jr.	560
Systemic Vasculitis in Association with Human Immunodeficiency Virus Infection Leonard H. Calabrese, Melinda Estes, Belinda Yen-Lieberman, Max R. Proffitt, Raymond Tubbs,	
Andrew J. Fishleder, and Kerry H. Levin	569 577
Immunosuppression with Chlorambucil, Versus Placebo, for Scleroderma: Results of a Three-Year, Parallel, Randomized, Double-Blind Study	211
Daniel E. Furst, Philip J. Clements, Steven Hillis, Peter A. Lachenbruch, Bruce L. Miller, Mildred G. Sterz, and Harold E. Paulus	584
Enhanced Production of Interleukin-6 in Mice with Type II Collagen-Induced Arthritis Yasuyuki Takai, Nobuo Seki, Hachiro Senoh, Takashi Yokota, Frank Lee, Toshiyuki Hamaoka, and	
Hiromi Fujiwara	594
Cartilage Proteoglycan Depletion in Acute and Chronic Antigen-Induced Arthritis	
E. R. Pettipher, B. Henderson, T. Hardingham, and A. Ratcliffe	601
Retardation of Articular Cartilage Degradation by Glycosaminoglycan Polysulfate, Pentosan Polysulfate, and DH-40J in the Rat Air Pouch Model	
D. J. Francis, M. J. Forrest, P. M. Brooks, and P. Ghosh	608
Changes in the Metaphysis and Diaphysis of the Femur Proximal to the Knee in Rabbits with Experimentally Induced Inflammatory Arthritis	
E. Bogoch, N. Gschwend, B. Bogoch, B. Rahn, and S. Perren	
Scott D. Boden, Panos A. Labropoulos, Bruce D. Ragsdale, Pietro M. Gullino, and Lynn H. Gerber Brief Reports	625
DNA Polymorphism of Immunoglobulin Kappa Confers Risk of Rheumatoid Arthritis	
George Moxley	634
Treatment of the Anemia of Rheumatoid Arthritis with Recombinant Human Erythropoietin: Clinical and In Vitro Studies	
Robert T. Means, Jr., Nancy J. Olsen, Sanford B. Krantz, Emmanuel N. Dessypris,	
Stanley E. Graber, William J. Stone, Vicki L. O'Neil, and Theodore Pincus	638
Ch. Humburg, and J. Brzoska	643
Lack of Association Between Serum Keratan Sulfate Concentrations and Cartilage Changes of Osteoarthritis after Transection of the Anterior Cruciate Ligament in the Dog	
Kenneth D. Brandt and Eugene J-M. A. Thonar Review: Involvement of the Cervical Spine in Rheumatoid Arthritis	647
James T. Halla, Joe G. Hardin, Jiri Vitek, and Graciela S. Alarcón	652
Letters	
Medical Treatment of Synovial Cysts of the Zygapophyseal Joints: Four Cases with Long-Term Followup	
Xavier Mariette, Yves Glon, Didier Clerc, Pascal Bennet, and Michel Bisson Lumbosacral Plexopathy in a Woman with CREST Syndrome and Vasculitis	660
Mary E. Moore, James M. Burke, John H. Hartman, and Edith Korenzwitt	661
M. Galeazzi, G. D. Sebastiani, S. Cappellacci, P. Lulli, M. C. Mazzilli, R. Tosi, and N. Tanigaki.	663
ACR Announcements	A21

Age- and Sex-Related Differences in Antigen-Induced Arthritis in C57Bl/10 Mice Henk M. van Beuningen, Wim B. van den Berg, Joost Schalkwijk, Onno J. Arntz, and Levinus B. A. van de Putte	789
Editorial: Another Interpretation of the Role of T Helper Cells in the Rheumatoid Synovium	
Michael Salmon, George D. Kitas, and Paul Emery Current Controversies in Rheumatology	795
The Controversy of Core Decompression of the Femoral Head for Osteonecrosis	797
Clifford W. Colwell, Jr	
David S. Hungerford	801
Special Article: Alphonsus of Ligouri: A Patron for the Handicapped	807
George E. McLaughlin, Gennaro Goglia, and Daniel J. McCarty	007
Normal Serologic Response to Epstein-Barr Virus in Patients with Sjögren's Syndrome	
Patrick J. W. Venables, Christina Baboonian, and Ravinder N. Maini	
Nobuyuki Miyasaka, Kunio Yamaoka, Mutsuto Tateishi, and Kohtaro Yamamoto Description of Psoriatic Arthropathy in the 17th Century	
Antonio Castillo-Ojugas and Iñigo R. Hernández	812
Hypergammaglobulinemia and the Anticardiolipin Antibody Test T. P. Hughes, P. Jones, and M. C. Rozenberg	813
Comment on the Letter by Howland	
Joel M. Kremer	813
Absence of Antibodies to Native Type I and Type II Collagen in a Rabbit Model of Osteoarthritic Daniel J. Hartmann, Guylène Charrière, Gérard Ville, Eric Vignon, and Jacques Bejui	814
Book Review	815
ACR'Announcements	A17
VOLUME 32 JULY	NO. 7
Current Comment: A Strategy for Determining the Pathogenesis of Systemic Sclerosis: Is Transform	ing
Growth Factor β the Answer? E. Carwile LeRoy, Edwin A. Smith, M. Bashar Kahaleh, Maria Trojanowska, and Richard M. Silve A Model for Disease Heterogeneity in Systemic Lupus Erythematosus: Relationships between	
Histocompatibility Antigens, Autoantibodies, and Lymphopenia or Renal Disease John B. Harley, Andrea L. Sestak, Larry G. Willis, Shu Man Fu, John A. Hansen, a	
Morris Reichlin	826
Gurkirpal Singh, James F. Fries, Patricia Spitz, and Catherine A. Williams	837
Jennifer J. Anderson, Hill E. Firschein, and Robert F. Meenan	844
Predicting Individual Differences in Pain and Functional Impairment among Patients with Rheumat Arthritis	
Kristofer J. Hagglund, William E. Haley, John D. Reveille, and Graciela S. Alarcón Detection of Clonally Expanded Salivary Gland Lymphocytes in Sjögren's Syndrome	
Bruce Freimark, Richard Fantozzi, Robert Bone, Gerald Bordin, and Robert Fox	859
Characterization of the Class I HLA 9.2-kb PVU II Restriction Fragment Length Polymorphism: Linkage HLA-A and Lack of Disease Association Leagh M. Abazen Jr., Jon. J. Calonisia, Frankish M. Wieley, Develop A. John William P. Richard M. Wieley, D. B. Richard M. Wieley, D. R. Richard M. Ri	
Joseph M. Ahearn, Jr., Jon J. Calomiris, Fredrick M. Wigley, Douglas A. Jabs, Wilma B. Bias, a Marc C. Hochberg	and 870
Antibodies to Histones H1 and H5 in Sera of Patients with Juvenile Rheumatoid Arthritis	

Activation Markers in Temporal Ar Maria Cinta Cid, Elias Camp	Lymphoid and Macrophage Cell Subsets and their Immunologic retritis: Influence of Corticosteroid Treatment too, Guadalupe Ercilla, Antonio Palacin, Jaume Vilaseca, Jaume Villalta,	
Chondrocyte Nonresponsiveness to	Insulin-Like Growth Factor 1 in Experimental Arthritis	884
Joost Schalkwijk, Leo A. B. Brief Reports	Joosten, Wim B. van den Berg, and Levinus B. A. van de Putte	894
An Antibody that Inhibits In Erythematosus and Aplastic	n Vitro Bone Marrow Proliferation in a Patient with Systemic Lupus Anemia lly, Luigi F. Bertoli, and Gene V. Ball	001
Successful Plasma Infusion Erythematosus: Clinical Exp	Treatment of a Patient with C2 Deficiency and Systemic Lupus perience over Forty-Five Months	901
MX Homologous Protein in Peter von Wussow, Detlef J.	Erlendsson, and Helgi Valdimarsson	906
Reactivity of Antinuclear A Arthritis	Antibodies with Histones and Other Antigens in Juvenile Rheumatoid	914
Editorial: Do Autoantibodies Inhibi	tty, Marinda Fung, and E. Peter M. Candidoit Function of their Cognate Antigens In Vivo?	919
Current Controversies in Rheumato Antiinflammatory Drug-Induced Sie	ology: Controversies in the Detection and Management of Nonsteroidal de Effects of the Upper Gastrointestinal Tract	924
Letters Charles H. Barrier and Basis	I. Hirschowitz	926
Prospective Pilot Study of Int Arthritis	travenous Pulse Cyclophosphamide Therapy for Refractory Rheumatoid	933
Disseminated Mycobacterium	n Avium-Intracellulare Infection in a Patient with Polymyositis p. F. J. López-Longo, J. C. Cobeta, and J. Rivera	
What are the Primary Goals Charles M. Plotz	of the American College of Rheumatology?	936
Reply Paulding Phelps		936
VOLUME 32	AUGUST	O. 8
Identification of a 2-Md Plasmid fro	om Shigella flexneri Associated with Reactive Arthritis	
H. Stieglitz, S. Fosmire, and Increased Expression of p150,95 at	d P. Lipsky	937
Increased Expression of HLA-DQ of Rheumatoid Arthritis Patients Co	Antigens by Interstitial Cells and Endothelium in the Synovial Membrane ompared with Reactive Arthritis Patients	947
Diana Barkley, Simon Allard Double-Blind Trial of Recombinant Grant W. Cannon, Seth	d, Marc Feldmann, and Ravinder N. Maini	955
John D. Schindler	ny Saway, Adrian M. Jaffer, Arthur L. Weaver, Lewis Cogen, and	964
Pain Control and Rational Thinking	L. Mahowald, Scott R. Bundlie, and Steven R. Ytterberg	974
	narr, Keith L. Buescher, Les R. Phillips, Robert G. Frank, Neils C. Beck, ara E. Walker	984

Validity of the Center for Epidemiological Studies Depression Scale in Arthritis Populations Susan J. Blalock, Robert F. DeVellis, Gregory K. Brown, and Kenneth A. Wallston	. 991
Prevalence of Scleroderma Spectrum Disorders in the General Population of South Carolina	
Hildegard R. Maricq, Martin C. Weinrich, Julian E. Keil, Edwin A. Smith, Frank E. Harper	,
Alan I. Nussbaum, E. Carwile LeRoy, Andrew R. McGregor, Francoise Diat, and Erick J. Rosal.	. 998
Psoriatic Arthritis in Children	
Taunton R. Southwood, Ross E. Petty, Peter N. Malleson, Egle A. Delgado, David W. C. Hunt	,
Betty Wood, and Maria-Louise Schroeder	. 1007
Differential Deoxyadenosine Toxicity to Immature Rabbit Cartilage In Vitro: A Model for the	
Chondro-Osseous Dysplasia of Adenosine Deaminase Deficiency	1014
Robert L. Wortmann, Judith A. Veum, Lawrence M. Ryan, and Herman S. Cheung	. 1014
Autoimmune Disease	1
	1022
Paul H. Wooley, James R. Seibold, Janey D. Whalen, and Joan M. Chapdelaine	. 1022
Judy van de Water, Lori Haapanen, Richard Boyd, Hans Abplanalp, and M. Eric Gershwin	1021
Brief Reports	. 1031
An Adsorption Procedure to Increase the Specificity of Enzyme-Linked Immunosorbent Assays fo	
Lyme Disease without Decreasing Sensitivity	1
Paul T. Fawcett, Ann E. O'Brien, and Robert A. Doughty	1041
Altered Metabolism of Poly(ADP-Ribose) in the Peripheral Blood Lymphocytes of Patients with	. 1041
Systemic Lupus Erythematosus	
John T. Sibley, Brenda L. Haug, and Jeremy S. Lee	1045
Letters	. 1045
More on the Posterior Tibial Tendon in Rheumatoid Arthritis	
Peter A. Simkin, Daniel J. Downey, and Michael L. Richardson	1050
Comment on the Article by DeRemee	. 1000
Dagmar Steppat and Wolfgang L. Gross	1050
Reply	. 1050
Richard A. DeRemee	1051
Wegener's Granulomatosis and Trimethoprim/Sulfamethoxazole Treatment	. 1051
Pol Boudes	. 1052
Corynebacterium kutscheri Septic Arthritis	
Osvaldo D. Messina, José A. Maldonado-Cocco, Adriana Pescio, Alicia Farinati, and	1
Osvaldo García-Morteo	. 1053
Comment on the Article by Stafford-Brady et al	
P. Merry, J. F. Acheson, and R. A. Asherson	. 1053
Reply	
M. B. Urowitz	. 1054
Comment on the Article by Sheerin et al	
John Baum	. 1054
Reply	
Kathleen A. Sheerin, Karyl S. Barron, Edward H. Giannini, and Earl J. Brewer, Jr.	. 1054
Physician Compensation for Drug Surveys	
Philip L. Cohen	. 1055
Reply	
Roy D. Altman, Peter Barland, John R. Ward, and Robert F. Willkens	. 1055
Book Review	. 1056
ACR Announcements	. A15
VOLUME 32 SEPTEMBER	NO. 9
Immune Responses to Borrelia burgdorferi in Patients with Reactive Arthritis	
Cornelia M. Weyand and Jörg J. Goronzy	1057
Inhibition of In Vitro Vascular Endothelial Cell Proliferation and In Vivo Neovascularization by Low-Dos	105/
Methotrexate	ie
S. Hirata T. Matsuhara P. Saura H. Tateishi and K. Hirahata	1066

Cytokines in Chronic Inflammatory Arthritis. III. Rheumatoid Arthritis Monocytes are Not Unusually Sensitive to \(\gamma\)-Interferon, but Have Defective \(\gamma\)-Interferon-Mediated HLA-DQ and HLA-DR Induction Ville Bergroth, Nathan J. Zvaifler, and Gary S. Firestein	1074
Involvement of Nonarticular Cartilage, as Demonstrated by Release of a Cartilage-Specific Protein, in Rheumatoid Arthritis	
Tore Saxne and Dick Heinegård	1080
Secretion of Antibodies to Types $\tilde{\mathbf{I}}$ and II Collagen by Synovial Tissue Cells in Patients with Rheumatoid Arthritis	
Andrej Tarkowski, Lars Klareskog, Hans Carlsten, Peter Herberts, and William J. Koopman Which Traditional Measures Should be Used in Rheumatoid Arthritis Clinical Trials?	
Jennifer J. Anderson, David T. Felson, Robert F. Meenan, and H. James Williams Disability and Depression in Rheumatoid Arthritis: A Multi-Trait, Multi-Method Investigation	
Judith R. Peck, Timothy W. Smith, John R. Ward, and RoseAnn Milano	
Matthew H. Liang, Steven A. Socher, Martin G. Larson, and Peter H. Schur Serum IgG Antibodies to C1q in Hypocomplementemic Urticarial Vasculitis Syndrome	1107
Jeffrey J. Wisnieski and George B. Naff	1119
David J. Helfrich, Barbara Banner, Virginia D. Steen, and Thomas A. Medsger, Jr	1128
Wendy P. Robinson, Sjef M. van der Linden, Muhammad A. Khan, Hans-Ueli Rentsch, Arnold Cats, Anthony Russell, and Glenys Thomson	
Gait Alterations in Dogs after Transection of the Anterior Cruciate Ligament	
Brian L. O'Connor, Denise M. Visco, David A. Heck, Stephen L. Myers, and Kenneth D. Brandt Brief Reports	1142
The Presence of Antibodies to Lymphotoxin and Tumor Necrosis Factor in Normal Serum Edward W. B. Jeffes, III, Elizabeth K. Ininns, Kristen L. Schmitz, Robert S. Yamamoto,	1140
Carmen A. Dett, and Gale A. Granger Development and Initial Validation of a Dual-Language English-Spanish Format for the Arthritis Impact Measurement Scales	1148
William D. Hendricson, I. Jon Russell, Thomas J. Prihoda, James M. Jacobson, Alice Rogan, George D. Bishop, and Richard Castillo	1153
Observations J. B. Shiroky, C. S. Watts, and C. Neville	
Autoantibodies to the Major Nucleolar Phosphoprotein B23 Define a Novel Subset of Patients with Anticardiolipin Antibodies	
Xiaozhou Li, L. Jane McNeilage, and Senga Whittingham	
Thomas T. Provost	1170
Septic Acromioclavicular Arthritis and Osteomyelitis in a Patient with Acquired Immunodeficiency Syndrome	
Bernard Zimmermann, III, Allan D. Erickson, and Dennis J. Mikolich	
Apostolos E. Kalovidouris, Frederick W. Miller, and Thomas J. Lawley Editorial: The Lyme Spirochete: Another Cause of Reiter's Syndrome?	
Frank C. Arnett	1182
Comment on the Article by van Kerckhove et al	
Mark N. Mueller	1185
Reply Catherine van Kerckhove, Daniel J. Lovell, and Edward H. Giannini	
Microbiology: The Forefront of Arthritis Research in the 1990s?	
Denys K. Ford	1186


Systemic Lupus Erythematosu	in-Releasing Hormone Analog as Adjunctive Therapy in Women with	1106
Treatment of Felty's Syndrom	Paola Motta, and Carlo Zanussi	
Subcutaneous Cholesterol Cry	estal Deposition and Tophus Formation	
Anti-Endothelial Cell Antibod	lies in Patients with Rheumatoid Vasculitis	
A. H. M. Heurkens, M. R. Da	nha, and F. C. Breedveld	A17
VOLUME 32	OCTOBER). 10
	ion: More Than Just Acknowledgment	1102
Current Comment: Factors Involved	in the Regulation of Proteoglycan Metabolism in Articular Cartilage	1193
Teresa I. Morales and Vincen	at C. Hascall	1197
Correlation with Light Microscopic I		
	I. Kaye	1202
	ohistologic Diagnostic Criterion for Sjögren's Syndrome J. P. A. Baak, J. C. van Houwelingen, R. J. Hené, and P. J. Slootweg.	1214
	actor, and HLA-DR4: Susceptibility Versus Severity, A Case-Control	
	, and Peter T. Klouda	1221
A Meta-Analysis of the Clinical Man	nifestations of Older-Onset Systemic Lupus Erythematosus	
	d P. Polisson.	
The Clinical Significance of iC3b N Erythematosus	leoantigen Expression in Plasma from Patients with Systemic Lupus	
	ura, Tadanao Takeda, Shinichi Koda, Koji Amatsu, Takatoshi Inoue,	
	Kanayama	
	Genes in American Blacks with Systemic Lupus Erythematosus	
	chrohenloher, Ronald T. Acton, and Bruce O. Barger	1243
	man and MRL/lpr Mice with Systemic Lupus Erythematosus	1252
Activation of the Complement Syste	D. Rhoads, D. J. Roufa, I. G. Wool, and K. B. Elkon	1232
Giorgio Senaldi, Salvatore Lu	upoli, Diego Vergani, and Carol M. Black	1262
Mass Spectrometric Quantitation of	Muramic Acid, A Bacterial Cell Wall Component, in Septic Synovial	
Fluids		
Bertil Christensson, James Gi	ilbart, Alvin Fox, and Stephen L. Morgan	1268
	ll Proliferation by Dihomo-y-Linolerae Acid Krakauer, Guillermo Tate, Michael Laposata, and Robert B. Zurier	1273
	Nonaggregating Proteoglycans at Articular Cartilage Contact Sites in the	
Knees of Young Dogs Subjected to	Moderate Running Exercise	
	kku Tammi, Ilkka Kiviranta, Jukka Jurvelin, and Heikki J. Helminen	1282
	abbits with Experimentally Induced Osteoarthritis	1202
Fuad Mehraban and Roland	W. Moskowitzsteoarthritis with Glycosaminoglycan Polysulfuric Acid Ester	1293
	an, Ofelia E. Muniz, and David S. Howell	1300
Brief Reports		
	in Temporal Arteritis: A Treatable Cause of Dementia in the Elderly	
	Roos, and Thomas E. Davis, Jr	1308
Inflammation of the Deep Infl	rapatellar Bursa of the Knee	1312

Isotype Analysis of the A Clonality	Anti-CENP-B Anticentromere Autoantibody: Evidence for Restricted	
	am C. Earnshaw, Bonnie J. Bordwell, Sylvia Y. Craven, Robert Cheek, and	
Naomi F. Rothfield	Rheumatoid Arthritis and Felty's Syndrome	1315
Michael G. Cohen and Joh	in Webb	1310
	striction Fragment Length Polymorphism for Serum Amyloid P Gene with	
Reactive Amyloidosis	striction Pragment Length Polymorphism for Serum Amyloid P Gene with	
Noam Harats, Barbara Klu	uve-Beckerman, Martha Skinner, Murray Passo, Linda Quinn, and	
Merrill D. Benson		1325
Antiarthritis Drugs; Labeling of A	itis Advisory Committee Meeting: Changes in the Review Process for analgesics	
Harold E. Paulus	Chartier F&C and Indianation of Education	1328
John R Winfield and the A	Education: Efficacy, Implementation, and Financing CR/AHPA/AF/NAAB Task Force on Arthritis Patient Education	1330
Letters	CRAIT AAF WAAD Tusk Porce on Armitis Fullent Education	1330
Cytokines and Immune Reg	gulation in Patients with Fibrositis	
	L. Bowman, Susan B. Wormsley, and James B. Peter	1334
Anserine Bursal Distention	: Diagnosis by Ultrasonography and Computed Tomography	1226
	larie Arenson, and Adel G. Fam	1335
	adman	1338
The First Descriptions of C	hondrocalcinosis	1336
Paul Dieppe and Michael I	Doherty	1339
Radiographic Features and	Functional Status in Rheumatoid Arthritis	
Marc C. Hochberg		1340
Reply		
Martha G. Regan-Smith, C	Gerald T. O'Connor, C. Kent Kwoh, Lin A. Brown, Elaine M. Olmstead,	1241
Impotence in Three Rheum	natoid Arthritis Patients Treated with Methotrexate	1341
	and Graciela S. Alarcón	1341
Polyarthritis in Human T L	Lymphotropic Virus Type I-Associated Myelopathy	
Isao Kitajima, Ikuro Maru	yama, Yoshikazu Maruyama, Shinji Ijichi, Nobutaka Eiraku,	
Yoshihiro Mimura, and Mi	tsuhiro Osame	1342
Salsalate Alters Thyroid Fu	unction Test Results	1244
ACK Announcements		Als
VOLUME 32	NOVEMBER NO	0. 11
Current Comment: The Control of Peter E. Lipsky	of Antibody Production by Immunomodulatory Molecules	1345
	ting Interleukin-2 Production by Normal Lymphocytes in Patients with	
Systemic Lupus Erythematosus	ting interleukin-2 Froduction by Normal Lymphocytes in Fatients with	
Jun Miyagi, Nagahiro Min	nato, Morito Sumiya, Tadashi Kasahara, and Shogo Kano	
	pe Confers Risk of Rheumatoid Arthritis among HLA-DR4 Negative	e
Individuals		12/5
George Moxley	'1 C 1 Fb.: 4 I b	. 1363
Antigenic Specificity of Kheumate	oid Synovial Fluid Lymphocytes amad A. Pahlavani, Edmund LaCour, Susan Sambol, and	
Rasayarai V Dasai	maa A. Paniavani, Lamuna LaCour, Susan Sumboi, and	. 1371
Differences in Responses of Norm	nal and Rheumatoid Arthritis Peripheral Blood T Cells to Synovial Fluid and	d
Peripheral Blood Dendritic Cells	in Allogeneic Mixed Leukocyte Reactions	
Ville Bergroth, Van Tsai.	and Nathan J. Zvaifler	. 1381
-		

Development of a Disability Measurement Tool for Juvenile Rheumatoid Arthritis: The Juvenile Arthritis Functional Assessment Scale Daniel J. Lovell, Steven Howe, Edith Shear, Sandra Hartner, Gerri McGirr, Marion Schulte, and	
	1200
Joseph Levinson	1390
	1206
Marian A. Minor, John E. Hewett, Richard R. Webel, Sharon K. Anderson, and Donald R. Kay	1390
Factor B Activation Products in Patients with Systemic Lupus Erythematosus: A Marker of Severe Disease	
Activity	
Leslie Dubin Kerr, Bernard R. Adelsberg, Paul Schulman, and Harry Spiera	1406
Maternal Antibodies to Ro (SS-A) are Associated with Both Early Onset of Disease and Male Sex among Children with Systemic Lupus Erythematosus	
Thomas J. A. Lehman, Morris Reichlin, Thomas J. Santner, Earl Silverman, Ross E. Petty, Charles H. Spencer, and John B. Harley	1414
Congenital Heart Block Immunogenetics: Evidence of an Additional Role of HLA Class III Antigens and	
Independence of Ro Autoantibodies	
A. Arnaiz-Villena, J. J. Vazquez-Rodriguez, J. L. Vicario, P. Lavilla, D. Pascual, F. Moreno, and	
J. Martinez-Laso	1421
Elevated Plasma Levels of α_2 -Plasmin Inhibitor-Plasmin Complex in Patients with Rheumatic Diseases:	1421
Possible Role of Fibrinolytic Mechanism in Vasculitis	
Makoto Kawakami, Mitsuhiro Kawagoe, Masayoshi Harigai, Masako Hara, Tatsuo Hirose,	
Wataru Hirose, Ken-Ichi Norioka, Kimihiro Suzuki, Atsushi Kitani, and Haruo Nakamura	1427
	1427
Increased Levels of Proteoglycan Fragments in Knee Joint Fluid after Injury	1424
L. Stefan Lohmander, Leif Dahlberg, Leif Ryd, and Dick Heinegård	1434
Inflammatory Microcrystals Stimulate Interleukin-6 Production and Secretion by Human Monocytes and	
Synoviocytes	
Pierre-André Guerne, Robert Terkeltaub, Bruce Zuraw, and Martin Lotz	1443
Brief Reports	
Rheumatoid Arthritis Complicated by Infection with the Human Immunodeficiency Virus and the Development of Sjögren's Syndrome	
Leonard H. Calabrese, William S. Wilke, Alvin D. Perkins, and Raymond R. Tubbs	1453
Immunohistologic Demonstration of Type II Collagen in Synovial Fluid Phagocytes of Osteoarthritis and Rheumatoid Arthritis Patients	
Larry W. Moreland, Tod Stewart, Renate E. Gay, Guo Qiang Huang, Nancy McGee, and	
Steffen Gay	1458
The Frequency of Complement Receptor Type 1 (CR1) Gene Polymorphisms in Nine Families with Multiple Cases of Systemic Lupus Erythematosus	
J. G. Tebib, C. Martinez, J. Granados, D. Alarcon-Segovia, and P. H. Schur	1465
Solitary Plasmacytoma of the Skull Revealed by a Mononeuritis Multiplex Associated with Immune Complex Vasculitis	
Romain K. Gherardi, Hélène Amiel, Claude Martin-Mondiere, Jean-Paul Viard, Jeffrey Salama, and	
Pierre Delaporte	1470
Hereditary Amyloidosis: Evidence Against Early Amyloid Deposition Noam Harats, Robert M. Worth, and Merrill D. Benson	
Noam Harats, Robert M. Worth, and Merrill D. Benson	1474
Chondrolysis of the Hip Joint in a Patient Receiving Long-Term Hemodialysis: Histologic and Biochemical Evaluation	
Dragoslav R. Mitrovic, Nicole Darmon, Alain Barbara, Humberto Riera, and Thomas Bardin	1477
Radiologic Vignette: Tumoral Calcinosis	
Charles S. Resnik	1484
Letters	
Comment on the Article by Goldenberg	
Robert G. Gray and Martin J. Poppo	1487
Reply Don K. Coldonboro	1.405
Don L. Goldenberg "Renal Raynaud's Phenomenon" in Systemic Lupus Erythematosus: Measurement of the Glomerular	1487
Filtration Rate with 99mTechnetium-DTPA	1.400
Kunihiko Yamauchi, Yutaka Suzuki, and Shigeru Arimori	1487

Colchicine and Leukocytoclastic Vasculitis Stephen Plotnick, Arthur S. Huppert, and Gary Kantor	1489
Drug Company "Honoraria" Michael D. Reynolds Catastrophic Arterial Thrombosis Associated with an Unsuspected Anticardiolipin Antibody, Following Pyelography	1490
R. Deaver Collins, Jr. Comment on the Letter by Hurst and Van den Berg	1490
D. Kuntz Histocompatibility Antigens in Systemic-Onset Juvenile Rheumatoid Arthritis	1492
Gurkirpal Singh, N. K. Mehra, V. Taneja, V. Seth, A. N. Malaviya, and O. P. Ghai	
Eric S. Schned	
Bernhard H. Singsen	
Riitta Lahesmaa-Rantala, Auli Toivanen, Kaisa Granfors, Sebahattin Yurdakul, Vedat Hamuryudan, and Hasan Yazici	1494
Prolonged Improvement in Refractory Rheumatoid Arthritis After Antithymocyte Globulin Therapy of Brief Duration	
Robert H. Shmerling and David E. Trentham	1495
ACR Announcements	Al9
VOLUME 32 DECEMBER NO	0. 12
Current Comment: Stress Proteins, Arthritis, and Autoimmunity	
John B. Winfield	1497
Antoine Helewa, Claire Bombardier, Charles H. Goldsmith, Bruce Menchions, and Hugh A. Smythe	1505
Demonstration of a New Antinuclear Antibody (Anti-RA33) that is Highly Specific for Rheumatoid Arthritis Wolfgang Hassfeld, Günter Steiner, Klaus Hartmuth, Gernot Kolarz, Othmar Scherak,	
Winfried Graninger, Norbert Thumb, and Josef S. Smolen	
Interleukin-1-Inhibitory IgG in Sera from Some Patients with Rheumatoid Arthritis Hiroshi Suzuki, Takao Akama, Masato Okane, Ichiro Kono, Yoshiki Matsui, Kazuhide Yamane,	
and Heihachiro Kashiwagi	1528
Regulation of Human Synovial Fibroblast Collagenase Messenger RNA by Interleukin-1 S. Spence McCachren, Paula K. Greer, and James E. Niedel Arthritis in Nursing Home Residents: A Validation of its Prevalence and Examination of its Impact on Institutionalization and Functional Status	1539
Andrew A. Guccione, Robert F. Meenan, and Jennifer J. Anderson	1546
Immunosorbent Assay in Patients with Systemic Lupus Erythematosus Mitsutaka Sakamoto, Yoshinari Takasaki, K. Yamanaka, A. Kodama, H. Hashimoto,	
and S. Hirose	1554
Michael D. Rader, Chris Codding, and Morris Reichlin	1563
Leukocytes: Possible Subclinical Autoimmune Disease J. Bruce Smith, F. Susan Cowchock, Barbara Hankinson, and Anwerunisa Iftekhar Can the Provision of Information to Patients with Osteoarthritis Improve Functional Status? A Randomized,	1572
Controlled Trial Morris Weinberger, William M. Tierney, Patricia Booher, and Barry P. Katz	. 1577

New Radiographic Grading Scales for Osteoarthritis of the Hand: Reliability for Determining Prevalence and	
Progression	
Douglas A. Kallman, Fredrick M. Wigley, William W. Scott, Jr., Marc C. Hochberg, and	
Jordan D. Tobin	1584
Brief Reports	
Elevated Mean Corpuscular Volume as a Predictor of Hematologic Toxicity Due to Methotrexate Therapy	
Michael E. Weinblatt and Patricia Fraser	1592
Lack of Association Between Scleroderma and Types I and III Procollagen Gene Restriction Fragment Length Polymorphisms	
Lisa E. Kratz, Joann A. Boughman, and Barbara White Needleman	1597
IgG Subclasses of Antibodies to the Collagen-Like Region of C1q in Patients with Systemic Lupus Erythematosus	
Shu Uwatoko and Mart Mannik	1601
Prevalence of the Use of Unconventional Remedies for Arthritis in a Metropolitan Community	
Terry A. Cronan, Robert M. Kaplan, Linda Posner, Elaine Blumberg, and Franklin Kozin	
Wanda K. Bernreuter	1608
Editorial: Psychosocial Factors and Disease Outcomes in Rheumatoid Arthritis: Old Problems, New Solutions, and a Future Agenda	
Laurence A. Bradley	1611
Review: Rheumatic Manifestations Associated with Human Immunodeficiency Virus Infection Luis R. Espinoza, Jose L. Aguilar, Alberto Berman, Francisco Gutierrez, Frank B. Vasey,	
and Bernard F. Germain	1615
Letters	
HLA-DR Antigens and Anticardiolipin Antibodies in Patients with Systemic Lupus Erythematosus	
Neil J. McHugh and Peter J. Maddison	1623
Reply	
M. Savi, G. F. Ferraccioli, T. M. Neri, P. Zanelli, A. Tincani, G. Balestrieri, G. Carella,	
and R. Cattaneo	1624
. Spontaneous Dissection of the Internal Carotid Artery in a Patient with Polyarteritis Nodosa	
Rosalia M. Lomeo, Richard M. Silver, and Michael Brothers	1625
Infectious Complications of Cyclophosphamide Treatment for Vasculitis	
Gary S. Hoffman, Randi Y. Leavitt, and Anthony S. Fauci	1626
Reply	
John D. Bradley, Kenneth D. Brandt, and Barry P. Katz	1627
Effect of Temperature and Humidity on Daily Pain Score in a Patient with Rheumatoid Arthritis	
Wiebe R. Patherg	1627
Arthropathy of Behçet's Disease: A Case with "Pencil-in-Cup" Deformities	
Akiteru Takeuchi and Takashi Hashimoto	1629
Comment on the Article by Thomson et al	
Sharad Lakhanpal, William W. Ginsburg, and S. Breanndan Moore	1630
Reply	
Ian M. Chalmers	1631
Comment on the Article by Furst et al	
Larry Moreland and Graciela S. Alarcón	1631
Reply	
Daniel E. Furst and Philip J. Clements	1632
Reviewers	1633
Contents, Volume 32, 1989.	1636
Indexes	
ACR Announcements	



L

AUTHOR INDEX

Arthritis and Rheumatism, Volume 32, Numbers 1 through 12, 1989

A
Abplanalp H, 1031
Abramson SB, 1
Acheson JF, 1053
Acton RT, 1243
Adelsberg BR, 1406
Aguilar JL, 1615
Ahearn JM. Jr., 870
Akama T, 1528
Alarcón GS, 113, 236, 652,
671, 851, 1341, 1631
Alarcon-Segovia D, 1465
Albrecht ME, 486
Allard S, 955
Allen CA, 947
Allouache M, 785
Altman RD, 360, 759, 1055
1300
Amatsu K, 1233
Amiel H, 1470
Amor B, 31, 430
Anderson JJ, 166, 844,
1093, 1546
Anderson SK, 984, 1396
Andersson GBJ, 100
Arai H, 748
Arenson AM, 1335
Arimori S, 1487
Ariza A, 386
Arnaiz-Villena A, 1421
Arner EC, 288
Arnett FC, 413, 1182
Arnold WJ, 108
Arnold MH, 933
Arntz OJ, 789
Arthur MW, 706
Arvilommi H, 511
Asherson RA, 359, 1053
Athreya BH, 480
Axford JS, 235
Ayad S, 139
11yau 0, 137

Baak JPA, 1214
Baboonian C, 811
Baglioni AJ, Jr., 706
Bailey FA, 901
Baker MS, 461
Baker DG, 1273
Balestrieri G, 1624
Ball GV, 901
Ballester A, 420
Banerjee S, 105
Banner B, 1128
Barbara A, 1477
Bardin T, 785, 1477

Barger BO, 1243
Barkley D, 955
Barland P, 1055
Barnett AJ, 209
Barrier CH, 926
Barron KS, 1054
Barth WF, 343
Bauer K, 117
Baum J, 1054
Beck NC, 984
Beigel Y, 491
Bejui J, 814
Benhamou C, 785
Benner R, 330
Bennet P, 660
Bennett RM, 454
Benson MD, 1325, 1474
Berger RG, 239, 1056 Bergroth V, 1074, 1381
Bergroth V, 10/4, 1381
Berman A, 1615 Bernreuter WK, 1608
Perquist WE 212
Berquist WE, 212 Bertoli LF, 901
Bias WB, 413, 870
Bilazarian SD, 1170
Bishop GD, 1153
Bisno AL, 230
Bisson M, 660
Björk J, 306
Black CM, 1262
Blackburn WD, Jr., 671,
1341
Blalock SJ, 991
Bleiberg I, 173
Blever WA, 677
Block JA, 100
Blumberg E, 1604
Boden SD, 625
Bodman K, 235
Bogoch B, 617
Bogoch E, 617
Bole GG, 233
Bomalaski JS, 506
Bombardier C, 1505
Bonafede RP, 454
Bonagura VR, 265
Bone R, 859
Bonfa E, 1252 Booher P, 1577
Bordin G, 859
Berdwell BJ, 1315
Borenstein DG, 119
Boudes P, 1052
Boughman JA, 1597
Bourgeois P, 393
Boweack SI 250

Bowcock SJ, 259

Bowman RL, 1334
Boyd R, 1031
Bradley JD, 45, 1627
Bradna P, 505
Brandt KD, 45, 468, 486,
647, 1142, 1627
Breedveld FC, 1191
Bresnihan B, 361, 523, 68
Brewer EJ, Jr., 1054
Brezinski D, 1170
Brick JE, 236
Brochier J, 505
Brooks RH, 531
Brooks PM, 608, 934
Brothers M, 1625
Brown LA, 128, 1341
Brown GK, 991
Brunk SE, 706
Brunner CM, 706
Brzoska J, 643
Buescher KL, 984
Bundlie SR, 974
Bunning RAD, 780
Burdge D, 352
Burke JM, 661
Burnett JB, 128, 1341
Buskila D, 1338
Byers P, 15

C Calabrese LH, 114, 217, 569, 1453 Calin A, 77, 158, 1221 Callahan LF, 531 Calomiris JJ, 870 Campo E, 884 Candido EPM, 919 Cannon GW, 964 Cappellacci S, 663 Capraro JA, 217 Carella G, 1624 Carette S, 158 Carlsten H, 1087 Carson DA, 72 Cassar G, 355 Castillo R, 1153 Castillo-Ojugas A, 812 Catania A, 1186 Cats A, 1135 Cattaneo R, 1624 Caturla A, 406 Caudwell V, 393 Chalmers IM, 96, 1631 Chamorro MJ, 406 Chapdelaine JM, 1022 Charrière G, 814

Chastain RL, 37, 91 Cheek R, 1315 Chen PP, 72 Cheung HS, 1014 Cho F, 748 Christensson B, 1268 Cid MC, 884 Clague RB, 139 Clark SR, 454 Clark WS, 112 Clayburne G, 271 Clements PJ, 212, 584, 1632 Clerc D, 660 Clough JD, 114 Cobeta JC, 934 Codding C, 1563 Cogen L. 964 Cohen AS, 82 Cohen AH, 513 Cohen JHM, 393 Cohen MR, 734 Cohen MF, 1319 Cohen PL, 1055 Cohen SA, 964 Collins I, 139 Collins RD, Jr., 1490 Colwell CW, Jr., 797 Combe B, 10 Connor JR, 279 Conte C, 151 Cooperstein L, 776 Cornélis F, 785 Cowchock FS, 1572 Crapper RM, 251 Craven SY, 1315 Cremer MA, 748 Cronan TA, 1604 Cuesta AJ, 386 Curd JG, 1233

Daha MR, 1191
Dahlberg L, 1434
Dalton BJ, 279
Daniel WW, 341, 767
Darmon N, 1477
Dauphinée MJ, 420
David CS, 105
Davis TE, Jr., 1308
Day N, 151
Dayer J-M, 173
de la Concha EG, 406
de Wilde PCM, 1214
Dean DD, 759, 1300
Deguchi Y, 247
Deicher H, 914

Delaporte P, 1470 Delgado EA, 1007 Denes A, 964 DeRemee RA, 1051 Desai N. 61 Desai BV, 1371 Dessypris EN, 638 Dett CA, 1148 DeVellis RF, 991 Diat F, 998 Dieppe P, 1339 Dippell J, 643 Doherty M, 1339 Dorner RW, 699 Doshi H. 236 Doughty RA, 1041 Dowdy MJ, 343 Downey DJ, 1050 Duston MA, 82 Dwek RA, 235

Earnshaw WC, 1315 Ebling FM, 513 Egger MJ, 508 Eichenfield AH, 480 Eiraku N, 1342 Eisenberg RA, 1315 Elkon KB, 1252 Elliott TG, 352 Elswood J, 77, 1221 Emery P, 795 Emkey RD, 964 Emlen W, 298 Ercilla G, 884 Erickson AD, 1175 Erlendsson K. 906 Espinoza LR, 1615 Estes M. 569 Eulderink F, 510

Faaber P. 1521 Faller B. 785 Fam AG, 741, 1198, 1335 Fantozzi R, 859 Farinati A, 1053 Fauci AS, 1626 Fawcett PT, 1041 Feighery C. 361, 523, 682 Feldmann M, 955 Felson DT, 166, 1093 Ferraccioli GF, 1624 Fiechtner JJ, 194 Fifield J, 538 Figueredo MA, 406 Firestein GS, 1074 Firschein HE, 844 Fishleder AJ, 569 Fishman AB, 358 Ford DK, 1186

Forrest MJ, 608 Fosmire S, 937 Fournie A, 355 Fournie B, 355 Fournier C. 31 Fox A, 1268 Fox R. 859 Francis DJ, 608 Frank RG, 984 Fraser P, 1592 Freedman RR, 61 Freimark B, 859 Fremont-Smith K, 507 Fries JF, 837 Fritzler MJ, 877 Fu SM, 826 Fuchs HA, 531 Fujimoto K. 748 Fujiwara H, 594 Fukuda T, 748 Fung M, 919 Furst DE, 115, 212, 584, 1631

Galeazzi M. 663 Garancis JC, 734 García-Morteo O, 1053 Gates RH, 475 Gauthier VJ, 298 Gay RE, 1458 Gay S. 1458 Gazapo E, 406 Gepner P. 31 Gerber LH, 625 Gerfaux J, 430 Germain BF, 1615 Gershwin ME, 1031 Ghai OP, 1492 Gherardi RK, 1470 Ghosh P, 608 Giannini EH, 1054, 1185 Gibson T, 359 Gilbart J, 1268 Ginsburg WW, 503, 1630 Giorno R. 475 Gladman D, 1338 Glass CA, 72 Glon Y, 660 Goeppinger J, 706 Goglia G. 807 Goldberg L, 454 Goldberg RL, 312 Goldenberg DL, 496, 1487 Goldman JA, 358 Goldsmith DP, 480 Goldsmith CH, 1505 Goldstein IM, 1193 Goodenow C, 538 Goodman M, 776 Goren M. 491

Goronzy JJ, 1057 Graber SE, 638 Grady KE, 538 Granados J, 1465 Granfors K. 1494 Granger GA, 1148 Graninger W, 1515 Grav RG, 1487 Green SP, 461 Greer PK, 1539 Gregersen PK, 251 Gross WL, 1050 Gschwend N, 617 Guarnieri T, 1170 Guccione AA, 1546 Guerne P-A, 1443 Gullino PM, 625 Gutierrez F. 1615

Haapanen L, 1031 Hagglund KJ, 851 Hahn BH, 513 Hale LP, 22 Haley WE, 851 Halla JT, 652 Hamaoka T. 594 Hamidou M, 355 Hamilton RG, 413 Hammond A, 259 Hamuryudan V, 1494 Handler RP, 234 Hankinson B, 1572 Hanly JG, 523 Hannan MT, 166 Hannonen P. 511 Hansen JA, 826 Hara H, 552 Hara M, 1427 Harats N, 1325, 1474 Hardin JG, 652 Hardingham T, 601 Harigai M, 1427 Harley JB, 413, 826, 1414 Harper FE, 998 Hartman JH, 661 Hartmann DJ, 814 Hartmuth K, 1515 Hartner S, 1390 Hartung K, 914 Hascall VC, 1197 Hashimoto H, 1554 Hashimoto T, 1629 Haskard DO, 116 Hassan J, 523, 682 Hassfeld W, 1515 Haug BL, 1045 Hay FC, 235 Haynes BF, 22 Healey LA, 15

Heinegård D, 1080, 1434 Helewa A, 1505 Helfrich DJ, 776, 1128 Helminen HJ, 1282 Henderson B, 601 Hendricson WD, 1153 Hené RJ. 1214 Herberts P. 1087 Hernández IR, 812 Heurkens AHM, 1191 Hewett JE, 1396 Heyman S, 480 Highton J, 947 Hirata S, 1065 Hirohata K, 1065 Hirose S, 1554 Hirose T, 1427 Hirose W. 1427 Hirschowitz BI, 926 Hillis S, 584 Ho G, Jr., 86 Hochberg MC, 870, 1170, 1340, 1584 Hochkeppel H, 914 Hoffman GS, 1626 Holden D. 217 Holman HR, 37, 91 Holt PJL, 139 Honjo S, 748 Horgan C, 298 Horisberger M, 914 Howe S, 1390 Howell DS, 759, 1300 Hrnčíř Z, 505 Huang GQ, 1458 Hugenberg ST, 468 Hughes TP, 813 Humburg Ch, 643 Hungerford DS, 801 Hunt DWC, 1007 Huppert AS, 1489 Husby G. 437

I Iftekhar A, 1572 Igarashi T, 552 Ijichi S, 1342 Ilowite NT, 265 Inbal A, 491 Ingelmo M, 884 Ininns EK, 1148 Inoue T, 1233 Isenberg DA, 235

Jabs DA, 870 Jacobson JM, 1153 Jacoby RK, 117 Jaffer AM, 964 Jakschies D, 914 Janssen B, 933

Heck DA, 1142

Jeffery R, 100
Jeffes EWB, III, 1148
Job-Deslandre C, 1188
Johnson RJ, 358
Johnson RJ, 298
Johnson WJ, 279
Jokinen I, 511
Jones P, 813
Jones VE, 117
Joosten LAB, 66, 894
Joret A-M, 430
Juji T, 691
Jurvelin J, 1282

Kahaleh MB, 817 Kahan A, 430 Kahan A, 430 Kaine J, 513 Kallman DA, 1584 Kalovidouris AE, 446, 1179 Kalunian K, 108, 513 Kanayama Y, 1233 Kannel WB, 166 Kano S, 1356 Kantor G. 1489 Kaplan SR, 86 Kaplan RM, 1604 Kapur S, 717 Kasahara T, 1356 Kashiwagi H, 1528 Kater L, 1214 Katz BP, 45, 1577, 1627 Kawagoe M, 1427 Kawakami M, 1427 Kay DR, 1396 Kay GI. 1202 Kazatchkine MD, 393 Keat A, 437 Keil JE, 998 Kerolus G, 271 Kerr LD, 1406 Khan AS, 322 Khan MA, 1135 Kimberly RP, 717 Kingsley GH, 116 Kinsella MB, 577 Kipps TJ, 72 Kakham BW, 359 Kishimoto S, 247, 552 Kitajima I, 1342 Kitani A. 1427 Kitas GD, 795 Kiviranta I, 1282 Klareskog L, 1087 Klasen IS, 330 Kleinau S, 306 Klouda PT, 1221 Kluve-Beckerman B, 1325 Koda S, 1233

Kodama A, 1554

Kolarz G, 1515 Konda S, 234 Kono I, 1528 Koo AP, 114 Koopman WJ, 236, 1087 Korenzwitt E, 661 Kozin F, 1604 Krakauer KA, 1273 Krantz SB, 638 Kratz LE, 1597 Krause E, 10 Kremer JM, 115, 121, 813, 1202 Krieg AM, 322 Kuhlein E, 355 Kujala GA, 236 Kuntz D, 785, 1492 Kuritani T, 552

Kwoh CK, 128, 1341 Labropoulos PA, 625 Lachenbruch PA, 584 LaCour E, 1371 Ladestein RMT, 330 Laffon A, 386 Lahesmaa-Rantala R, 1494 Lakhanpal S, 1630 Lally EV, 86 Laposata M, 1273 Larson MG, 1107 Lasky HP, 117 Lassoued S, 355 Laukaitis JP, 119 Lavilla P, 1421 Lawley TJ, 1179 Laxer RM, 877 Leavitt RY, 1626 Lee F, 594 Lee JE, 358 Lee RG, 121 Lee S. 251 Lee JS, 1045 Lehman TJA, 1414 Leipold HR, 312 Lenz ME, 100 LeRoy EC, 577, 817, 998 Leventhal LJ, 506 Levi-Strauss M, 393 Levin KH, 569 Levinson J, 1390 Li JZ, 726 Li X, 1165 Liang MH, 1107 Lilly M, 901 Lipsky P, 937, 1345 Liu M-F, 72 Lockshin MD, 665 Lohmander LS, 1434 Loizou S, 259

Lomeo RM, 1625

López-Longo FJ, 934 Lorig K, 37, 91 Lotz M, 1443 Louie JS, 513 Lovell DJ, 1185, 1390 Lowther DA, 461 Lubeck D, 91 Lulli P, 663 Lupoli S, 1262 Lust G, 312 Lydyard PM, 235

MacDougall B, 96 Macfarlane JD, 510 Mackay IR. 509 Mackenzie AH, 114 Mackenzie L, 235 Mackiewicz A. 347 Mackiewicz SH, 347 Maddison PJ, 1623 Maeda H. 691 Mahowald ML, 974 Mahowald MW, 974 Maini RN, 811, 955 Malaviya AN, 1492 Maldonado-Cocco JA, 1053 Malleson PN, 919, 1007 Malone DG, 357 Mangone I, 1186 Mannik M, 298, 544, 1601 Maricq HR, 998 Mariette X, 660 Martel-Pelletier J. 181 Martin ME, 22 Martin-Mondiere C. 1470 Martinez C. 1465 Martinez-Laso J, 1421 Maruyama I, 1342 Maruyama Y, 1342 Matsubara T, 1065 Matsui Y. 1528 Matsuki K, 691 Matsuta K., 691 Matsuyama T, 398 Matteson EL, 356 Maury CPJ, 146 Mayes M, 61 Mayne R, 241 Mazanec DJ, 114 Mazzilli MC, 663 McCachren SS, 1539 McCafferty JP, 158 McCarty DJ, 807 McCollum DE, 22 McConnell RJ, 1344 McGee N, 1458 McGirr G, 1390 McGregor AR, 998 McHugh NJ, 1623 McLaughlin GE, 807

McNeilage LJ, 54, 1165 McNeill TW, 100 Means RT, Jr., 638 Medsger TA, Jr., 151, 1128 Meenan RF, 82, 166, 844, 1093, 1546 Mehra NK, 1492 Mehraban F, 1293 Menchions B, 1505 Menkès CJ, 430, 1188 Merry P, 1053 Merryman PF, 251 Mervhew NL, 717 Messina OD, 1053 Meyer FA. 173 Mikolich DJ, 1175 Milano R, 1100 Miller BL, 584 Miller DR, 194 Miller KS, 577 Miller FW, 1179 Mimori A, 691 Mimura Y, 1342 Minato N, 1356 Minor MA, 1396 Mitrovic DR, 1477 Miyagi J, 1356 Miyamoto T, 691 Miyasaka N. 811 Mond CB, 202 Monteagudo I, 934 Moore ME, 661 Moore TL, 699 Moore SB, 1630 Mor F. 491 Morales TI, 1197 Moreland LW, 1458, 1631 Moreno F, 1421 Morgan K, 139 Morgan SL, 113 Morgan SL, 1268 Moriarty M, 523 Morimoto C, 398 Moskowitz RW, 1293 Motta P, 186 Möttönen T. 511 Moxley G, 634, 1365 Mozes E, 370 Mueller MN, 1185 Muniz OE, 759, 1300 Murray LM, 378 Myers SL, 468, 1142

N Naff GB, 1119 Nagai Y, 748 Naimark A, 166 Nakamura H, 1427 Nakano K, 691 Needleman BW, 1597 Negoro S, 247, 552 Negoro N, 1233 Nelson D, 454 Nepom BS, 15 Nepom GT, 15 Neri TM, 1624 Neville C, 1160 Ng SC, 212 Nicholas JJ, 776 Niedel JE, 1539 Nigra TP, 343 Noel LH, 785 Nordstrom DM, 205, 475 Norioka K-I, 1427 Nuñez JM, 934 Nunley JA, 22 Nussbaum AI, 998

O'Brien AE, 1041 O'Connor GT, 128, 1341 O'Connor BL, 1142 O'Neil VL, 638 Oka M, 511 Okamura M, 1233 Okane M, 1528 Okubo F. 748 Oldstone MBA, 437 Olmstead EM, 128, 1341 Olsen NJ, 378, 638 Omoto K, 691 Ortíz de Landázuri M. 386 Osame M, 1342 Osborn TG, 699 Ossorio C, 386

Pahlavani M, 1371 Pahle JA, 437 Palacin A, 884 Pallela TD, 356 Palmer DG, 947 Panavi GS, 116 Panosian-Sahakian N, 513 Parekh RB, 235 Parker JC, 984 Parnassa AP, 1252 Pascual D. 1421 Pascual-Salcedo D, 406 Pascuzzi RM, 1308 Passo MH, 446, 1325 Patberg WR, 1627 Paul WA, 236 Pauls JD, 877 Paulus HE, 212, 584, 1328 Pawlowski T, 347 Peck JR. 1100 Pelletier J-P, 181 Perkins AD, 1453 Pernice W, 643 Perren S, 617 Pescio A. 1053

Peter JB, 1334 Peterson MGE, 202 Petropolis AA, 475 Pettipher ER, 601 Petty RE, 919, 1007, 1414 Phelps P, 936 Phillips LR, 984 Phinn SD, 139 Pidrman V, 505 Pincus T. 531, 638 Pincus SH, 964 Pitzalis C, 116 Plotkin Z, 446 Plotnick S, 1489 Plotz CM, 936 Polisson RP, 1226 Pope RM, 117, 1371 Poppo MJ, 1487 Porter J, 454 Portier M. 505 Posner L, 1604 Pourmand R, 446 Pratta MA, 288 Presno-Bernal M. 134 Prihoda TJ, 1153 Proffitt MR, 569 Provost TT, 1170

Quinn L, 1325

Rademacher TW, 235 Rader MD, 1563 Ragsdale BD, 625 Rahn B, 617 Ramsey-Goldman R, 151 Ratcliffe A, 601 Rautiainen J, 511 Raymond P, 785 Reading JC, 508 Reddy VB, 475 Regan-Smith MG, 128, 1341 Reichlin M, 413, 826, 1414, 1563 Reid GD, 352 Reisine ST, 538 Rème T. 505 Rentsch H-U, 1135 Resnik CS, 1484 Reveille JD, 413, 851, 1243 Reynolds MD, 1490 Rhoads DD, 1252 Richardson ML, 1050 Riera H, 1477 Rivera J. 934 Robinson WP, 1135 Rogan A, 1153 Roitt IM, 235 Rook G, 235

Rooney M, 361

Roos KL, 1308 Rosal EJ, 998 Rothfield NF, 202, 1315 Rottembourg J, 785 Roubinet F. 355 Roufa DJ, 1252 Rowley MJ, 509 Rozenberg MC, 813 Rubenstein J. 741 Rubin RL, 205 Rudge AC, 259 Ruiz-Arguelles A, 134 Runquist OA, 717 Russell RGG, 780 Russell A. 1135 Russell IJ, 1153 Ryan LM, 1014 Ryd L, 1434

Säämänen A-M, 1282 Sabando P, 386 Sabharwal SC, 61 Saiki O. 552 Sakamoto M, 1554 Salama J, 1470 Salmon JE, 717 Salmon M, 795 Salmonson KL, 677 Sambol S, 1371 Sánchez-Madrid F. 386 Santner TJ, 1414 Sany J, 10, 505 Saura R, 1065 Savi M, 1624 Saway A, 113, 946 Saxne T, 1080 Schalkwijk J, 66, 789, 894 Scheetz RJ, 114 Scherak O, 1515 Schindera F, 643 Schindler JD, 964 Schlossman SF, 398 Schmid FR, 815 Schmitz KL, 1148 Schned ES, 1493 Schnitzer TJ, 100 Schrieber L. 933 Schroeder M-L, 1007 Schrohenloher RE, 236, 1243 Schuchmann L, 643 Schulman P. 1406 Schumacher HR, Jr., 271, Schur PH, 1107, 1465 Schwimmbeck PL, 437 Scott DL, 523 Scott WW, Jr., 1584 Sebastiani GD, 663

Segal AM, 114 Segal R, 370 Seibold JR, 1022 Seki N. 594 Seleznick M. 91 Senaldi G, 1262 Senoh H, 594 Sestak AL, 826 Seth V, 1492 Seyfried C. 15 Sharp JT, 221 Shear E, 1390 Sheerin KA, 1054 Sherry DD, 677 Shimozuru Y, 748 Shimuzu S, 234 Shiroky JB, 1160 Shmerling RH, 1495 Shoor S, 37 Schulte M, 1390 Sibley JT, 1045 Silver RM, 577, 817, 1625 Silverman E, 877, 1414 Simkin PA, 1050 Singer KH, 22 Singh G, 837, 1492 Singsen BH, 1494 Sinha S, 72 Skinner M. 82, 1325 Slootweg PJ, 1214 Slowman-Kovacs SD, 486 Smarr KL, 984 Smedegård G, 306 Smith DL, 770 Smith EA, 577, 817, 998 Smith JB, 1572 Smith TW, 1100 Smolen JS, 1515 Smythe HA, 1505 Socher SA, 1107 Soden M. 523 Southwood TR, 1007 Specht D, 454 Spencer CH, 1414 Spiera H, 1406 Spitz P, 837 Springer TA, 22 Stage D, 15 Starkebaum G, 194 Steen VD, 151, 1128 Steinberg AD, 322, 398 Steiner G, 1515 Steinman CR, 726 Steinsson K, 906 Steppat D, 1050 Sterz MG, 584 Stewart T, 1458 Stieglitz H, 937 Stone WJ, 638 Subiza JL, 406 Suemura M. 552

Sebes JI, 338

Sugai S, 234 Sulaiman AR, 734 Sumar N, 235 Sumiya M, 1356 Suschke J, 643 Suzuki H, 1528 Suzuki K, 1427 Suzuki Y, 1487

Tachibana J, 234 Tait BD, 509 Takai Y, 594 Takasaki Y, 1554 Takeda T, 1233 Takeuchi F. 691 Takeuchi A. 1629 Talal N, 420 Tammi M, 1282 Tan WD, 510 Tan EM, 924 Tanaka H. 748 Tanaka S, 398 Tanaka T, 552 Taneja V, 1492 Tanigaki N, 663 Tarkowski A, 1087 Tartakovsky B, 370 Tate G, 1273 Tateishi M, 811 Tateishi H, 1065 Taylor AJ, 1170 Taylor PW, 1312 Tebib JG, 1465 Tengblad A, 306 Teppo A-M, 146 Terato K, 748 Terkeltaub R, 1443 Thomson GTD, 96 Thomson G, 1135 Thonar EJ-MA, 100, 647 Thumb N, 1515 Tierney WM, 1577 Tiliakos NA, 115

Tincani A, 1624 **Tobin JD**, 1584 Toivanen A, 1494 Tokunaga K. 691 Tolman KG, 121 Tomana M, 236 Tosi R, 663 Tourliére D. 785 Tovar Z, 420 Tracy IC, 671 Trentham DE, 1495 Trojanowska M, 817 Truckenbrodt H, 643 Tsai V, 1381 Tsuchiya N, 437 Tubbs RR, 569, 1453

U Ung E, 37, 91 Urowitz MB, 1054 Uwatoko S, 544, 1601

Valdimarsson H, 906 van Beuningen HM, 789 van de Putte LBA, 66, 789, 894, 1521 van de Water J, 1031 van den Berg WB, 66, 330, 789, 894, 1521 van den Bersselaar LAM. 1521 van der Linden SM, 1135 van Houwelingen JC, 1214 van Kerckhove C, 1185 van Wyk J, 66 Vasey FB, 1615 Vazquez-Rodriguez JJ, 1421 Venables PJW, 811 Vergani D, 1262 Verger C, 785 Veum JA, 1014 Viard J-P. 1470 Vicario JL, 1421

Vignon E, 814 Vilaseca J, 884 Villalta J, 884 Ville G, 814 Visco DM, 1142 Vitek J, 652 Vivino FB, 480, 560 Vogel P, 643 von Wusso P, 914 Voorneveld C, 1335

Walker SE, 984 Wallace CA, 677 Wallace DJ, 1334 Wallin BA, 158 Wallston KA, 991 Walport MJ, 259 Ward JR, 508, 1055, 1100 Ward MM, 1226 Watanabe H, 748 Watson PH. 96 Watts CS, 1160 Weaver AL, 964 Webb J, 1319 Webel RR, 1396 Wedgwood JF, 265 Wedgwood RJ, 677 Weinberger M, 1577 Weinblatt ME, 116, 1592 Weinrich MC, 998 Weinstein A. 114 Weissman BN, 116 Weissman G, 1 Wener MH, 544 Wenig P, 61 Wernick R, 770 West SG, 205 Weyand CM, 1057 Whalen JD, 1022 Whelan A, 361, 523, 682 White CS, 114 Whittingham S, 54, 1165 Wigley FM, 870, 1584

Wilder RL, 357 Wilke WS, 114, 1453 Williams HJ, 508, 1093 Williams RC, Jr., 437 Williams CA, 837 Willis LG, 826 Willkens RF, 1055 Wilske KR. 15 Winchester RJ, 251 Winfield JB, 1330, 1497 Wisnieski JJ, 1119 Wolfe F, 964 Wood B, 1007 Wool IG, 1252 Wooley PH, 1022 Wormslev SB, 1334 Worth RM, 1474 Wortmann RL, 734, 1014 Wysenbeek AJ, 491

Y
Yamamoto K, 811
Yamamoto RS, 1148
Yamanaka K, 1554
Yamane K, 1558
Yamaoka K, 811
Yamauchi K, 1487
Yaron I, 173
Yaron M, 173, 370
Yazici H, 1494
Yen-Lieberman B, 569
Yokota T, 594
Youngchaiyud U, 54
Ytterberg SR, 974
Yurdakul S, 1494

Z Zanelli P, 1624 Zanussi C, 1186 Zelenski JD, 217 Zimmermann B, 86, 1175 Zuraw B, 1443 Zurier RB, 1273 Zvaifler NJ, 1074, 1381

SUBJECT INDEX

Arthritis and Rheumatism, Volume 32, Numbers 1 through 12, 1989

A

Abdominal fat, in diagnosis of amyloidosis, 82 Abortion

missed, hepatic infarction, lupus anticoagulant and, 491 spontaneous, HLA-DR5 and paternal leukocytes in, 1572 Acetaminophen, mechanisms of action of, 1

Acetone-precipitable Mycobacterium tuberculosis antigen complex, antigen specificity in RA SF and, 1371

Acquired immunodeficiency syndrome (AIDS)

inflammatory myopathy and, 475 septic acromioclavicular arthritis and osteomyelitis in, 1175

Actinomycin D, collagenase mRNA, IL-1 and, 1539
Activities of daily living, simplified articular index in RA and, 531

Acute peritendinitis calcarea, 767 Acute-phase proteins, IL-6 and, 1443

Acute rheumatic fever and coexistent acute glomerulonephritis, 230, 236

Adenosine deaminase deficiency, deoxyadenosine toxicity in rabbit cartilage and, 1014

Adenylate cyclase, chondrocytes, insulin-like growth factor 1 and, in experimental arthritis, 894

Adherent cells, IL-2 inhibition in SLE and, 1356

Adjuvant arthritis, serum hyaluronate and disease activity in, 306

Adverse reactions

to auranofin in psoriatic arthritis, 158 to azathioprine in RA, 837

CNS toxicity after methotrexate, 770

to NSAID, in the upper gastrointestinal tract, 926

Aerobic exercise, in RA and OA, 1396 Aerobic fitness, in fibrositis, 454

Affinity electrophoresis, α_1 -acid glycoprotein in infection in RA studied by, 347

antigen-induced arthritis in C57Bl/10 mice and, 789 arthritis in nursing home residents and, 1546 meta-analysis in older-onset SLE and, 1226 in OA, 166, 312

RF, HLA-DR4 and, in destructive arthritis, 1221 Age at onset

in AS, 77

in juvenile psoriatic arthritis, 1007

Albumin

electron microscopic analysis of liver biopsy in RA and, 1202

flare reactions of joint inflammation in mice and, 330

Alcohol consumption in RA, 121, 1202

smoking in OA and, 166

Alkaline phosphatase, electron microscopic analysis of liver biopsy in RA and, 1202

Alleles, procollagen gene restriction fragment length polymorphisms in scleroderma and, 1597 Allogenic mixed leukocyte reactions, T cells, dendritic cells and, 1381

Alopecia, older-onset SLE and, 1226

α-adrenergic responses, in idiopathic Raynaud's disease, 61 Alpha-methyldopa-induced systemic vasculitis, confused with Wegener's granulomatosis, 356

α₁-acid glycoprotein, in infection in RA, 347

 α_2 -plasmin inhibitor-plasmin complex, in rheumatic diseases, 1427

Alu sequence, plasma DNA in SLE and, 726

Alveolar macrophages, production of fibronection by, in SSc, 577

Alveolitis, fibronection production by alveolar macrophages in SSc and, 577

American College of Rheumatology (ACR)
Arthritis Patient Education conference, 1330

Audiovisual Aids Subcommittee, 503 drug company "honoraria" and, 1490

goals of, 936

Presidential Address, 1193

slide competition and collection, 503 American Rheumatism Association (ARA)

criteria for SLE, clinical assessment of disease activity in,

functional class, articular index in RA and, 531

Medical Information System (ARAMIS), 837

Amino acids

class II major histocompatibility complex genes in RA and, 251

cross-reactive antiidiotypic antibodies, RF and, in JRA, 699

immunoglobulin V_H genes, human RF and, 72

2-Md plasmid from Shigella flexneri in reactive arthritis and, 937

Aminotransferase, liver histology, rectnotrexate and, in RA, 121

Animonium sulfate precipitation, Ki antigen in SLE and, 1554

Amyloidosis

abdominal fat in, 82

 β_2 -microglobulin, in peritoneal dialysis, 785

hereditary, 1474

lack of restriction fragment length polymorphism for amyloid P gene in, 1325

Analgesic drugs, labeling of, 1328

Anemia

autoimmune hemolytic, CR1, anticardiolipin antibodies in SLE and, 259

hemolytic, 205, 1128

recombinant human erythroipoietin therapy in RA and, 638

Angiitis

benign lymphocytic, systemic vasculitis in HIV infection and, 569

cerebrai, in Behçet's syndrome, 217

Angiitis (cont'd)

CNS, infectious complication of cyclophosphamide in, 45, 1626

Angiocentric immunoproliferative disorders, systemic vasculitis in HIV infection and, 569

Angioedema, IgG anti-C1q and, in hypocomplementemic urticarial vasculitis syndrome, 1119

Angiography

in vasculitis, 217, 503

Animal studies. See also Bovine, Canine, Chicken, Pond-Nuki dog model, Mouse, Rabbit, Rat

serum hyaluronate in experimental models of arthritis, 306 Ankle, in retinyl acetate-induced arthritis in mice, 625

Ankylosing spondylitis (AS)

cross-reactive epitopes in, 437

genetics and environmental factors in, 77

HLA-B27+, HLA-Bw60 in, 1135

juvenile, definition of, 1054

large granular lymphocytes and neutropenia in, 355 methotrexate in, 234

9.2-kb Pvu II restriction fragment length polymorphism and, 870

Anserine bursal distention, diagnosis of, by ultrasonography and CT, 1335

Anterior cruciate ligament

in OA, 181, 486, 637, 759, 1142, 1300 proteoglycans in knee joint and, 1434

Anterior uveitis, chronic, in juvenile psoriatic arthritis, 1007 Anti-denatured collagen, anticollagen antibodies in RA and, 139

Anti-B23, major nucleolar phosphoprotein B23, anticardiolipin antibodies and, 1165

Anti-B2-microglobulin, in peritoneal dialysis, 785

Antibiotics, Borrelia burgdorferi in reactive arthritis and, 1057, 1182

Antibodies

anti-C1q, 1119

anticardiolipin, 259, 665, 813, 1165, 1490 anticollagen, 139, 1007, 1022, 1087

anti-DNA, 406

anti-dsDNA, 259

anti-endothelial cell, 1191

antigen-induced arthritis in C57Bl/10 mice and, 789

antihistone, 919, 1319 antiidiotypic, 134, 513, 699

anti-IFN, 914

anti-Ki, 1554 anti-La, 1226

antilymphocyte, 398, 1572

antineutrophil, 194 anti-nRNP, 1243

antinuclear, 54, 205, 413, 877, 919, 1007

antinucleolar, 1165

antiphospholipid, 359, 1053

antiribosomal S10, 1252

anti-Ro, 202

anti-Yersinia, 1494

in bone marrow proliferation in SLE and aplastic anemia, 901, 924

cell adhesion molecules and, 22

to collagen-like region of C1q in SLE, 1601

Antibodies (cont'd)

effects of methotrexate on peripheral blood mononuclear cells and 378

HLA-DR5 in spontaneous abortion and, 1572

IL-2 inhibition in SLE and, 1356

IL-6 and, 1443

immunoglobulin idiotypes in SLE and, 513

lymphotoxin and tumor necrosis factor in normal serum and, 1148

maternal Ro (SS-A) in childhood SLE and, 1414

monoclonal, 66, 251, 361, 406, 420, 513, 901, 924, 947, 1031, 1233, 1293, 1427, 1458

nRNP (U1 RNP), 1170

polyclonal, 1601

production of, by immunomodulatory molecules, 1345

specificity of anti-Ro (SS-A) and, 1563

synthesis of, effects of methotrexate on peripheral blood mononuclear cells and, 378

U1 RNP, 1170

Anti-Borrelia burgdorferi, immune responses in reactive arthritis and, 1057, 1182

Anti-C1q, IgG, in hypocomplementemic urticarial vasculitis syndrome, 1119

Anticardiolipin antibodies

in arterial thrombosis, after pyelography, 1490

hypergammaglobulinemia and, 813

major nucleolar phosphoprotein B23 and, autoantibodies to, 1165

in SLE, 259, 665, 1623

Anti-CD3, 420, 1371

Anti-CD5 monoclonal antibody, CD3 and CD5 in Sjögren's syndrome and, 420

Anti-CENP-B anticentromere autoantibody, isotype analysis of, 1315

Anticollagen

antibodies, 139, 1007, 1022

C1q and, in autoimmune rheumatic diseases, 544 in collagen arthritis in monkeys, 748

in synovial tissue in RA, 1087

Anti-DNA

antibodies, DNA-anti-DNA complexes in SLE and, 406 binding of dsDNA to glomeruli in rats and, 298 immunoglobulin idiotypes in SLE and, 513

Anti-dsDNA

antibodies, CR1, anticardiolipin antibodies and, in SLE, 259

disease heterogeneity model in SLE and, 826

subacute cutaneous LE during PUVA for psoriasis and, 343

Anti-endothelial cell antibodies, in rheumatoid vasculitis,

Antigen-induced arthritis

in C57Bl/10 mice, 789

cartilage proteoglycans in, 601

Antigens

ANA, histones and, in JRA, 919

anti-CENP-B anticentromere autoantibody analysis and, 1315

anti-LFA-3, 22

Antigens (cont'd) anti-RA33, in RA, 1515 B-L (Ia), 1031 binding of dsDNA to glomeruli in rats and, 298 Borrelia burgdorferi, 1057, 1182 CD45R, 795 cell adhesion molecules and, 22 cognate, 901, 924 corticosteroids, cell subsets and, in temporal arteritis, 884 cross-reactive, 437, 699 extractable nuclear, 54 flare reactions of joint inflammation in murine arthritis and, 330 HIV, 1615 HLA, disease heterogeneity model for SLE and, 826 HLA-DR, anticardiolipin antibodies and, in SLE, 1623 Ia, 1031 Ki, 1554 nuclear, 54 in RA, 139, 682, 947, 1371 S10 protein, 1252 viral, 569 Antiglobulin tests, CR1, anticardiolipin antibodies and, in SLE, 259 Antihistones antibodies, 919, 1319, 1515 in JRA, 877, 919 in SLE, 205, 406 Antihypertensive drugs, alpha-methyldopa-induced systemic vasculitis and, 356 Anti-ICAM-1, cell adhesion molecules and, 22 Antiidiotypic antibodies cross-reactive, RF and, 134, 699 immunoglobulin idiotypes in SLE and, 513 Anti-IFN antibodies, MX protein in mononuclear cells in SLE and, 914 Anti-IgG, anticollagen in RA and, 1087 Anti-IL-6, IL-6 production and, 1443 Anti-Ki antibody, in SLE, 1554 Anti-La in Sjögren's syndrome, 413 in SLE, 413, 1226, 1414 Anti-La (SS-B) in SLE, 826, 1243 specificity of anti-Ro (SS-A) and, 1563 Anti-LFA-3, cell adhesion molecules and, 22 Antilymphocyte antibodies HLA-DR5 in spontaneous abortion and, 1572 Antilymphotoxin, in normal serum, 1148 Anti-native collagen in RA, 139 in rabbit OA, 814 Anti-native DNA, in methyldopa-induced SLE, 205 Antineutrophil antibodies, methotrexate in neutropenia in Felty's syndrome and, 194 Anti-nRNP

in Sjögren's syndrome, 413

in SLE, 413, 826, 1170, 1243, 1414

specificity of anti-Ro (SS-A) and, 1563

Antinuclear antibodies (ANA) anti-RA33 in RA, 1515 histones and, in JRA, 877, 919 HLA-DR5 in spontaneous abortion and, 1572 in juvenile psoriatic arthritis, 1007 racial differences in scleroderma and, 54 in Sjögren's syndrome, 413 in SLE, 205, 413 Antinucleolar antibodies, major nucleolar phosphoprotein B23 and, 1165 Antiphospholipid antibodies, 359, 1053 syndrome, CR1, anticardiolipin antibodies and, in SLE, 259 Anti-RA33, in RA, 1515 Antirheumatic drugs review process for, 1328 synovial membrane lymphocyte infiltration in RA and, 361 Antiribosomal S10 antibodies, in SLE, 1252 Anti-RNA protein autoantibodies, disease heterogeneity in SLE and, 826 Anti-Ro in Sjögren's syndrome, 413 in SLE 202, 413 Anti-Ro (SS-A) in SLE 826, 1243, 1414 specificity of, 1563 Anti-S10 antibodies, in SLE, 1252 in Sjögren's syndrome, 413 in SLE, 413, 1252 Antispirochetes, ELISA in Lyme disease and, 1041 Anti-ssDNA in Sjögren's syndrome, 413 in SLE, 413, 826 Antithymocyte globulin therapy, in refractory RA, 1495 Anti-Yersinia antibodies, in Behçet's disease, 1494 Anxiety, physical conditioning and, 1396 Aorta, dissection of, in temporal arteritis, 504 Apatite-like crystals, in SF after arthrocentesis, 271 Aplastic anemia, bone marrow proliferation and, in SLE, 901, 924 Arachidonic acid, suppression of synovial cells by dihomoy-linolenic acid and, 1273 Arteparon, cartilage degradation by, 608 Arteries α-adrenergic responses in Raynaud's disease and, 61 corticosteroid, cell subsets and, in temporal arteritis, 884 internal carotid, spontaneous dissection of, in polyarteritis nodosa, 1625 renal, binding of dsDNA to glomeruli of rats and, 298 thrombosis of, anticardiolipin antibodies and, after pyelography, 1490 Arteritis, temporal, 504, 884, 1308 Arthralgia, HIV infection and, 1615 **Arthritis** adjuvant, 306 antigen-induced, 601, 789 calcific periarthritis, 741 centers multipurpose, evaluation of, 1493 chronic, 37, 1074

Arthritis (cont'd) collagen, 306, 594, 748 destructive, 1221 examination of SF in. 271 experimental, 306, 617, 894, 1022 in hypocomplementemic urticarial vasculitis syndrome, 1119 infectious, 496, 1053, 1487 inflammatory, 617, 1022, 1074 in methyldopa-induced SLE, 205 in nursing home residents, 1546 peri-, 741 pristane-induced, 1022 psoriatic, 158, 1007, 1615 reactive, 437, 937, 955, 1057, 1080, 1615 research, microbiology in, 1186 retinyl acetate-induced, 625 in rheumatic fever and poststreptococcal glomerulonephritis, 236 self-care education in, 706 septic, 352, 496, 506, 1052, 1175, 1615 seropositive inflammatory, 1022 stress proteins, autoimmunity and, 1497 unconventional remedies for, 1604 Arthritis Foundation, 1330 Arthritis Health Professions Association, 1330 Arthritis Impact Measurement Scales (AIMS) in English-Spanish format, 1153 hand radiographs in disability assessment in RA and, 128, 1340 sensitivity of, 844 Arthritis Patient Education conference, 1330 Arthritis Self-Efficacy Scale, 37 Arthritis Self-Management Course, beneficial outcomes of, Arthrocentesis, examination of SF after, 271 Arthrography, in therapy of synovial cysts in zygapophyseal joints, 660 Arthropathy of Behçet's disease, "pencil-in-cup" deformities in, 1629 destructive, in peritoneal dialysis, 785 HIV-associated, 1615 Arthroscopic synovectomy for chronic knee synovitis, 10, 108 rheumatologists and, 108 Articular cartilage in canine OA, 181, 486, 647, 759 chondrocytes and insulin-like growth factor in, 66, 894 collagen in, 241 degradation of, 608, 647 deoxyadenosine toxicity in, in rabbits, 1014 in dogs after running, 1282 effect of tumor necrosis factor and y-IFN on, 780 matrix, in chondrolysis of hip joint in hemodialysis, 1477 proteoglycan metabolism in, 1197 in retinyl acetate-induced arthritis in mice, 625

glycosaminoglycan synthesis and, 173, 468

on, 780

Articular chondrocytes, effect of tumor necrosis and 7-IFN

Articular index, in RA, 523, 531 Articular involvement, in herpes zoster eruption, 506 Articular tissue, cross-reactive epitopes in AS and, 437 Artifactual crystals, in SF after arthrocentesis, 271 Aspartate aminotransferase, liver histology, methotrexate and, in RA, 121 Aspartate transaminase, electron microscopic analysis of liver biopsy in RA and, 1202 mechanisms of action and, 1 sensitivity of AIMS in RA and, 844 Athymic C57Bl nude mice, flare reactions of joint inflammation in, 330 Athymic (nu/nu) loci, in pristane-induced arthritis, 1022 Atlantoaxial subluxation, in psoriatic arthritis, 1338 Atlantooccipital joint, cervical spine in RA and, 652 Atrioventricular heart block, in SLE, 1170 Auranofin methylprednisolone and, in Felty's syndrome, 1188 in psoriatic arthritis, 158 Autoantibodies antibodies to collagen-like region of C1q in SLE and, 1601 anti-CENP-B anticentromere, isotype analysis of, 1315 in aplastic anemia, 901, 924 in collagen arthritis in monkeys, 748 in major nucleolar phosphoprotein B23, anticardiolipin antibodies and, 1165 in RA, 1087, 1515 racial differences in ANA in scleroderma and, 54 Ro, congenital heart block and, 1421 in SLE, 826, 901, 924, 1252 specificity of anti-Ro (SS-A) and, 1563 to stress proteins, arthritis, autoimmunity and, 1497 Autoimmune disease anticollagen and Clg in, 544 antihistone antibodies in RA and Felty's syndrome and, 1319 antilymphotoxin and antitumor necrosis factor in, 1148 effects of methotrexate on peripheral blood mononuclear cells and, 378 HLA-DR5 in spontaneous abortion and, 1572 hypocomplementemic urticarial vasculitis syndrome, 1119 major histocompatibility complex in, 509 multiple, predisposition to, 119 pristane-induced arthritis, 1022 retroviral transcripts in murine lupus and, 322 T cells in dermal lymphocytes in avian scleroderma and, 1031 Autoimmune reactions anticollagen in RA and, 1087 corticosteroids, cell subsets and, in temporal arteritis, 884 Autoimmunity collagen, in RA, 1087 in PM/DM with dermatitis herpetiformis, 1179 stress proteins, arthritis and, 1497 Autoradiography, effects of, on synovium and cartilage, 468 Avascular necrosis, core decompression of femoral head in, 797, 801

Azathioprine, toxic effects of, in RA, 837

B cells

antibody production by immunomodulatory molecules and, 1345

corticosteroids and, in temporal arteritis, 884

in RA, 3€1, 955, 1087

in reactive arthritis, 955

salivary gland lymphocytes in Sjögren's syndrome and, 859

in SSc, 430, 817, 1031

B-L (Ia) antigen, T cells in dermal lymphocytes in avian scleroderma and, 1031

Ba fragments, complement activation in SSc and, 1262 Bacteria, gram-negative, *Shigella*-associated plasmid in re-

active arthritis and, 937

Bacterial cell wall, detection of muramic acid by gas chromatography-mass spectrometry and, 1268

Bacterial infection, tumor necrosis factor in SLE and, 146 Baltimore Longitudinal Study of Aging, radiograph grading scales for OA of hand and, 1584

Beck Depression Inventory, disability and depression in RA

and, 1100

Behavior changes, beneficial outcomes of Arthritis Self-Management Course and, 91

Behçet's syndrome

anti-Yersinia antibodies in, 1494

cytotoxic drugs in CNS vasculitis in, 217 "pencil-in-cup" deformities in, 1629

Benign lymphocytic angiitis, systemic vasculitis in HIV infection and, 569

 β_2 -microglobulin amyloidosis, rheumatic diseases and, in peritoneal dialysis, 785

BfS, congenital heart block and, 1421 Bilingual (English-Spanish) AIMS, 1153

Bilirubin, electron microscopic analysis liver biopsy in RA and, 1202

Biology, stress proteins, arthritis, autoimmunity and, 1497 Biomechanics, gait in dogs after anterior cruciate ligament transection, 1142

Biopsy

in amyloidosis, 82, 1474

cell subsets, corticosteroids and, in temporal arteritis, 884 in eosinophilic fasciitis in siblings, 96, 1629

liver, 121, 356, 1202

muscle, in inflammatory myopathy and AIDS, 475

in RA, 361, 1202, 1453 renal, 230, 236, 513

of salivary gland lymphocytes, in Sjögren's syndrome, 859 skin, T cells in lymphocytes in avian scleroderma and, 1031

synovial tissue, polyarthritis in human T lymphotropic virus type I-associated myelopathy and, 1342 synovium, in synovial analysis in drug-induced lupus, 560 in vasculitis, 356, 1470

Bleeding, adverse reaction of NSAID in upper gastrointestinal tract, 926

Blood flow

in aerobic fitness in fibrositis, 454 α-adrenergic responses in Raynaud's disease and, 61 binding of dsDNA to glomeruli in rats and, 298 Blood pressure

α-adrenergic responses in Raynaud's disease and, 61 normal, in renal failure in SSc, 1128

Blood vessels

cytotoxic drugs in CNS vasculitis in Behçet's syndrome and, 217

inhibition of neovascularization by methotrexate and, 1065

Bone

changes in, in inflammatory arthritis in rabbits, 617 coccidioidomycosis of (desert rheumatism), 1608 deoxyadenosine toxicity in rabbit cartilage and, 1014 infection of, in septic arthritis and osteomyelitis in AIDS, 1175

involvement of, in retinyl acetate-induced arthritis in mice, 625

marrow, 813, 901, 924

in Paget's disease, etidronate disodium and, 776 resorption of, in experimental inflammatory arthritis, 617 scans, in childhood reflex neurovascular dystrophy, 480 subchondral, cysts in, in peritoneal dialysis, 785

Book Reviews

Arthritis and Allied Conditions: A Textbook of Rheumatology (McCarty, ed), 1056

Arthroscopy of the Knee (Chassaing), 360

Infections in the Rheumatic Diseases (Espinoza et al, eds), 815

Bor RF, immunoglobulin V_H gene and, 72

Borrelia burgdorferi, immune responses to, in reactive arthritis, 1057, 1182

Bovine studies

antigen-induced arthritis in C57Bl/10 mice and, 789 of cartilage, 288, 1080, 1197

flare reactions of joint inflammation in mice and, 330 insulin-like growth factor and chondrocyte metabolism, 66 specificity of anti-Ro (SS-A) and, 1563 viscosity of hyaluronic acid, 461

British Isles Lupus Assessment Group Scale, in clinical assessment of disease activity in SLE, 1107

Bronchoalveolar lavage, fibronectin production by alveolar macrophages in SSc and, 577

Bursa

anserine, distention of, diagnosis of, by ultrasonography and CT, 1335

deep infrapatellar, of knee, inflammation of, 1312 Bursitis, olecranon, chronic fungal, caused by *Penicillium*,

Buserelin, in SLE, 1186

C

C3d molecules, CR1, anticardiolipin antibodies and, in SLE, 259

C3H-A^{vy} mice, retinyl acetate-induced arthritis in, 625 C4d molecules, CR1, anticardiolipin antibodies and, in SLE, 259

C57Bl/6 mice, flare reactions of joint inflammation in, 330 C57Bl/10 mice, antigen-induced arthritis in, 789

Calcaneal spurs, in rheumatic diseases, 338

Calcifications, urate-mediated inflammation in nodal OA and, 86

Calcinosis, tumoral, 1484

Calcium pyrophosphate dihydrate (CPPD) crystals, 271, 1339, 1443

cAMP, suppression of synovial cells by dihomo-γ-linolenic acid and, 1273

Canine studies

alteration to articular cartilage after running, 1282 effects of radiation on synovium and cartilage, 468 gait after anterior cruciate ligment transection, 1142 of OA

corticosteroids, cartilage, and osteophytes in Pond-Nuki dog model, 181 glycosaminoglycan polysulfuric acid in, 759, 1300

salicylates in, 486

serum keratan sulfate and hyaluronate in, 312

Carbon monoxide diffusing capacity, fibronectin production by alveolar macrophages in SSc and, 577

Cardiac involvement, atrioventricular heart block in SLE, 1170

Carotid artery, internal, spontaneous dissection of, in polyarteritis nodosa, 1625

Carpal tunnel

biopsy, in hereditary amyloidosis, 1474 syndrome, in peritoneal dialysis, 785

Carpo:metacarpal ratios, radiographic outcome measures in RA and, 221

Carpometacarpal joint, radiographic grading scales for OA of hand and, 1584

Carrageenan, bone changes near joints in experimental arthritis and, 617

Cartilage

in canine OA

collagen in, 241, 1458

degradation of, 100, 139, 312, 780, 894

effect of chemonucleolysis on serum keratan sulfate and, 100

effects of radiation on, 468 erosions of, 181, 1458

glycosaminoglycan polysulfuric acid ester and, 759, 1300

keratan sulfate and, 100, 312, 647

IL-1, proteoglycans, and PGE₂ in, 288 insulin-like growth factor and, 66, 894

lesions of, 181, 647

matrix, protein in RA and, 1080

metabolism of, 66, 468 patellar, 894, 1282

protein in RA and, 1080

proteoglycans in, 601, 1434

rabbit, deoxyadenosine toxicity in, 1014

salicylates, chondrocytes and, 486

Caseinase, effect of tumor necrosis factor and γ -IFN on, 780 Catabolism, effect of chemonucleolysis on serum keratan sulfate and, 100

Catheters, in home central venous hyperalimentation in scleroderma bowel disease, 212

CD2 T cells, cell adhesion molecules and, 22

CD3, in Sjögren's syndrome, 420

CD3+ cells, in systemic vasculitis in HIV infection, 569

CD4 cells

corticosteroids and, in temporal arteritis, 884 in RA 31, 505, 795

in systemic vasculitis in HIV infection, 569

CD4+2H4+ cells, antilymphocyte antioodies against, in SLE, 398

CD4+,CDw29+ cells, response of, to dendritic cells, 1381 CD5, in Sjögren's syndrome, 420

CD8 cells

response of, to dendritic cells, 1381

in systemic vasculitis in HIV infection, 569

CD45R antigen, in RA synovium, 795

Cell adhesion molecules, immunohistologic analysis of, 22 Cell surface localization of stress proteins, arthritis, autoimmunity and, 1497

Center for Epidemiological Studies Depression Scale, validity of, in arthritis, 991

Central nervous system (CNS)

angiitis of, infectious complications of cyclophosphamide in, 45, 1626

dementia in temporal arteritis in elderly and, 1308 in inflammatory myopathy and AIDS, 475

Ki antigen in SLE and, 1554

toxicity, methotrexate and, 770

vasculitis of, cytotoxic drugs in, in Behçet's syndrome, 217

Central venous hyperalimentation, at home, in scleroderma bowel disease, 212

Centromeres

B fusion protein (CENP-B), isotype analysis of, 1315 racial differences in ANA in scleroderma and, 54

Cerebral angiitis, in Behçet's syndrome, 217

Cerebral vasculitis, angiography of, 504

Cervical spine

atlantoaxial subluxation in psoriatic arthritis and, 1338 in RA, 652

Chemonucleolysis, effect of, on serum keratan sulfate in humans, 100

Chicken studies, T cells in dermal lymphocytes, 1031

Childhood psoriatic arthritis, 1007

Childhood reflex neurovascular dystrophy, 480

Chlamydia, immune responses to Borrelia burgdorferi in reactive arthritis and, 1057, 1182

Chlorambucil, immunosuppression with, in SSc, 584, 1631 Chloroquine, IL-1 in cartilage and, 288

Cholesterol

lowering agents, in drug-induced rhabdomyolysis and polymyositis, 358

subcutaneous, crystal deposition, tophus formation and, 1190

Chondrocalcinosis

first descriptions of, 1339

IL-6 in, 1443

proteoglycan in knee joint and, 1434

Chondrocytes

in canine OA, 486, 1300

cartilage and, 468, 1014, 1197

effect of tumor necrosis factor and y-IFN on, 780

effects of radiation on, 468

insulin-like growth factor 1 in experimental arthritis and, 894

Chondroitin-4-sulfate, chondroitin-6-sulfate, articular cartilage after running in dogs and, 1282

Chondrolysis, of hip joint, in hemodialysis, 1477

Chondro-osseous dysplasia, deoxyadenosine toxicity in rabbit cartilage and, 1014

Chorea, in acute rheumatic fever and poststreptococcal glomerulonephritis, 235

Chronic arthritis, self-efficacy scale and, 37

Chronic fungal olecranon bursitis, caused by *Penicillium*, 239

Chronic inflammatory arthritis, 1074, 1497

Chymopapain, serum keratan sulfate, hyaluronate and, in canine OA, 312

Cigarette consumption, OA and, 166

Circulating immune complexes, pulse intravenous methylprednisolone in SLE and, 717

cis-encoded third diversity region of DR4 (Dw14) haplotype, in RA, 251

Class I HLA 9.2-kb Pvu II restriction length polymorphism, characterization of, 870

Clindamycin, in inflammatory myopathy and AIDS, 475 Clonidine, α-adrenergic responses in Raynaud's disease and,

c-myc, c-myb proto-oncogenes, in SSc, 430

Coccidioidomycosis of bone (desert rheumatism), 1608

Coffee consumption, smoking in OA and, 166 Cognate antigens, autoantigens and, 901, 924

Colchicine, in leukocytoclastic vasculitis, 1489

Collagen

arthritis, 306, 594, 748

C1q and, in autoimmune rheumatic diseases, 544 cartilage, 241

in cynomolgus monkeys, 748

in Cytomologus monkeys, 746 diseases of, α_2 -plasmin inhibitor-plasmin complex in, 1427 in OA, 759, 814, 1300

in RA, 139, 241, 1087, 1202, 1458

Collagenase

glycosaminoglycan polysulfuric acid ester in canine OA and, 759

IL-1 and, 279, 1539

Complement

activation of, 1233, 1262, 1406 in aplastic anemia, 901, 924

fixation of, in plasmacytoma of skull in immune complex vasculitis, 1470

in SLE, 259, 393, 398, 901, 924, 1465

Complement Clq

antibodies to collagen-like region of, in SLE, 1601 anticollagen in autoimmune rheumatic diseases and, 544 joint erosions and, in early RA, 511

Complement C2

deficiency of, plasma infusion therapy of, in SLE, 906 in RA, 691

Complement C2C, allele, in RA, 691

Complement C3

CR3 leukocyte adhesion molecules in RA synovial membrane and, 947

plasmacytoma of skull in immune complex vasculitis and, 1470

in SLE, 1233, 1406

in SSc, 1262

Complement C4

in RA, 691

in SLE, 259, 1406

in SSc, 1262

Complement C4A, in SLE, 1406

Complement C4AQ0, 691, 1421

Complement C4B5 allele, in RA, 691

Complement C5, hemolytic, in pristane-induced arthritis, 1022

Complementary DNA

autoantibodies to major nucleolar, phosphoprotein, anticardiolipin antibodies and, 1165

CR1 expression in SLE and, 393

 $DQ\beta$, in RA, 251

immunoglobulin VH genes, human RF and, 72

Computed tomography (CT)

cervical spine in RA and, 652

diagnosis of anserine bursal distention by, 1335 in hepatic infarction and lupus anticoagulant, 491

Concanavalin A, α_1 -acid glycoprotein in infection in RA and, 347

Congenital heart block immunogenetics, 1421

Connective tissue, human cytokines in glycosaminoglycan synthesis and, 173

Connective tissue disease

HIV infection and, 1615

response of peripheral blood mononuclear cells to muscle in PM/DM and, 446

T cells in dermal lymphocytes in avian scleroderma and, 1031

Coping Strategies Questionnaire, pain in RA and, 851, 984 Core decompression, of femoral head for osteonecrosis, 797,

Cornea, inhibition of neovascularization by methotrexate and, 1065

Corpuscular volume, as predictor of hematologic toxicity after methotrexate, 1592

Cortical collapse, in radiographic grading scales for OA of hand, 1584

Cortical dysfunction, dementia in temporal arteritis in elderly, 1308

Cortical erosions, in urate-mediated inflammation in nodal OA, 86

Corticosteroid drugs

bone marrow proliferation and, in SLE and aplastic anemia, 901, 924

cartilage, osteophytes and, in Pond-Nuki dog model of OA, 181

cell subsets in temporal arteritis and, 884

infection after cyclophosphamide in vasculitis and, 45, 1626

injection of, in synovial cysts of zygapophyseal joints, 660 in *Mycobacterium avium-intracellulare* infection in polymyositis, 934

in normotensive renal failure in SSc, 1128

Corynebacterium kutscheri septic arthritis, 1053

Cost-effectiveness, of inpatient and outpatient treatment of RA. 1505

c-ras proto-oncogene, in SSc, 430

C-reactive protein y-IFN in systemic JRA and, 643 in RA, 117, 139 Creatinine, CNS toxicity after methotrexate and, 770 CREST syndrome racial differences in ANA in scleroderma and, 54 vasculitis and, lumbosacral plexopathy in, 661 Cross-reactive antihistone antibodies, in RA and Felty's syndrome, 1319 Cross-reactive epitopes in AS and Reiter's syndrome, 437 Cross-reactive idiotypes, RF and, 134, 265, 699 Cruciate ligament, anterior, 181, 486, 637, 759, 1142, 1300, 1434 Crystals first descriptions of chondrocalcinosis and, 1339 micro-, IL-6 and, 1443 in SF after arthrocentesis, 271 subcutaneous cholesterol, tophus formation and, 1190 in urate-mediated inflammation in nodal OA, 86 CTLD cells, methotrexate, IL-1 and, 370 Cutaneous LE, subacute, during PUVA for psoriasis, 343 Cutaneous SSc, complement activation and, 1262 Cutaneous vasculitis, factor B activation in SLE and, 1406 Cyanogen bromide peptides, in collagen arthritis in monkeys, 748 Cycloheximide HLA-DR expression on RA monocytes and, 682 IL-1 regulation of collagenase mRNA and, 1539 Cyclophosphamide infectious complications of, in vasculitis, 45, 1626 in RA, 933, 1080 nonarticular cartilage in RA and, 1080 Cyclosporin A, 1,25-dihydroxyvitamin D₃, T cells and, in RA, 31 Cynomolgus monkey studies, collagen arthritis, 748 Cysts subchondral, 785, 1584

synovial, therapy of, in zygapophyseal joints, 660 Cytokines

antibody production by immunomodulary molecules and, 1345 antilymphotoxin, tumor necrosis factor and, 1148

in chronic inflamnatory arthritis, 1074 effect of tumor necrosis factor and 7-IFN on cartilage and, 780

IL-6 in collagen arthritis in mice, 594 immune regulation and, in fibrositis, 1334

recombinant human, glycosaminoglycan synthesis, fibroblasts, cartilage and, 173

Cytotoxic cells, in inflammatory myopathy and AIDS, 475 Cytotoxic drugs

in CNS vasculitis in Behçet's syndrome, 217

in Mycobacterium avium-intracellulare infection in polymyositis, 934

Cytotoxic/suppressor cells, in dermal lymphocytes in avian scleroderma, 1031

D

D10.G4.1 (D10) cells, methotrexate, IL-1 and, 370 Dactylitis, in childhood psoriatic arthritis, 1007

Danazol, in methyldop, induced SLE, 205 DBA/1 mice, IL-6 in collagen arthritis in, 594 Definite juvenile psoriatic arthritis, 1007 Degenerative joint disease, anticollagen in RA and, 1087 Dementia, senile, 1308, 1546 Dendritic cells HLA-DQ antigens and, in RA and reactive arthritis, 955 response of T cells to, 1381

Deoxyadenosine toxicity, in rabbit cartilage, 1014 Deoxyuridine, tritiated, inhibition of neovascularization by methotrexate and, 1065

Depression

physical conditioning and, 1396 in RA, 991, 1100, 1396, 1611 self-care education in arthritis and, 706

Dermal lymphocytes, T cells in, in avian scleroderma, 1031 **Dermatitis**

gold, 507

herpetiformis, in PM/DM, 1179

Dermatomyositis (DM)

dermatitis herpetiformis and, 1179 HIV-associated, 1615

juvenile, intravenous pulse methylprednisolone in, 505 response of peripheral blood mononuclear cells to muscle in, 446

Desert rheumatism (coccidioidomycosis of bone), 1608 Destructive arthritis, RF and HLA-DR4 in, 1221 Destructive arthropathy, in peritoneal dialysis, 785

Destructive spondylarthropathy, in chronic renal failure, 1492

Dexamethasone, cytokines in chronic inflammatory arthritis and, 1074

DH-40J, cartilage degradation by, 608

Diaphysis, femur, in experimental inflammatory arthritis,

Diclofenac, sensitivity of AIMS in RA and, 844

Diethyltriaminepentacetic acid, viscosity of hyaluronic acid and, 461

Diffuse idiopathic skeletal hyperostosis (DISH) calcaneal spurs in, 338 retinyl acetate-induced arthritis and, 625

Diffuse scleroderma

cutaneous, complement activation and, 1262 proto-oncogenes in SSc and, 430 racial differences in ANA in, 54

Digital ischemia, α-adrenergic responses in Raynaud's disease and, 61

Digits. See also Fingers

T cells in dermal lymphocytes in avian scleroderma and,

Dihomo-y-linolenic acid, suppression of synovial cells by, 1273

Disability in AS, 77

in childhood reflex neurovascular dystrophy, 480 in RA, 538, 1100, 1611

Disaccharides, chrondroitinase, alteration to cartilage after running in dogs and, 1282 Discs, herniated, MRI of, 504

Disease activity proto-oncogenes in SSc and, 430 complementary, 251, 393 double-stranded, 259, 298, 343, 406, 826 in RA α_1 -acid glycoprotein in infection and, 347 hereditary amyloidosis and, 1474 anticollagen antibodies and, 139 HLA genes in RA and, 15 depression and, 991, 1100 immunoglobulin VH genes, human RF and, 72 disability and, 538, 1100 polymorphisms, 634, 1243, 1365 effects of lymphoid irradiation on, 523 salivary gland lymphocytes in Sjögren's syndrome and, 859 HLA-DQ antigens and, 955 in SLE, 634, 726, 1243 IL-1-inhibitory IgG in, 1528 as outcome measure in clinical trials, 1093 single-stranded, 413, 826 synthesis of, inhibition of neovascularization by methpain, functional impairment and, 851 sleep and, 974 otrexate and, 1065 synovial membrane lymphocyte infiltration and, 361 tetrapeptide, mutant fibronectin gene in PSS and, 247 2-Md plasmid from Shigella flexneri in reactive arthritis self-care education in arthritis and, 706 and, 937 serum hyaluronate and, in experimental arthritis, 306 in SLE, 398, 665, 1107, 1233, 1406 **DNA-anti-DNA complexes** binding of dsDNA to glomeruli in rats and, 298 Disease assessment in SLE, 406 Juvenile Arthritis Functional Assessment Scale in, 1390 **DNase** in SLE, 1107 Disease duration anti-RA33 in RA and, 1515 anticollagen antibodies in RA and, 139 in SLE, 406, 1045 DQw1β. in RA, 251 in AS, 77 DOw2, in blacks with SLE, 1243 corticosteroids, cell subsets and, in temporal arteritis, 884 DQB complementary DNA, class II major histocompatibility RF, HLA-DR4 and, in destructive arthritis, 1221 self-care education in arthritis and, 706 complex gene sequence in RA and, 251 Disease exacerbation, pregnancy in SLE and, 665 antigens, RA monocytes and, 682 Disease expression in AS, 77 typing, RF, HLA-DR4 and, in destructive arthritis, 1221 DR1 retroviral transcripts in murine lupus and, 322 Disease flares, in joint inflammation in murine arthritis. 330 alleles, in RA, 663 Disease heterogeneity, in SLE, 826 gene, in RA, 251 Disease modifying antirheumatic drugs (DMARD) DR3, in blacks with SLE, 1243 and methotrexate in RA, folic acid after, 115 DR4, in RA, 15, 251, 663 RF, HLA-DR4 and, in destructive arthritis, 1221 DR5, spontaneous abortion and, 1572 Disease onset DRw10, gene, in RA, 251 in AS, 77 DRw17, in blacks with SLE, 1243 pregnancy in SSc and, 151 DRw53β₂, class II major histocompatibility complex gene Disease outcomes, psychosocial factors and, in RA, 1100, 1611 sequence in RA and, 251 Disease progression $DR\beta^{b1}$ gene, in RA, 251 after arthroscopic synovectomy for knee synovitis, 10, 108 Drug-induced LE, synovial analysis in, 560 and disease prevalence, radiographic grading scales in OA Drug-induced rhabdomyolysis, polymyositis and, cholesterollowering agents in, 358 of hand and, 1584 in RA, T cells and, 116 Drugs Disease severity acetaminophen, 1 clinical assessment of disease activity in SLE and, 1107 actinomycin D, 1539 complement activation and in SSc, 1262 alpha-methyldopa, 356 in RA analgesic, 1328 disability, depression and, 1100 antibiotics, 1057, 1182 pain and, 851, 984 antihypertensive, 356 RF, HLA-DR4 and, in destructive arthritis, 1221 antirheumatic, 361, 1328 serum hyaluronate in experimental arthritis and, 306 antithymocyte globulin, 1495 Disease susceptibility, T cell receptor genes and, 105 Arteparon, 608 DISH. See Diffuse idiopathic skeletal hyperostosis aspirin, 1, 844 Disse's space, electron microscopic analysis of liver biopsy auranofin, 158, 1188 in RA and, 1202 azathioprine, 837 Distal interphalangeal joint buserelin, 1186 in peritoneal dialysis, 785 chlorambucil, 584, 1631 chloroquine, 288 radiographic grading scales for OA of hand and, 1584 Diuretics, urate-mediated inflammation in nodal OA and, 86 cholesterol-lowering, 358

chymopapain, 312

Dizziness, methotrexate toxicity and, 770

Drugs (cont'd) clindamycin, 475 colchicine, 1487 corticosteroid, 45, 181, 660, 884, 901, 924, 934, 1128, 1626 cycloheximide, 682, 1539 cyclophosphamide, 45, 933, 1080, 1626 cytotoxic, 217, 934 danazol, 205 DH-40J, 608 diclofenac, 844 diuretic, 86 DMARD, 115, 1221 etidronate disodium, 776 glucocorticoid, 181, 475, 717, 1080, 1186 hydrocortisone, 173, 288 hydroxychloroquine, 1185 immunosuppressive, 31, 933, 1186 indomethacin, 173, 682, 1273 levamisole, 288 methotrexate, 113, 114, 115, 194, 234, 370, 378, 671, 677, 770, 813, 1057, 1065, 1093, 1160, 1182, 1202 methyldopa, 205 methylprednisolone, 505, 717, 1188 naproxen, 844 NSAID, 1, 158, 288, 844, 926 penicillamine, 1093, 1185 piroxicam, 1 prednisone, 181, 205, 665, 884, 1160 pulse intravenous methylprednisolone, 717 pyrimethamine, 475 razoxane, 288 retinyl acetate, 625 salsalate, 1344 sodium salicylate, 1, 486 SP-54, 608 steroid, 181, 217, 357 sulfasalazine, 1057, 1160, 1182 triamcinolone hexacetonide, 181 trimethoprim/sulfamethoxazole, 1052 Dw10 subtypes, HLA-DR in RA and, 663 Dw14, in RA, 15, 251 Dysplasia, chondro-osseous, deoxyadenosine toxicity in rabbit cartilage and, 1014 Early-onset SLE, 1243, 1414 Educational status, AIMS in English-Spanish format and,

Educational status, AIMS in English-Spanish format and, 1153
8-methoxypsoralen and longwave ultraviolet light (PUVA), during psoriasis, subacute cutaneous LE during, 343
Elbow
Panner's disease and, 341
simplified articular index in RA and, 531
Elderly
cross-reactive idiotype (IdRQ) in RF in, 134
dementia in, temporal arteritis and, 1308
men, infection after cyclophosphamide in vasculitis in, 45, 1626
meta-analysis in older-onset SLE, 1226
OA in, 86, 166
subacute cutaneous LE during PUVA for psoriasis in, 343

Electrocardiography, atrioventricular heart block in SLE and, 1170 Electron microscopy analysis of liver biopsy samples in RA by, 1202 collagen in RA and OA studied by, 1458 corticosteroids in Pond-Nuki dog model of OA studied by, Electrophoresis, affinity, in study of α_1 -acid glycoprotein in infection in RA, 347 Endogenous retroviral transcripts, in murine lupus, 322 Endoplasmic reticulum, smooth, electron microscopic analysis of liver biopsy in RA and, 1202 Endothelial cells IL-1-inhibitory IgG in RA and, 1528 pathogenesis of SSc and, 817 proliferation of, inhibition of, by methotrexate, 1065 Endothelium HLA-DQ antigens in RA and, 955 vascular, 22, 437 Enteric infections, 2-Md plasmid in Shigella flexneri in reactive arthritis, 937 Enthesopathic disease, in retinyl acetate-induced arthritis, Enthesopathy, in juvenile ankylosing spondylitis, 1054 **Environmental factors** in AS, 77 eosinophilic fasciitis in siblings and, 96, 1629 racial differences in ANA in scleroderma and, 54 Enzyme-linked immunospot assay, for anticollagen in RA, Enzyme-linked immunosorbent assay (ELISA) α2-plasmin inhibitor-plasmin complex in rheumatic diseases and, 1427 in analysis of anti-CENP-B anticentromere autoantibody, 1315 cross-reactive antiidiotypic antibodies against RF in JRA cross-reactive epitopes in AS and, 437 effect of chemonucleolysis on serum keratan sulfate and, in Lyme disease, 1041 to measure serum keratan sulfate in rabbit OA, 1293 in Sjögren's syndrome, 413, 811 in SLE, 413, 1406 to study antihistone antibodies in RA and Felty's syndrome, 1319 deoxyadenosine toxicity in rabbit cartilage and, 1014 glycosaminoglycan polysulfuric acid ester in canine OA and, 1300 Hind III restriction, CR1 expression in SLE and, 393 Eosinophilic fasciitis, in siblings, 96, 1630 Epidemiologic studies Lyme spirochete and Reiter's syndrome, 1057, 1182

prevalence of scleroderma in South Carolina, 998

Epstein-Barr virus (EBV), in Sjögren's syndrome, 811

in collagen arthritis in monkeys, 748 cross-reactive, in AS, 437 in RA, 139, 663, 1371

shared, in autoimmune disease, 509

Epitopes

Ergonometers, in aerobic fitness in fibrositis, 454 **Erosions**

joint, in RA, 115, 511, 523

marginal, in pristane-induced arthritis, 1022 in OA, 86, 181

Erythema

in hydroxyapatite pseudopodagra, 741

marginatum, in rheumatic fever and poststreptococcal glomerulonephritis, 236

Erythrocyte sedimentation rate

as outcome measure in RA clinical trials, 1093

sensitivity of AIMS and, 844

Erythrocytes, in SLE, 259, 393, 717, 1465

Erythropoietin therapy for anemia in RA, 638 Escherichia coli, ELISA in Lyme disease and, 1041

Estrogen, buserelin in SLE and, 1186

Etidronate disodium treatment of Paget's disease, 776

Exercise

aerobic fitness in fibrositis, 454

articular cartilage alterations after running in dogs, 1282 in RA, 1396

smoking in OA and, 166, 1396

as unconventional remedy for arthritis, 1604

Experimental arthritis

chondrocytes and insulin-like growth factor 1 in, 894 pristane-induced, 1022

in rabbits, 617, 1293

serum hyaluronate and disease activity in, 306

Extraarticular features of systemic JRA, 7-IFN in, 643

Extracellular matrix, salicylates, chondrocytes and, in canine OA, 486

Extractable nuclear antigens, racial differences in ANA in scleroderma and, 54

Factitious septic arthritis, 352

Factor analysis, of Coping Strategies Questionnaire, pain control in RA and, 984

Factor B

in RA, 691

in SLE, activation of, 1406

in SSc, complement activation and, 1262

Factors

growth, 66, 817, 894, 1065, 1197

proteoglycan metabolism in articular cartilage and, 1197 tumor necrosis, 146, 173, 279, 780, 1148, 1528

Family, work disability in women with RA and, 538 Fat

abdominal, in diagnosis of amyloidosis, 82

neutral, electron microscopic analysis of liver biopsy in RA and, 1202

Fatigue, sleep and, in RA, 974

Fatty acids, suppression of synovial fluid by dihomo-γlinolenic acid and, 1273

Fc fragments

cross-reactive antiidiotypic antibodies, RF and, in JRA,

in hypocomplementemic urticarial vasculitis syndrome,

Fcy receptor function, pulse intravenous methylprednisolone in SLE and, 717

FDA Arthritis Advisory Committee, antiarthritis drugs and analgesics, 1328

Feet

in Behçet's disease, 1629

hydroxyapatite pseudopodagra and, 741 in RA, 359

Felty's syndrome

antihistone antibodies in, 1319

auranofin and methylprednisolone in, 1188

Femoral condyle

in canine OA, 181, 759, 1300

cartilage of, effects of radiation on, 468

serum keratan sulfate in rabbit OA and, 1293

Femoral head, core decompression of, in osteonecrosis, 797,

Femur, proximal, in acute peritendinitis calcarea, 767

Fetus

calf, proteoglycan metabolism in articular cartilage and,

morbidity and mortality of, in mothers with SSc, 151 survival of, pregnancy in SLE and, 665

Fever

IL-6 and, 1443

in older-onset SLE, 1226

Fibrinolysis, α2-plasmin inhibitor-plasma complex and, in rheumatic diseases, 1427

Fibroblasts

in SSc, 247, 817, 1031

synovial, 22, 173, 279, 1539

Fibronectin

in SSc, 247, 577

Fibrosis

in RA, 121, 1202

in SSc, 577, 1031

Fibrositis

aerobic fitness in, 454

cytokines and immune regulation in, 1334

Fine specificity of anti-Ro (SS-A), 1563

Fingers

acute peritendinitis calcarea, 767

alpha-adrenergic responses in Raynaud's disease and, 61 arthropathy of Behçet's disease and, 1629

joints of, in urate-mediated inflammation in nodal OA, 86 in Raynaud's phenomenon in SLE, 1487

simplified articular index in RA and, 531

First Health and Nutrition Examination Survey (HANES I), smoking in OA and, 166

Flare reactions, of joint inflammation, in murine arthritis,

Flow cytometry studies

in immunohistologic analysis of cell adhesion molecules,

CR1 expression in SLE, 393

very late activation antigen in SF T cells, 386

Fluorescence-activated cell sorter studies

cytokines in chronic inflammatory arthritis, 1074 response of T cells to dendritic cells, 1381

Folate, hematologic toxicity after methotrexate and, 1592

Folic acid, methotrexate in RA and, 113 Folinic acid, effects of methotrexate on PBMC and, 378 Forskolin, chondrocytes, insulin-like growth factor 1 and, in experimental arthritis, 894

Framingham Heart Study, Framingham Osteoarthritis Study, smoking in OA and, 166

Freund's adjuvant, IL-6 in collagen arthritis in mice and, 594 Functional class, articular index in RA and, 531

Functional impairment, pain and, in RA, 851

Functional status

arthritis in nursing home residents and, 1546 in AS, 77

auranofin in psoriatic arthritis and, 158 information dissemination in OA and, 1577 in RA, 128, 991, 1100, 1340, 1611 self-care education in arthritis and, 706

Fungal olecranon bursitis, chronic, caused by Penicillium, 239

Gait, in dogs after anterior cruciate ligament transection,

Galactose, glycosylation, IgG and, in chronic inflammatory diseases, 235

2-IFN

cytokines and, 173, 1074

effect of, on cartilage, prostaglandin E, and caseinase, 780 IL-1 gene expression in synovial fibroblasts and, 279 pulse intravenous methylprednisolone in SLE and, 717 recombinant, in RA, 964 in systemic JRA, 643

Gas chromatography-mass spectrometry, to detect muramic acid, 1268

Gastrointestinal involvement

adverse reactions of NSAID and, 926

home central venous hyperalimentation in scleroderma bowel disease and, 212

methotrexate toxicity in JRA and, 677 toxic effects of azathioprine in RA and, 837

Gene expression

of IL-1 in synovial fibroblasts, 279

of retroviral transcripts in murine lupus, 322

Genes

CR1 in SLE, 1465

in hereditary amyloidosis, 1474

immunoglobulin V_H genes and human RF, 72 mutant fibronectin, in skin fibroblasts in SSc, 247

restriction fragment length polymorphism and, 393, 870, 1325, 1597

T cell receptor, disease susceptibility and, 105

Genetics

in AS, 77, 1135

DNA and, 634, 1243

endogenous retroviral transcript in murine lupus, 322 eosinophilic fasciitis in siblings, 96, 1630

hereditary amyloidosis, 1474

IL-1 in synovial fibroblasts and, 279

immuno-, congenital heart block and, 1421

immunoglobulin k in RA, 1365

PM/DM with dermatitis herpetiformis, 1179

pristane-induced arthritis, 1022

racial differences in ANA in scleroderma and, 54 in Sjögren's syndrome, 413, 859

in SLE, 413, 859

Genitourinary infections, immune responses to Borrelia burgdorferi in reactive arthritis and, 1057, 1182

immunoglobulin k. HLA-DR4 and, in RA, 1365

9.2-kb Pvu II restriction fragment length polymorphism,

plasma DNA in SLE and, 726

Global assessment

of auranofin in psoriatic arthritis, 158

radiographic grading scales for hand OA and, 1584 in SLE, 665, 1107

Glomerular filtration rate, in "renal Raynaud's phenomenon" in SLE, 1487

Glomeruli

binding of dsDNA to, in rats, 298

immunoglobulin idiotypes in SLE and, 513

Glomerulonephritis

acute, coexistent acute rheumatic fever, 230, 236 immune, immunoglobulin idiotypes in SLE and, 513 poststreptococcal, 236

Glucocorticoid drugs

cartilage, osteophytes and, in Pond-Nuki dog model of OA. 181

in inflammatory myopathy and AIDS, 475 nonarticular cartilage in RA and, 1080 in SLE, 717, 1186

Glycoprotein

 α_1 -acid, in infection in RA, 347

fibronectin, production of, by alveolar macrophages in SSc. 57

Glycosaminoglycan polysulfuric acid, in canine OA, 759, 1300

Glycosaminoglycans

cartilage proteoglycans in antigen-induced arthritis and,

in chondrolysis of hip joint in hemodialysis, 1477 polysulfated, cartilage degradation by, 608

serum keratan sulfate, 100, 312, 647 synthesis of, 173, 468, 486, 647

Glycosylation, IgG and, in chronic inflammatory diseases, 235

Gold

dermatitis, treatment failure and, 507

in RA, 682, 1093

Gonadotropin-releasing hormone, in SLE, 1186

Gonarthrosis, proteoglycan fragments in knee joint SF and,

Gout, IL-6 in, 1443

Gouty podagra, hydroxyapatite pseudopodagra and, 741 Gram-negative bacteria, 2-Md plasmid from Shigella flexneri

in reactive arthritis and, 937

Granulocytes

flare reactions in joint inflammation in mice and, 330 immune complexes and, in RA, 1521

Granulomatosis

lymphomatoid, systemic vasculitis in HIV infection and,

Wegener's, 45, 356, 1050, 1052

Grip strength

physical conditioning and, 1396 in RA, 523, 531, 1092, 1396

Group A streptococcal infection, in coexistent acute rheumatic fever and acute glomerulonephritis, 230, 236

Growth and development, intrauterine, of infants of mothers with SSc. 151

Growth factors

β, 817, 1197

inhibition of neovascularization by methotrexate and, 1065

insulin-like, 66, 894, 1197 in pathogenesis of SSc. 817

H allele, CR1 expression in SLE and, 393

Hand

in Behçet's disease, 1629

joints, RF, HLA-DR4 and, in destructive arthritis, 1221 in OA, 86, 1584

in RA, 128, 523, 1340

Haplotypes, C4AQ0 and C4B5 in RA and, 691

Hardy-Weinberg law, CR1 expression in SLE and, 393

Hashimoto's thyroiditis, myasthenia gravis and SLE coexisting, 119

³H-deoxyuridine, effects of methotrexate on PBMC and, 378

Head, in "neck sign" in scleroderma, 209

Headache

dementia in temporal arteritis in elderly and, 1308 methotrexate toxicity and, 770

Health Assessment Questionnaire, in RA, 837, 1100, 1611 Health education

Arthritis Patient Education conference and, 1330

Arthritis Self-Management Course and, 91

Health status

AIMS and, 844, 1153

Arthritis Self-Management Course and, 91 information dissemination in OA and, 1577

physical conditioning and, 1396

in RA, 128, 538, 984, 1340 self-efficacy scale and, 37

α-adrenergic responses in Raynaud's disease and, 61 congenital heart block immunogenetics, 1421

HeLa cells

anti-RA33 and, 1515

major nucleolar phosphoprotein B23 and, autoantibodies to, 1165

Helper cells

in dermal lymphocytes in avian scleroderma, 1031 in RA, 361, 795

Helper/inducer cells, in RA, 116

Helplessness, self-care education in arthritis and, 706 Hematocrit, erythropoietin therapy of anemia in RA and,

Hematoidin crystals, in SF after arthrocentesis, 271 Hematologic involvement, methotrexate toxicity and, 677, 1592

Hemodialysis

 β_2 -microglobulin in, 785

chondrolysis of hip joint in, 259

Hemoglobin, outcome measures in RA clinical trials and, 1093

Hemolytic anemia

in SLE, 205, 259

normotensive renal failure in SSc and, 1128

Hemolytic complement, plasma infusion therapy of C2 deficiency in SLE and, 906

Hemorrhage, pulmonary, in normotensive renal failure in SSc. 1128

HEp-2 cells, ANA, histones, antigens and, in JRA, 919

Hepatic infarction, lupus anticoagulant and, 491

Hepatic injury, in alpha-methyldopa-induced systemic vasculitis, 356

Hepatocytes

electron microscopic analysis of liver biopsy in RA and, 1202

IL-6 and, 1443

Hereditary amyloidosis, 1474

Herpes zoster, articular presentation in, 506

HH genotype, CR1 expression in SLE and, 393

Hidden IgM-RF, cross-reactive antiidiotypic antibodies in JRA and, 699

Hind III restriction enzyme, CR1 expression in SLE and, 393

Hip

in AS, 77

joint, chondrolysis of, in hemodialysis, 1477

keratan sulfate and hyaluronate in, in canine OA, 312 synovium, β₂-microglobulin in peritoneal dialysis and, 785 tumoral calcinosis in, 1484

Histamine, synovial mast cells in intermittent hydrarthrosis

Histology, liver, methotrexate and, in RA, 121

Histones

H1, 205, 877, 919

H5, 877

in JRA, 877, 919

in SLE, 205, 406, 1045

Histopathology

glycosaminoglycan polysulfuric acid ester in canine OA and, 1300

of inclusion body myositis, 734

History of rheumatology

Alphonsus of Ligouri, 807

psoriatic arthritis in the 17th century, 812 HL genotype, CR1 expression in SLE and, 393

HLA

alleles, in RA, 691

antigens, 826, 1421, 1492, 1572

class I, 9.2-kb Pvu restriction fragment length polymorphism and, 870

genes, in RA, 15

positivity, in juvenile psoriatic arthritis, 1007

in RA, 15

typing of, in DM/PM with dermatitis herpetiformis, 1179

HLA-A alleles, in HLA-B27+ AS, 1135

antigens, 96, 1572, 1629

9.2-kb Pvu II restriction fragment length polymorphism

HLA-A1;B8,DR3 haplotype, congenital heart block and, 1421

HLA-B

antigen, in eosinophilic fasciitis in siblings, 96, 1629 locus, in AS, 1135

HLA-B8

disease heterogeneity model in SLE and, 826 in PM/DM with dermatitis herpetiformis, 1179

HLA-B27

in AS, 437, 1135

9.2-kb Pvu II restriction fragment length polymorphism and, 870

in Reiter's syndrome, 1057, 1182, 1615

2-Md plasmid in Shigella flexneri, in reactive arthritis, 937

HLA-Bw60, in HLA-B27+ AS, 1135

HLA-DP, HLA-DQ antigens and, in RA and reactive arthritis, 955

HLA-DQ

antigen, 96, 955, 1629

cytokines in chronic inflammatory arthritis and, 1074 DNA analysis of, in blacks with SLE, 1243

HLA-DQ1/DQ2 heterozygotes, disease heterogeneity model in SLE and, 826

HLA-DR

antigen, 96, 682, 1221, 1623, 1629

cytokines in chronic inflammatory arthritis and, 1074

DNA analysis of, in blacks with SLE, 1243

macrophages, corticosteroids and, in temporal arteritis, 884 in RA, 663, 682, 955, 1221, 1365

very late activation antigen in SF T cells and, 386 HLA-DR1, immunoglobulin κ in RA and, 1365

HLA-DR1, immunogioouin k in KA and, 1363 HLA-DR2, Ro (SS-A), La (SS-B) and, in SLE and Sjögren's syndrome, 413

HLA-DR3

congenital heart block and, 1421

in PM/DM with dermatitis herpetiformis, 1179

in Sjögren's syndrome, 413

in SLE, 413, 826

HLA-DR4

disease heterogeneity model in SLE and, 826

in juvenile psoriatic arthritis, 1007

in RA, 15, 1365, 1371

RF and, in destructive arthritis, 1221

HLA-DR5, spontaneous abortion and, 1572

HLA-DR8

in blacks with SLE, 1243

in juvenile psoriatic arthritis, 1007

HLA-DRB

alleles, in RA, 15

immunoglobulin k in RA and, 1365

 HLA-DRw52b, DNA analysis of, in blacks with SLE, 1243
 Home central venous hyperalimentation, in scleroderma bowel disease, 212

Homeostatis, proteoglycan, articular cartilage and, 1197 Hormones, female, in antigen-induced arthritis in C57B1/10

mice, 789

Hospitalization

cost-effectiveness of, in RA, 1505

toxic effects of azathioprine in RA and, 837

³H-thymidine, effects of methotrexate on PBMC and, 378

Human immunodeficiency virus (HIV)

infection, 569, 1453, 1615

in inflammatory myopathy and AIDS, 475

Human studies

antibody production by immunomodulatory molecules and, 1345

collagen in SF phagocytes, 1458

cross-reactive antiidiotypic antibodies, RF and, in JRA, 699

cytokines, glycosaminoglycan synthesis, fibroblasts, cartilage and, 173

effect of chemonucleolysis on serum keratan sulfate, 100 fine specificity of anti-Ro (SS-A), 1563

IL-1, 279, 370

IL-6, 594, 1443

immunoglobulin V_H genes, 72

insulin-like growth factor and chondrocyte proteoglycan synthesis, 66

polyarthritis in T-lymphotropic virus type I-associated myelopathy, 1342

in RA, 638, 964, 1080

RF. 72, 699

in SLE, 146, 513, 726, 1252

suppression of synovial cells by dihomo-γ-linolenic acid, 1273

synovial fibroblast collagenase mRNA and IL-1, 1539 T cells, 105, 1031

tumor necrosis factor, 146, 780

Human T lymphotropic virus type I (HLVT-I)-associated myelopathy and polyarthritis, 1342

Humidity, effect of, on pain scores in RA, 1627

Humoral autoimmunity, stress proteins, arthritis and, 1497 Hyaluronate

disease activity and, in experimental arthritis, 306 serum keratan sulfate and, in canine OA, 312

Hyaluronic acid

alterations in cartilage after running in dogs and, 1282 human cytokines in glycosaminoglycan synthesis and, 173 immune complexes and, in RA, 1521

proteoglycan metabolism in articular cartilage and, 1197 synthesis of, after radiation exposure, 468

viscosity of, 461

Hybridization, plasma DNA in SLE and, 726 Hybridoma cell proliferation, IL-6 and, 1443

Hydrarthrosis, intermittent, synovial mast cells in, 357

Hydrocortisone

human cytokines in glycosaminoglycan synthesis and, 173 IL-1 in cartilage and, 288

Hydroxyapatite

crystals, IL-6 and, 1443

pseudopodagra, in young women, 741

Hydroxychloroquine, in JRA, 1185

Hydroxyproline, glycosaminoglycan polysulfuric acid ester in canine OA and, 759, 1300

Hyperalimentation, home central venous, in scleroderma bowel disease, 212

Hypercoagulability, hepatic infarction, lupus anticoagulant and, 491

Hypergammaglobulinemia, anticardiolipin antibodies and, 813

Hyperostosis, diffuse idiopathic skeletal. See Diffuse idiopathic skeletal hyperostosis

Hyperplasia, synovial, in pristane-induced arthritis, 1022

Hypertension, normotensive renal failure in SSc and, 1128

Hypertrophy, synovial lining, HLA-DQ antigens in RA and, 955

Hypocomplementemia

in SLE, 665, 1226

subacute cutaneous LE during PUVA for psoriasis and,

Hypocomplementemic urticarial vasculitis syndrome, IgG anti-Clq in, 1119

I

Ia antigen, T cells in dermal lymphocytes in avian scleroderma and, 1031

Idiopathic LE, synovial analysis in drug-induced lupus and, 560

Idiopathic Raynaud's disease, α-adrenergic responses in, 61 Idiopathic thrombocytopenic purpura, antilymphotoxic and tumor necrosis factor in, 1148

Idiotypes

cross-reactive, RF and, 134, 265 of immunoglobulins in SLE, 513 in JRA, 265

IgA

anticollagen in RA and, 1087

immunohistologic diagnosis of Siögren's syndrome and,

immunosuppression with chlorambucil in SSc and, 584, 1631

IgG

anti-Clq, in hypocomplementemic urticarial vasculitis syndrome, 1119

antibodies, Borrelia burgdorferi in reactive arthritis and, 1057, 1182

anticollagen, C1q and, 544

binding of dsDNA to renal glomeruli in rats and, 298 glycosylation and, in chronic inflammation diseases, 235 IL-1 inhibitory, in RA, 1528

IL-6 and, 1443

immune complexes and, 1521

in JRA, 265, 699, 919

methotrexate in neutropenia in Felty's syndrome and, 194 in Sjögren's syndrome, 420, 1214

in SLE, 205, 259, 398, 717, 1356, 1601

T cells in dermal lymphocytes in avian scleroderma and, 1031

IgG1

idiotypes of, in SLE, 513

isotype, anti-CENP-B anticentromere autoantibody analysis and, 1315

IgM

antibodies, Borrelia burgdorferi in reactive arthritis and,

immunohistologic diagnosis of Sjögren's syndrome and,

immunosuppression with chlorambucil in SSc and, 584, 1631

monoclonal, cross-reactive idiotype (IdRQ) in RF and, 134

effects of methotrexate on PBMC and, 378 immune complexes and, 1521

in JRA, 265, 699

IgM (cont'd)

in RA, 361, 1087

in SLE, 205

T cells in dermal lymphocytes in avian scleroderma and,

Immune complexes

anticollagen, Clq and, 544

methotrexate in neutropenia in Felty's syndrome and, 194 plasma infusion therapy for C2 deficiency in SLE and, 906 in RA, 117, 1521

in vasculitis, 1119, 1470

Immune glomerulonephritis, immunoglobulin idiotypes in SLE and, 513

Immune regulation, cytokines and, in fibrositis, 1334

Immune response

antihistones H1 and H5 in JRA and, 877

to Borrelia burgdorferi, in reactive arthritis, 1057, 1182 in collagen arthritis in monkeys, 748

HIV and, 1453, 1615

IL-1 gene expression in synovial fibroblasts and, 279 salivary gland lymphocytes in Sjögren's syndrome and,

Immunization, HLA-DR5, spontaneous abortion and, 1572 Immunoblotting studies

anti-RA33, 1515

JRA, 877, 919

SLE, 1252, 1554

Immunodiffusion, in SLE, 1554, 1601

Immunofluorescence studies

antihistones H1 and H5 in JRA and, 877 binding of dsDNA to glomeruli in rats and, 298

immune complexes in RA and, 1521

in study of VLA antigen in SF T cells, 386

Immunogenetics of congenital heart block, 1421 Immunoglobulin k genotype, HLA-DR4 and, in RA, 1365

Immunoglobulin V_H genes, human RF and, 72

Immunoglobulins

anticollagen in RA and, 1087

antilymphotoxin, tumor necrosis factor and, in autoimmune diseases, 1148

idiotypes of, in SLE, 513

IL-6 and, 1443

immune complexes and, in RA, 1521 κ, DNA polymorphism of, in RA, 634

in Sjögren's syndrome, 420, 859

Immunohistochemistry

corticosteroid drugs, cell subsets and, in temporal arteritis, 884

in study of leukocyte adhesion molecules in RA, 947 Immunohistology

analysis of cell adhesion molecules by, 22

of collagen in OA, 1458

in diagnosis of Sjögren's syndrome, 1214

in RA, 361, 1458

Immunomodulation

after lymphoid irradiation in intractable RA, 523 antibody production and, 1345

cross-reactive antiidiotypic antibodies, RF and, in JRA,

Immunology, of stress proteins and autoimmunity, 1497

Immunoperoxidase

cross-reactive epitopes in AS and, 437

staining, 955, 1458

Immunoprecipitation

in hypocomplementemic urticarial vasculitis syndrome, 1119

IL-6 and, 1443

plasma DNA in SLE and, 726

to study VLA antigen in SFT cells, 386

Immunoproliferative disorders, angiocentric, systemic vasculitis in HIV infection and, 569

Immunoreactivity, insulin-like growth factors, chondrocyte metabolism and, 66

Immunosuppression

chlorambucil and, in SSc, 584, 1631 in collagen arthritis in monkeys, 748

lymphoid irradiation in intractable RA and, 523

Immunosuppressive drugs buserelin in SLE and, 1186

in RA, 31, 933

Impotence after methotrexate in RA, 1341

Inclusion body myositis, 734

Indomethacin

HLA-DR expression on RA monocytes and, 682 human cytokines in glycosaminoglycan synthesis and, 173 suppression of synovial cells by dihomo-γ-linolenic acid and, 1273

Inducer cells in RA, 116

Infants of mothers with SSc, 151

Infection

in AIDS, 475, 1175

α₁-acid glycoprotein in, in RA, 347

Borrelia burgdorferi in reactive arthritis and, 1057, 1182 cyclophosphamide in vasculitis and, 45, 1626

enteric, in reactive arthritis, 937

in factitious septic arthritis, 352

HIV, 569, 1453, 1615

inflammation of deep infrapatellar bursa of knee and, 1312 methotrexate in neutropenia in Felty's syndrome and, 194 Mycobacterium avium-intracellulare, in polymyositis, 934 in SLE, 146, 914

streptococcal, in rheumatic fever and glomerulonephritis, 230, 236

in synovial fluid, detection of muramic acid in, 1268 Yersinia, in Behçet's disease, 475

Infectious arthritis

complicating RA and other rheumatic disorders, 496, 1487 Corynebacterium kutscheri septic arthritis, 1053

Inflammation

calcaneal spurs in rheumatic diseases and, 338

cross-reactive epitopes in AS and, 437

of deep infrapatellar bursa of knee, 1312

in drug-induced rhabdomyolysis and polymyositis, 358 fibronectin production by alveolar macrophages in SSc and, 577

glycosylation, IgG and, 235

human cytokines in glycosaminoglycan synthesis and, 173 IL-1 gene expression in synovial fibroblasts and, 279

IL-6 production and, 1443

immunohistologic analysis of cell adhesion molecules and, 22

Inflammation (cont'd)

in inclusion body myositis, 734

inhibition of neovascularization by methotrexate and, 1065

joint, 66, 306, 330, 894

in myopathy, AIDS and, 475

plasma infusion therapy of C2 deficiency in SLE and, 906 in pristane-induced arthritis, 1022

in RA, 1087, 1371, 1521

rat air pouch, cartilage degradation and, 608

restriction fragment length polymorphism for serum amyloid P gene in amyloidosis and, 1325

SF examination after arthrocentesis and, 271

suppression of synovial cells by dihomo-γ-linolenic acid and, 1273

synovial, chondrolysis of hip joint in hemodialysis and, 1477

synovial analysis in drug-induced lupus and, 560 systemic vasculitis in HIV infection and, 569

urate-mediated, in nodal OA, 86

Inflammatory arthritis cytokines in, 1074

experimental, bone changes in, in rabbits, 617

stress proteins, autoimmunity and, 1497

Inflammatory joint disease, anticollagen in RA and, 1087 Inflammatory polyarthritis, HIV in RA and, 1453

Inflammatory polyarthropathy, 2-Md plasmid from Shigella flexneri in, in reactive arthritis, 937

Inflammatory synovitis, cell adhesion molecules and, 22
Influenza virus, infection, MX protein in mononuclear cells in SLE and, 914

Information dissemination, functional status in OA and, 1577 Infrapatellar bursa, deep, of knee, inflammation of, 1312 Injectable gold, outcome measures in RA clinical trials and,

1093

Injuries, knee, 166, 1434 Inpatient treatment of RA, 1505

Institutionalization, arthritis in nursing home residents, 1546 Insulin like-growth factors

chondrocytes and, 66, 894

proteoglycan metabolism in articular cartilage and, 1197

Intercellular adhesion molecule 1, 22 Interdigitating reticulum cells, corticosteroids and, in tem-

poral arteritis, 884
Interferon (IFN)

gamma, 643, 717, 780, 964, 1074

MX protein in mononuclear cells in SLE and, 914

Newcastle disease virus-induced, in pristane-induced arthritis, 1022

Interleukin-1 (IL-1)

cartilage proteoglycans in antigen-induced arthritis and,

cyclosporin A, 1,25-dihydroxyvitamin D₃, T cells and, in RA, 31

gene expression of, in synovial fibroblasts, 279

IL-2 inhibition of SLE and, 1356

methotrexate and, 370

proteoglycans, and, 288, 1197

regulation of human synovial fibroblast collagenase mRNA by, 1539

Interleukin-1-inhibitory IgG, in RA, 1528 Interleukin-1 β (IL-1 β), suppression of synovial cells by dihomo-y-linolenic acid and, 1273 Interleukin-2 (IL-2) antibody production by immunomodulatory molecules and, 1345 cyclosporin A, 1,25-dihydroxyvitamin D3, T cells and, in

RA, 31 methotrexate and, 370 receptors for, 386, 420, 884 in SLE, 552, 1356

Interleukin-6 (IL-6)

antibody production by immunomodulatory molecules and, 1345

in mice with type II collagen arthritis, 594 production of, inflammatory microcrystals and, 1443

Internal carotid artery, spontaneous dissection of, in polyarteritis nodosa, 1625

Interphalangeal joint, 785, 1584

Interstitial cells, HLA-DQ antigens in RA and, 955 Interstitial collagenase mRNA, regulation of, by IL-1, 1539 Interstitial pulmonary disease, in older-onset SLE, 1226

Interstitial pulmonary fibrosis, production of fibronectin by alveolar macrophages in SSc in, 577 Intestinal pseudoobstruction, home central venous hyperali-

mentation in scleroderma bowel disease and, 212 Intraarticular erosions, in urate-mediated inflammation in nodal OA, 86

Intraarticular injections

cartilage proteoglycan in antigen-induced arthritis and,

factitious septic arthritis and, 352

radionuclide, in arthroscopic synovectomy for chronic knee synovitis, 10, 108

steroid, synovial mast cells in intermittent hydrarthrosis

Intraarticular triamcinolone hexacetonide, in Pond-Nuki dog model of OA, 181

Intrauterine growth retardation, of infants of mothers with SSc. 151

Intravenous pulse cyclophosphamide, in refractory RA, 933 Intravenous pulse methylprednisolone, in juvenile dermatomyositis, 505

Intravenous pyelography, arterial thrombosis after, anticardiolipin antibodies and, 1490

Ionomycin, CD3, CD5 and, in Sjögren's syndrome, 420 Iron chelators, viscosity of hyaluronic acid and, 461 Irradiation, lymphoid, in intractable RA, 523

Ischemic necrosis, core decompression of femoral head in,

Isotype analysis, of anti-CENP-B anticentromere autoantibody, 1315

J

Joints

carpometacarpal, 1584

acromioclavicular, septic arthritis and osteomyelitis in AIDS and, 1175 aspiration of, examination of SF after, 271 atlantooccipital, 652

Joints (cont'd) counts of, 531, 844, 1093

cytokines in chronic inflammatory arthritis and, 1074 damage to, 523, 789

diseases of, 894, 1087, 1443 distal interphalangeal, 785, 1584

erosions of, 115, 511, 523 finger, in urate-mediated inflammation in nodal OA, 86

fluid in, cartilage proteoglycans and, 601, 1434 function of, 7-IFN in systemic JRA and, 643

hand, 1221, 1584

hip, chondrolysis of, in hemodialysis, 1477 IL-1 gene expression in synovial fibroblasts and, 279 infection of, complicating RA, 496, 1175, 1487 inflammation of

flare reactions of, in murine arthritis, 330 insulin-like growth factors, chondrocytes and, 66, 894 serum hyaluronate in experimental arthritis and, 306

interphalangeal, 1584 involvement of, 1007, 1160, 1342, 1629

keratan sulfate in, 312, 1293 knee, 330, 625, 894, 1434

lateral facet, 652

metacarpophalangeal, simplified articular index in RA and, 531

metatarsophalangeal, 625, 741, 1190 physical conditioning and, 1396 proximal interphalangeal, 531, 1093, 1584 in RA

anticollagen in, 1087 cartilage, protein and, 1080 cervical spine and, 652 immune complexes and, 1521 index of, 531

leukocyte adhesion molecules in, 947 swelling of, y-IFN and, 964 tenderness of, 531, 741, 844, 964, 1093

space, radiographic grading scales for hand OA and, 1584 stifle, unstable, after anterior cruciate ligament transection, 1142

surgery of, pain scores in RA and, 1627

trapezioscaphoid, 1584 zygapophyseal, synovial cysts in, 660

Juvenile ankylosing spondylitis, definition of, 1054 Juvenile Arthritis Functional Assessment Scale, 1390 Juvenile dermatomyositis, intravenous pulse methylprednis-

olone in, 505

Juvenile psoriatic arthritis, 1007 Juvenile rheumatoid arthritis (JRA) ANA, histones, and antigens in, 919 antihistones H1 and H5 in, 877 cross-reactive idiotype and RF in, 265

juvenile psoriatic arthritis and, 1007 methotrexate toxicity in, 677

penicillamine and hydroxychloroquine in, 1185 polyarticular, cartilage in, 1080

systemic, 7-IFN in, 643

K cells, corticosteroids and, in temporal arteritis, 884 Kas RF, immunoglobulin V_H genes and, 72

Kawasaki syndrome, lymphotoxin and tumor necrosis factor in, 1148

Kellgren/Lawrence scale, radiographic grading scales for OA of hand and, 1584

Keratan sulfate

in canine OA, 312, 647

effect of chemonucleolysis on, in humans, 100 in rabbit OA, 1293

Ki antigen, in SLE, 1554

Kidney

binding of dsDNA to renal glomeruli in rats, 298 normotensive renal failure in SSc, 1128

Klebsiella pneumoniae nitrogenase, cross-reactive epitopes with, in AS, 437

Knee

anserine bursa of, diagnosis of distention of, by ultrasonography

and computed tomography, 1335

in canine, studies, 468, 1282 in coccidioidomycosis of bone, 1608

in coccidioidomycosis of bone, 1608

deep infrapatellar bursa of, inflammation of, 1312 in experimental inflammatory arthritis in rabbits, 617

factitious septic arthritis of, 352

injury to, 166, 1434 joint

chondrocytes and insulin-like growth factor 1 in experimental arthritis in. 894

flare reactions in inflammation in, in mice, 330 proteoglycan fragments in fluid of, after injury to, 1434 in retinyl acetate-induced arthritis in mice, 625 in OA, 166, 486

serum keratan sulfate, cartilage and, in canine OA, 647 simplified articular index in RA and, 531

synovitis of, arthroscopic synovectomy in, 10, 108

I

L alleles, CR1 expression in SLE and, 393

L3T4+ T cells, IL-6 in collagen arthritis in mice and, 594 La (SS-B)

autoantibodies, in SLE and SS, 413

maternal Ro (SS-A) in childhood SLE and, 1414

Lactic acidosis, aerobic fitness in fibrositis and, 454

Large granular lymphocytes in AS, 355

Lateral deformity, radiographic grading scales for OA of hand and, 1584

Lateral facet joint, cervical spine in RA and, 652

LBRM-33-1A5 cells, methotrexate, IL-1 and, 370

Leg

claudication of, peripheral neuropathy and, in systemic necrotizing vasculitis, 510

diagnosis of anserine bursal distention in, by ultrasonography and computed tomography, 1335

Lesions

cartilage, in canine OA, 181, 759

lytic, in coccidioidomycosis of bone, 1608

muscosal, adverse reaction of NSAID in gastrointestinal tract, 926

sclerotic, mutant fibronectin gene in SSc and, 247 serum hyaluronate in experimental arthritis and, 306

Lesions (cont'd)

subacute cutaneous LE during PUVA for psoriasis and, 343

T cells in dermal lymphocytes in avian scleroderma and, 1031

Leu-1 cells, Leu-14 cells, synovial membrane lymphocyte infiltration in RA and, 361

Leukemia, toxic effects of azathioprine in RA and, 837 Leukocytes

adhesion molecules of, in phagocytes in RA synovial membrane, 947

cartilage degradation by polysulfated polysaccharides and, 608

MX protein in mononuclear cells in SLE and, 914

paternal, HLA-DR5, spontaneous abortion and, 1572 SF examination after arthrocentesis and, 271 synovial analysis in drug-induced lupus and, 560

T cells, dendritic cells and, 1381

Leukocytoclastic vasculitis

colchicine in, 1487

plasmacytoma of skull in, 1470

Leukocytosis, IL-6 and, 1443

Leukopenia

cartilage proteoglycans in antigen-induced arthritis and, 601

infection after cyclophosphamide in vasculitis and, 45 in RA, 837, 1453

Levamisole, IL-1 in cartilage and, 288

LFA-3, cell adhesion molecules and, 22

Ligaments, anterior cruciate, 181, 486, 647, 1142, 1300, 1434 Light microscopy

electron microscopic analysis of liver biopsy in RA and, 1202

examination of SF after arthrocentesis by, 271

Limited cutaneous SSc, complement activation and, 1262 Linolenic acid, dihomo- γ , suppression of synovial cells by,

Lipopolysaccharide, methotrexate, IL-1 and, 370

Little Leaguer's elbow, 341

Liver

in alpha-methyldopa-induced systemic vasculitis, 356 binding of dsDNA to renal glomeruli in rats and, 298 infarction of, lupus anticoagulant and, 491 in RA, 121, 1202

LL genotype, CR1 expression in SLE and, 393

Low back pain, in Paget's disease after etidronate disodium, 776

Lumbar spine

in AS, 77

in Paget's disease, etidronate disodium and, 776

Lumbosacral plexopathy, in CREST syndrome and vasculitis, 661

Lung

aerobic fitness in fibrositis and, 454

fibrosis of, fibronection production by alveolar macrophages in SSc and, 577

Lupus. See also Systemic lupus erythematosus murine, retroviral transcripts in, 322

retinopathy, occlusive ocular vascular disease in SLE and, 1053

Lupus anticoagulant
hepatic infarction and, 491
major nucleolar phosphoprotein B23, anticardiolipin antibodies and, 1165
Lupus erythematosus (LE)
drug-induced, synovial analysis in, 560
subacute cutaneous, during PUVA for psoriasis, 343
Lupus nephritis
iC3b neoantigen and, 1233
immunoglobulin idiotypes and, 513
murine autoimmune, tumor necrosis factor and, 146
pulse intravenous methylprednisolone in, 717

Lyme arthritis, *Borrelia burgdorferi* in reactive arthritis and, 1057, 1182

Lyme disease, ELISA in, 1041
Lyme spirochete, Reiter's syndrome and, 1057, 1182
Lymph nodes, IL-6 in collagen arthritis in mice and, 594
Lymphadenopathy
in older-onset SLE, 1226
in RA, HIV infection, Sjögren's syndrome and, 1453

Lymphocyte function-associated antigen 3 (LFA-3), cell adhesion molecules and, 22

Lymphocytes

Borrelia burgdorferi in reactive arthritis and, 1057, 1182 cell adhesion molecules and, 22 IL-2 inhibition by, in SLE, 1356 large granular, neutropenia and, in AS, 355 peripheral blood, 420, 1045, 1371 in RA, 361, 523, 795, 955, 1371 in Sjögren's syndrome, 420, 859, 1214 in SSc, 584, 817, 1031 in systemic vasculitis in HIV infection, 569 T. See T cells

Lymphocytic angiitis, benign, systemic vasculitis in HIV infection and, 569

Lymphocytic vasculitis, plasmacytoma of skull in 1470

Lymphocytic vasculitis, plasmacytoma of skull in, 1470 Lymphoid cells, corticosteroids and, in temporal arteritis, 884

Lymphoid irradiation, in intractable RA, 523 Lymphoma

angiocentric, systemic vasculitis in HIV infection and, 569 methotrexate, IL-1 and, 370 non-Hodgkin's, salivary gland in Sjögren's syndrome and,

toxic effects of azathioprine in RA and, 837 Lymphomatoid granulomatosis, systemic vasculitis in HIV infection and, 569

Lymphopenia, disease heterogeneity model for SLE and, 826

Lymphoproliferation disorders of, systemic vasculitis in HIV infection and, 569 of salivary gland lymphocytes in Sjögren's syndrome, 859 Lymphotoxin, antibodies to, in normal serum, 1148

Lysosomes, electron microscopic analysis of liver biopsy in RA and, 1202

Lytic lesions, in coccidioidomycosis of bone, 1608

M

Macrocytosis, hematologic toxicity, methotrexate and, 1592

Macrophages

Borrelia burgdorferi in reactive arthritis and, 1057, 1182 cell adhesion molecules and, 22

corticosteroids and, in temporal arteritis, 884

cytokines in chronic inflammatory arthritis and, 1074

IL-2 inhibition in SLE and, 1356

in inflammatory myopathy and AIDS, 475

in RA, 947, 955

in reactive arthr is, 955

in SSc, 577, 1031

Magnesium, antiribosomal S10 antibodies in SLE and, 1252 Magnetic resonance imaging (MRI)

cervical spine in RA and, 652 of herniated disc, 504

Major histocompatibility complex

class II, 251, 1074

in pristane-induced arthritis, 1022

Ro (SS-A) and La (SS-B) and, in SLE and Sjögren's syndrome, 413

shared epitopes of, autoimmune disease and, 509 T cell receptor genes, disease susceptibility and, 105

Major nucleolar phosphoprotein B23, autoantibodies to, anticardiolipin antibodies and, 1165

Mammalian stress proteins, arthritis, autoimmunity and, 1497

Marine sponge, Microciona prolifera, NSAID and, 1

Marrow erythroid, erythropoietin therapy of anemia in RA and, 638

Mass spectrometry, detection of muramic acid by, 1268 Mast cells

pathogenesis os SSc and, 817

synovial, in intermittent hydrarthrosis, 357

Maternal Ro (SS-A), in childhood SLE, 1414 Matrix

articular cartilage, in chondrolysis of hip joint in hemodialysis, 1477

extracellular, salicylates, chondrocytes and, in canine OA, 486

Medial femoral condyle

in dogs, alteration to articular cartilage, after running, 1282

glycosaminoglycan polysulfuric acid acid ester in, in canine OA, 1300

Megakaryocyte progenitor cells, erythropoietin therapy of anemia in RA and, 638

Memory

dementia in temporal arteritis in elderly and, 1308 methotrexate toxicity and, 770

Meniscectomy, serum keratan sulfate in rabbit OA and, 1293 Meniscus. proteoglycans in knee joint and, 1434

Menopause, hydroxyapatite pseudopodagra and, 741

Mental status, in temporal arteritis, 1308

Messenger RNA (mRNA), IL-1 in synovial fibroblasts and, 279, 1539

Meta-analysis, in older-onset SLE, 1226

Metabolism, proteoglycan, in articular cartilage, 1197

Metacarpophalangeal joints, simplified articular index in RA and, 531

Metalloproteinase, glycosaminoglycan polysulfuric acid ester in canine OA and, 1300 Metaphysis, femur, in experimental inflammatory arthritis, 617

Metatarsophalangeal joint

in hydroxyapatite pseudopodagra, 741 in retinyl acetate-induced arthritis, 625

subcutaneous cholesterol crystal deposition, tophus and, 1190

Methionine, viscosity of hyaluronic acid and, 461

Methotrexate

in AS, 234

bone marrow toxicity after, 813

Borrelia burgdorferi in reactive arthritis and, 1057, 1182 CNS toxicity and, 770

effects of, on peripheral blood mononuclear cells, 378 IL-1 and, 370

low dose, 1065, 1592

in neutropenia in Felty's syndrome, 194

in RA

corpuscular volume and hematologic toxicity in, 1592 electron microscopic analysis of liver biopsy and, 1202 folic acid after, 113

impotence after, 1341

long-term, liver histology in, 121

outcome measures in clinical trials in, 1093 sulfasalazine and, 1160

toxicity of, 671, 677

Methylated bovine serum albumin, flare reactions of joint inflammation in mice and, 330

Methyldopa-induced SLE, 205

Methylprednisolone

auranofin and, in Felty's syndrome, 1188 intravenous pulse, 505, 717

Microangiopathic hemolytic anemis, in normotensive renal failure in SSc, 1128

Microbiology, in arthritis research, 1186

Microciona prolifera, marine sponge, NSAID and, 1 Microcrystals, inflammatory, IL-6 production and, 1443 Microheterogeneity, of α_1 -acid glycoprotein in infection in

RA, 347 Mink cell focus-forming gene expression, in retroviral tran-

scripts in murine lupus, 322 Miscarriage, in SSc, 151

Missed abortion, hepatic infarction, lupus anticoagulant and,

Mitogens, antigen specificity in RA SF and, 1371

Mixed leukocyte reactions, allogeneic, T cells, dendritic cells and, 1381

Mobility, musculoskeletal, in retinyl acetate-induced arthritis, 625

Monarthritis, inflammatory, of knee, bone changes in, 617 Monkey studies, cynomolgus, collagen arthritis, 748

Monoclonal antibodies α-plasmin inhibitor-plasmin complex in rheumatic diseases and, 1427

anti-CD5, CD3 and CD5 in Sjögren's syndrome, 420 autoantibodies, cognate antigens and, 901, 924 collagen in SF phagocytes and, in RA and OA, 1458 insulin-like growth factor, chondrocyte metabolism and, 66

in RA, 251, 361, 947

Monoclonal antibodies (cont'd)

serum keratan sulfate in rabbit OA and, 1293

in SLE, 406, 513, 1233

T cells in dermal lymphocytes in avian scleroderma and, 1031

Monoclonal antiisotype reagents, anti-CENP-B anticentromere autoantibody and, 1315

Monoclonal IgM

cross-reactive idiotype (IdRQ) in RF and, 134

RF, in JRA, 265

Monoclonal RF, 72, 265

Monocytes

cytokines in inflammatory arthritis and, 1074

human, 279, 1443

pathogenesis of SSc and, 817

peripheral blood. See Peripheral blood monocytes pulse intravenous methylprednisolone in SLE and, 717 in RA, 31, 682, 955

in reactive arthritis, 955

T cells in dermal lymphocytes in avian scleroderma and, 1031

Mononeuritis multiplex, solitary plasmacytoma of skull revealed by, in immune complex vasculitis, 1470

Mononuclear cells

anticollagen in RA and, 1087

corticosteroids in temporal arteritis and, 884

inhibition of neovascularization by methotrexate and, 1065

MX protein in, in SLE, 914

paternal, HLA-DR5, spontaneous abortion and, 1572 peripheral blood. See Peripheral blood mononuclear cells synovial analysis in drug-induced lupus and, 560

Mononuclear phagocytes

Fcγ, pulse intravenous methylprednisolone in SLE and, 717

leukocyte adhesion molecules in, in RA synovial membrane, 947

Monosodium urate (MSU) crystals

IL-6 and, 1443

in SF after arthrocentesis, 271

Mood

alterations of, methotrexate toxicity and, 770 disability and depression in RA and, 1100, 1611

Morbidity

arthroscopic synovectomy for chronic knee synovitis and, 10, 108

factor B activation in SLE and, 1406

Morning stiffness

physical conditioning and, 1396 in RA, 523, 1160

sensitivity of AIMS and, 844

Mortality

from adverse reactions to NSAID, 926 factor B activation in SLE and, 1406

Mouse studies. See also Athymic C57Bl mice; C3H-A^{vy} mice; C57Bl/10 mice; C57Bl/6 mice; DBA/1 mice; MRL/lpr mice; Murine; New Zealand black mice chondrocytes and insulin-like growth factor 1, 894 flare reactions of joint inflammation, 330

IL-1, 370, 1528

IL-2 in type II collagen arthritis, 594

Mouse studies (cont'd)

MX protein in mononuclear cells in SLE, 914

pristane-induced arthritis, 1022

retroviral transcripts in lupus, 322

T cells in dermal lymphocytes in avian scleroderma and,

MRL/lpr mice, antiribosomal S10 antibodies in SLE in, 1252 MT4+, Lyt-2- T cells, flare reaction of joint inflammation in murine arthritis and, 330

Mucous membrane, methotrexate toxicity in JRA and, 677 MUI 36, T cells in dermal lymphocytes in avian scleroderma and, 1031

Multiplanar tomography, cervical spine in RA and, 652

Multiple sleep latency testing, in RA, 974

Multipurpose arthritis centers, evaluation of, 1493

Mumps skin test, immunosuppression with chlorambucil in SSc and, 584

Munchausen syndrome, factitious septic arthritis and, 352 Muramic acid, detection of, by gas chromatography-mass spectrometry, 1268

Murine lupus

antiribosomal S10 antibodies in, 1252

autoimmune nephritis in, tumor necrosis factor in SLE and, 146

endogenous retroviral transcripts in, 322

Muscle

aerobic fitness in fibrositis and, 454

biopsy of, 475, 1470

in drug-induced rhabdomyolysis and polymyositis, 358 inclusion body myositis and, 734

response of peripheral blood mononuclear cells to, in PM/DM, 446

skeletal, in systemic vasculitis in HIV infection, 569 weakness of, in AIDS, 475

Muscosal lesions, adverse reaction of NSAID in upper gastrointestinal tract, 926

Musculoskeletal complaints, unconventional remedies for, 1604

Musculoskeletal mobility, in retinyl acetate-induced arthritis, 625

Mutant fibronectin gene, in skin fibroblasts in PSS, 247 MX homologous protein, in mononuclear cells in SLE, 914 Myasthenia gravis, Hashimoto's thyroiditis and SLE coexisting, 119

Mycobacteria, stress proteins, arthritis, autoimmunity and,

Mycobacterium avium-intracellulare infection, in polymyositis, 934

Mycobacterium tuberculosis, antigen specificity in RA SF and, 1371

Myelopathy, human T lymphotropic virus type I-associated, polyarthritis in, 1342

Myeloperoxidase-derived oxidants, viscosity of hyaluronic acid after exposure to, 461

Myoepithelial sialadenitis, salivary gland lymphocytes in Sjögren's syndrome and, 859

Myopathy

inflammatory, 475, 734 response of peripheral blood mononuclear cells to muscle in PM/DM and, 446

Myositis

atrioventricular heart block in SLE and, 1170

inclusion body, 734

PM/DM and, 445, 1179

N

Nail pitting, in juvenile psoriatic arthritis, 1007

Naproxen, sensitivity of AIMS in RA and, 844

National Arthritis Advisory Board, Task Force on Arthritis Patient Education, 1330

National Arthritis Compliance Survey, 1055

National Health and Nutrition Examination Survey I (NHANES I), smoking in OA and, 166

National Institutes of Health system, for clinical assessment of disease activity in SLE, 1107

Natural killer cells, CD3 and CD5 in Sjögren's syndrome and, 420

Nausea, azathioprine in RA and, 837

Neck

pain in, cervical spine in RA and, 652

T cells in dermal lymphocytes in avian scleroderma and, 1031

"Neck sign," in scleroderma, 209

Necrosis

ischemic (avascular, osteo-), core depression of femoral head in, 797, 801

Necrotizing vasculitis

in HIV infection, 569, 1615

systemic, leg claudication and peripheral neuropathy in,

Needle biopsy, in synovial membrane lymphocyte infiltration in RA, 361

Neoantigens, iC3b, in SLE, 1233

Neonatal SLE, maternal Ro (SS-A) in childhood SLE and,

Neoplasms

salivary gland lymphocytes in Sjögren's syndrome and,

toxic effects of azathioprine in RA and, 837

Neovascularization, by low-dose methotrexate, 1065 Nephritis, lupus

iC3b neoantigen and, 1233

immunoglobulin idiotypes and, 513

pulse intravenous methylprednisolone in, 717

tumor necrosis factor and, 146

Nerves, in vasculitis, 504, 1470

Neuraminidase, pulse intravenous methylprednisolone in SLE and, 717

Neuro-Behçet's disease, CNS vasculitis treated by cytotoxic drugs in, 217

Neurologic involvement, in Paget's disease, etidronate disodium and, 776

Neuropathy, peripheral, leg claudication and, in vasculitis, 510

Neuropsychiatric involvement, in SLE, 1226, 1243

Neutropenia large granular lymphocytes and, in AS, 355 Neutrophils

cartilage proteoglycans in antigen-induced arthritis and,

IL-1 inhibitory IgG in RA and, 1528

methotrexate in Felty's syndrome and, 194

NSAID and, 1

synovial analysis in drug-induced lupus and, 560 viscosity of hyaluronic acid and, 461

New York Hospital for Special Surgery system, for clinical assessment of disease activity in SLE, 1107

New Zealand black mice, retroviral transcripts in lupus in,

Newcastle disease virus-induced IFN, in pristane-induced arthritis, 1022

9.2-kb Pvu II restriction fragment length polymorphism, class I HLA, characterization of, 870

Nitrogenase, Klebsiella pneumoniae, cross-reactive epitope with in AS, 437

Nodal OA, urate-mediated inflammation in, 86

Non-Hodgkin's lymphoma, salivary gland lymphocytes in Sjögren's syndrome and, 859

Nonarticular cartilage, protein in RA and, 1080 Nonsteroidal antiinflammatory drugs (NSAID)

adverse effects of, in upper gastrointestinal tract, 926 auranofin in psoriatic arthritis and, 158

IL-1 in cartilage and, 288 mechanisms of action of, 1 sensitivity of AIMS and, 844

Normotensive renal failure, in SSc, 1128

Northern blot analysis

of IL-1 gene expression in synovial fibroblasts, 279 of retroviral transcripts in murine lupus, 322

Nose cartilage, IL-1 in, in bovine studies, 288

Nuclear antigens, extractable, racial differences in SSc and, 54

Nuclear resonance imaging, in childhood reflex neurovascular dystrophy, 480

Nuclear ribonucleoprotein (nRNP), in SLE, 1170, 1414 Nucleolar phosphoprotein B23, autoantibodies to, anticardiolipin antibodies and, 1165

Nucleolysis, plasma DNA in SLE and, 726

Nucleosides, deoxyadenosine toxicity in rabbit cartilage and, 1014

Nucleotides

class II major histocompatibility complex gene sequence in RA and, 251

effects of methotrexate on peripheral blood mononuclear cells and, 378

plasmid DNA in SLE and, 726

Nursing homes, arthritis in residents of, 1546

O

Obituaries

Mitchell, Donald M., 112 Robinson, William Dodd, 233

Occlusive ocular vascular disease, in SLE, 1053

Occupational therapists, to administer Juvenile Arthritis Functional Assessment Scale, 1390

Odontoid process, cervical spine in RA and, 652

Older-onset SLE, meta-analysis in, 1226

Olecranon bursitis, chronic fungal, caused by Penicillium,

Oligoarticular JRA, nonarticular cartilage in, 1080

Oligoclonal rearrangement, of genes in salivary gland lymphocytes in Sjögren's syndrome, 859

Oligonucleotide probes

HLA genes in RA and, 15

in retroviral transcripts in murine lupus, 322

Oligosaccharide chains, glycosylation, IgG and, in chronic inflammatory diseases, 235

1,25-dihydroxyvitamin D₃, cyclosporin A, T cells and, in RA. 31

1A5 lymphoma cells, methotrexate, IL-1 and, 370

Opportunistic infections, HIV infection in rheumatic diseases and, 1615

Oral gold, outcome measures in RA clinical trials and, 1093 Organ culture studies, IL-1 in cartilage, 288

Osmic acid, arthroscopic synvectomy for chronic synovitis and, 10, 108

Osteoarthritis (OA)

AIMS in, 844

calcaneal spurs in, 338

corticosteroids in, 181

gait after anterior cruciate ligament transection in, 1142 glycosaminoglycan polysulfuric acid ester in, 759, 1300 salicylates and chondrocytes in, 486

serum keratan sulfate and hyaluronate in, 312

collagen in, 814, 1458

of hand, radiographic grading scale for, 1584

information dissemination, functional status and, 1577

leukocyte adhesion molecules in synovial membrane in RA and, 947

nodal, urate-mediated inflammation in, 86

in nursing home residents, 1546

Panner's disease and, 341

physical conditioning exercise in, 1396 proteoglycans in knee joint and, 1434

in rabbits, 814, 1293

serum keratan sulfate and cartilage in, 647, 1293

smoking and, 166

Osteogenesis, in experimental inflammatory arthritis in rabbits, 617

Osteolysis, periarticular, in urate-mediated inflammation in nodal OA, 86

Osteomyelitis, septic acromioclavicular arthritis in AIDS and, 1175

Osteonecrosis, core decompression of femoral head in, 797,

Osteophytes, in OA, 181, 1293, 1584

Outcome measures

in RA

in clinical trials, 1093

radiologic assessment as, 221 self-efficacy scale and, 37

Outcome studies

of pregnancy in SSc, 151

in RA, 851, 1505

sensitivity of AIMS and, 844

Outpatient treatment, cost-effectiveness of, in RA, 1505

Ovaries, buserelin in SLE and, 1186

Oxidants, myeloperoxidase-derived, viscosity of hyaluronic acid and, 461

Oxygen uptake, in aerobic fitness in fibrositis, 454

p150,95 leukocyte adhesion molecules, mononuclear phagocytes in RA synovial membrane and, 947

P protein, antiribosomal S10 antibodies in SLE and, 1252 Paget's disease of bone, etidronate disodium and, 776 Pain

in acute peritendinitis calcarea, 767

arthritis in nursing home residents and, 1546

bone in Paget's disease after etidronate disodium and, 776

in hydroxyapatite pseudopodagra, 741

index of, in AS, 77 inflammation of deep infrapatellar bursa of knee and, 1312 information dissemination to patients with OA and, 1577

in RA control of, rational thinking and, 984

depression and, 991, 1100

disability and, 1100

effect of temperature and humidity on, 1627

functional impairment and, 851

intractable, scores of, after lymphoid irradiation, 523 neck, cervical pain and, 652

self-care education in arthritis and, 706

sensitivity of AIMS and, 844

shoulder, in peritoneal dialysis, 785

Pancytopenia, subacute cutaneous LE during PUVA for psoriasis and, 343

Panner's disease, 341

Pannus, inhibition of neovascularization by methotrexate and, 1065

Paraprotein, monoclonal IgM, cross-reactive idiotype (IdRQ) in RF and, 134

Parotid salivary gland, swelling of, in Sjögren's syndrome,

Patellar cartilage

chondrocytes and insulin-like growth factor 1 in, in experimental arthritis, 894

in dogs, alterations to, after running, 1282

Paternal leukocytes, HLA-DR5 and, in spontaneous abortion, 1572

Pathogenesis

in childhood reflex neurovascular dystrophy, 480 in PM/DM with dermatitis herpetiformis, 1179 retinyl acetate-induced arthritis and, 625 of SSc, 247, 430, 817

Pathogenetics

chondrocytes and insulin-like growth factor 1 in experimental arthritis and, 894

complement activation in SSc and, 1262

congenital heart block and, 1421

erythropoietin therapy of anemia in RA and, 638

Patient assessment

clinical assessment of disease activity in SLE and, 1107 hand radiographs in disability assessment in RA and, 128, 1340

Patient education

efficacy, implementation, and financing, 1330 for self-care in arthritis, 706

Pauciarticular JRA, antihistones H1 and H5 in, 877 Pauciarticular juvenile psoriatic arthritis, 1007 "Pencil-in-cup" deformities, in Behçet's disease, 1629

Penicillamine in JRA, 1185

outcome measures in RA clinical trials and, 1093

Pentosan polysulfate, cartilage degradation by, 608

Pepsin, cross-reactive antiidiotypic antibodies, RF and, in JRA, 699

Peptides

cyanogen bromide, in collagen arthritis in monkeys, 748 synthetic, cross-reactive epitopes in AS and, 437

2-Md plasmid from Shigella flexneri in reactive arthritis and, 937

Peptidoglycans, detection of muramic acid by gas chromatography-mass spectrometry and, 1268

Peptones, cartilage degradation by polysulfated polysaccharides and, 608

Periarthritis, calcific, in hydroxyapatite pseudopodagra, 741 Periarticular bone formation, retinyl acetate-induced arthritis in mice and, 625

Periarticular osteolysis, in urate-mediated inflammation in nodal OA, 86

Perinatal death and SSc, 151

Periostitis, in pristane-induced arthritis, 1022

Peripheral blood

dendritic cells in, 1381

lymphocytes

antigen specificity of, in RA SF, 1371

CD3 and CD5 in Sjögren's syndrome, 420

poly(ADP-ribose) metabolism and, in SLE, 1045

monocytes, 279, 1074

mononuclear cells

methotrexate and, 371, 378

response of, to muscle in PM/DM, 446

synovial membrane lymphocytes in RA and, 361

T cells, 386, 1057, 1182, 1381

Peripheral neuropathy, leg claudication and, in systemic necrotizing vasculitis, 510

Peripheral vascular involvement, α-adrenergic responses in Raynaud's disease and, 61

Perisinusoidal space, electron microscopic analysis of liver biopsy in RA and, 1202

Peritendinitis calcarea, acute, 767

Peritoneal cells, methotrexate, IL-1 and, 370

Peritoneal dialysis, rheumatic disease and β_2 -microglobulin in, 785

Pertussis toxin, NSAID and, 1

Phagocytes

mononuclear, leukocyte adhesion molecules in, in RA,

pulse intravenous methylprednisolone in SLE and, 717 SF, type II collagen in, 1458

Phagocytosis, immune complexes in RA and, 1521

Pharmaceutical industry

drug surveys sponsored by, 1055

"honoraria" offered by, 1490

Phenotypes, HLA-DQ antigens and, in RA and reactive arthritis, 955

Phenylephrine, α-adrenergic responses in Raynaud's disease and, 61

Phorbol esters, IL-1 regulation of collagenase mRNA and, 1539

Phorbol myristate acetate, CD3, CD5 and, in Sjögren's syndrome, 420

Phosphatase, alkaline, electron microscopic analysis of liver biopsy in RA and, 1202

Phosphoprotein B23, major nucleolar, autoantibodies to, anticardiolipin antibodies and, 1165

Photochemotherapy, subacute cutaneous LE during PUVA for psoriasis and, 343

Photosensitivity, in SLE, 202, 205

Physical activity, smoking in OA and, 166

Physical fitness, in fibrositis, 454

Physical conditioning exercise, in RA and OA, 1396

Physical function, sensitivity of AIMS and, 844

Physical therapists to administer Juvenile Arthritis Functional Assessment Scale, 1390

arthritis in nursing home residents and, 1546 in assessment of disability and depression in RA, 1100

Physical therapy, cervical spine in RA and, 652 Physician assessment

of auranofin in psoriatic arthritis, 158 of disease activity in SLE, 1107

in RA, 128, 1093, 1340

Physicians and surgeons arthritis in nursing home residents and, 1546 clinical assessment of disease activity in SLE and, 1107

participation of, in drug surveys, 1055 Phytohemagglutinin

CD3, CD5 and, in Sjögren's syndrome, 420

cyclosporin A, 1,25-dihydroxyvitamin D₃, T cells and, in RA, 31

methotrexate, IL-1 and, 370

Piroxicam, prostaglandins and, 1

Plasma DNA, in SLE, 726

Plasma exchange, nonarticular cartilage in RA and, 1080 Plasma infusion treatment, of C2 deficiency in SLE, 906 Plasmacytoma, of skull, in immune complex vasculitis, 1470 Plasmacytoma cells, IL-6 in collagen arthritis in mice and, 594

Plasmalemma, NSAID and, 1

Plasmapheresis, bone marrow proliferation and, in SLE and aplastic anemia, 901, 924

Plasmid, 2-Md, from Shigella flexneri, in reactive arthritis, 937

Plasmin inhibitor-plasmin complex, in rheumatic diseases, 1427

Platelets

NSAID and, 1

in SSc, 584, 817, 1631

Plexopathy, lumbosacral, in CREST syndrome and vasculitis, 661

Pneumonia

coccidioidomycosis of bone and, 1608

infectious complications of cyclophosphamide in vasculitis and, 45, 1626

Podagra, gouty, hydroxyapatite pseudopodagra and, 741 Pokeweed mitogen

anti-CD4+2H4+ antilymphocyte antibodies in SLE and, 398 Pokeweed mitogen (cont'd)

effects of methotrexate on peripheral blood mononuclear cells and, 378

RF cross-reactive idiotype in JRA and, 265

Polyacrylamide gel electrophoresis, binding of dsDNA to glomeruli in rats and, 298

Poly(ADP-ribose) metabolism, in peripheral blood lymphocytes in SLE, 1045

Polyarteritis nodosa

infectious complications of cyclophosphamide in, 45 internal carotid artery in, 1625

Polyarthritis

auranofin in psoriatic arthritis and, 158

in human T lymphotropic virus type I-associated myelopathy, 1342

inflammatory, HIV infection and, 1453

Polyarthropathy, inflammatory, 2-Md plasmid in *Shigella flexneri* in reactive arthritis, 937

Polyarticular JRA

antihistones Hi and H5 in, 877 methotrexate toxicity in, 677

nonarticular cartilage in, 1080

Polyarticular juvenile psoriatic arthritis, 1007

Polychondritis, nonarticular cartilage in RA and, 1080 Polyclonal IgG antibodies, collagen, C1q and, in SLE, 1601 Polyclonal IgM rheumatoid factor, cross-reactive antiidiotypic antibodies in JRA and, 699

Polymorphisms

C4AQ0, C4B5 alleles and, 691

CR1 gene, in SLE, 1465

DNA, 634, 1243, 1365

restriction fragment length, 393, 870, 1243, 1325, 1597 T cell receptor genes, disease susceptibility and, 105

Polymyalgia rheumatica, Corynebacterium kutscheri septic arthritis in, 1053

Polymyositis (PM)

cholesterol-lowering agents in drug-induced rhabdomyolysis and, 358

dermatitis herpetiformis and, 1179

HIV infection and, 1615

inclusion body myositis and, 734

inflammatory myopathy, AIDS and, 475

Mycobacterium avium-intracellulare infection in, 934 response of peripheral blood mononuclear cells to muscle

in, 446 Polypeptides

Ki antigen in SLE and, 1554

major nucleolar phosphoprotein B23 and, autoantibodies to, 1165

racial differences in ANA in scleroderma and, 54

Polysulfates, cartilage degradation by, 608

Pond-Nuki dog OA studies

corticosteroid, cartilage, and osteophytes, 181 glycosaminoglycan polysulfuric acid ester in, 759

Prayer, as unconventional remedy for arthritis, 1604 Prednisone

cell subsets in temporal arteritis and, 884 methotrexate and sulfasalazine in RA and, 1160 in Pond-Nuki dog OA model, 181

in SLE, 205, 665

Pregnancy

HLA-DR5 in spontaneous abortion and, 1572

in SLE, 665 in SSc, 151

Primary Raynaud's disease, "neck sign" in scleroderma and, 209

Pristane-induced arthritis, 1022

Procollagen gene restriction fragment length polymorphisms, in scleroderma, 1597

Progressive systemic sclerosis (PSS), mutant fibronectin gene in skin fibroblasts in, 247

Prostaglandin E, effect of tumor necrosis factor and γ-IFN on, 780

Prostaglandin E,

NSAID and,

suppression of synovial cells by dihomo-γ-linolenic acid and, 1273

Prostaglandin E2

HLA-DR expression on RA monocytes and, 682

IL-1 and, 279, 288

suppression of synovial cells by dihomo-γ-linolenic acid and, 1273

Prosthetic joints, septic arthritis in, in RA, 496, 1487 Protein

antibodies to

in RA, 134, 1080, 1371 in SLE, 205, 914, 1252

antilymphotoxin, tumor necrosis factor, 1148

anti-RA33, in RA, 1515

Borrelia burgdorferi in reactive arthritis, 1057, 1182

centromere B fusion (CENP-B), 1315

C-reactive, 117, 139, 643

EBV, in Sjögren's syndrome, 811

HIV major core, in inflammatory myopathy and AIDS,

IL-1 regulation of collagenase mRNA, 1539

IL-6 and, 594, 1443

in JRA, 877, 919

major nucleolar phosphoprotein B23 and anticardiolipin antibodies, 1165

retinol-binding, in hereditary amyloidosis, 1474

Proteinase, serine, glycosaminoglycan polysulfuric acid ester in canine OA and, 1300

Proteinase K, antinuclear antibody (anti-RA33) in RA and, 1515

Proteinuria, pregnancy and, in SLE, 665

Proteoglycans

cartilage, 288, 601, 608, 1197, 1282

chondrocytes, insulin-like growth factor and, 66, 894

in knee joint after injury, 1434

serum keratan sulfate and, 100, 647

synthesis of, glycosaminoglycan polysulfuric acid ester in canine OA and, 759, 1300

Proto-oncogenes, in SSc, 430

Proximal interphalangeal joints

counts of, in RA, 531, 1093

in radiographic grading scales for OA of the hand, 1584
Pseudogout

proteoglycans in knee joint and, 1434

IL-6 in, 1443

Pseudolymphoma, salivary gland lymphocytes in Sjögren's syndrome and, 859

Pseudopodagra, hydroxyapatite, in young women, 741

Psoriatic arthritis

atlantoaxial subluxation in, 1338

auranofin in, 158

in children, 1007

HIV infection and, 1615

Psoriatic arthropathy, in the 17th century, 812

Psychological factors in RA, 851, 984, 1100, 1611 Psychological factors, self-efficacy scale in arthritis and, 37

Psychological status

information dissemination to patients with OA and, 1577 sensitivity of AIMS and, 844

Pulmonary hemorrhage, in normotensive renal failure in SSc, 1128

Pulmonary interstitial fibrosis, fibronectin production in SSc and, 577

Pulmonary involvement

methotrexate toxicity in JRA and, 677

in SLE, 1226, 1487

Pulse intravenous methylprednisolone, in SLE, 717

Purpura, idiopathic thrombocytopenic, antilymphotoxin and antitumor necrosis factor in, 1148

Pyelography, anticardiolipin antibodies and arterial thrombosis after, 1490

Pyrimethamine therapy for inflammatory myopathy and AIDS, 475

Pyrophosphate synovitis, proteoglycan in knee joint SF and, 1434

Q

Ouestionnaires

AIMS, 128, 1153, 1340

Beck Depression Inventory, 1100

Center for Epidemiological Studies Depression Scale, 991

Coping Strategies, 851, 984

Health Assessment Questionnaire, 837, 1100

Juvenile Arthritis Functional Assessment Scale, 1390

R

RA33 antigen, in RA, 1515

Rabbit studies

bone changes in experimental inflammatory arthritis, 617 cartilage changes, 601, 608, 1014

cross-reactive antiidiotypic antibodies to human RF and,

inhibition of neovascularization by methotrexate, 1065 Ki antigen in SLE and, 1554

of OA, 814, 1293

Racial differences

DNA analysis of DR and DQ genes in blacks with SLE, 1243

in scleroderma, 54, 1597

Radiographic grading scales for OA of the hand, 1584

Radiography

after arthroscopic synovectomy for knee synovitis, 10, 108 in AS, 77

in destructive arthritis, 1221

Radiography (cont'd) in RA, 128, 221, 652, 1341 in tumoral calcinosis, 1484

Radioimmunoassay

for anti-endothelial cell antibodies in rheumatoid vasculitis, 1191

for cartilage-specific proteins in RA, 1080 for insulin-like growth factors in RA, 66 for tumor necrosis factor in SLE, 146

Radionuclide injections, failure of, in chronic knee synovitis, 10, 108

Range of motion

in hydroxyapatite pseudopodagra, 741 physical conditioning and, 1396 in a simplified articular index for RA, 531

Rash

in children with psoriatic arthritis, 1007 photosensitivity, anti-Ro antibody and, in SLE, 202 Rat studies

binding of dsDNA to glomeruli, 298 cartilage degradation by polysulfated polysaccharides, 608 cross-reactive epitopes in human AS and, 437

IL-1 gene expression in synovial fibroblasts, 279 serum hyaluronate in experimental arthritis, 306 Rational thinking and pain control in RA, 984

Raynaud's disease

idiopathic, α -adrenergic responses in, 61 "neck sign" in, 209

Raynaud's phenomenon in SLE, 1226, 1487
Reactive amyloidosis, lack of restriction fragment length
polymorphism for amyloid P gene in, 1325

Reactive arthritis

cross-reactive epitopes in, 437 detection of muramic acid in synovial fluids in, 1268 HIV infection and, 1615

immune responses to *Borrelia burgdorferi* in, 1057, 1182 RA and, 955, 1080

Shigella flexneri plasmid in, 937

Reactive arthritides, stress protein, autoimmunity and, 1497 Recombinant y-IFN

in RA, 964 in systemic JRA, 643

Recombinant human cytokines in cultures of human articular cartilage, 173

Recombinant human erythropoietin, treatment of anemia in RA with, 638

Recombinant IL-1

cartilage proteoglycans in antigen-induced arthritis and, 601

suppression of synovial cells by dihomo-γ-linolenic acid and, 1273

Rectal biopsy for amyloid in hereditary amyloidosis, 1474 Red blood cells

erythropoietin therapy for anemia in RA and, 638 fine specificity of anti-Ro (SS-A) and, 1563 Reflex neurovascular dystrophy in children, 480

Refractory RA antithymocyte globulin therapy for, 1495 intravenous pulse cyclophosphamide for, 933

Rehabilitation after arthroscopic synovectomy for chronic synovitis, 10, 108

Reiter's syndrome

calcaneal spurs in, 338 HIV infection in, 1615

immune responses to *Borrelia burgdorferi* in, 1057, 1182 Lyme spirochete and, 1057, 1182

Relaxation, as unconventional remedy for arthritis, 1604 Renal biopsy

in acute rheumatic fever and acute glomerulonephritis, 230, 236

immunoglobulin idiotypes in SLE and, 513

Renal crisis, in SSc, 151, 1128 Renal disease, in SLE, 398, 826

Renal failure

chronic, destructive spondylarthropathy and, 1492 normotensive, in SSc, 1128

in rheumatic fever and poststreptococcal glomerulonephritis, 236

Renal glomeruli, binding of dsDNA to, in rats, 298 Renal involvement

in acute rheumatic fever and glomerulonephritis, 230, 236 CNS toxicity after methotrexate and, 770 in SLE, 1233, 1243

"Renal Raynaud's phenomenon," in SLE, 1487

Respiratory gas exchange and aerobic fitness in fibrositis,

Restriction fragment length polymorphism for serum amyloid P gene in reactive amyloidosis, 1325 in scleroderma, 1597

in SLE, 1243, 1465

Restriction site polymorphisms in RA, 634

Retinol-binding protein, in hereditary amyloidosis, 1474 Retinyl acetate-induced arthritis, in C3H-A^{vy} mice, 625 Retroviral transcripts, endogenous, in murine lupus, 322

Rhabdomyolysis, drug-induced, cholesterol-lowering agents in, 358

Rheumatic diseases

 α_1 -plasmin inhibitor-plasmin complexes in, 1427 anticollagen and C1q in, 544

 β_2 -microglobulin amyloidosis and, in long-term peritoneal dialysis, 785

calcaneal spurs in, 338 HIV infection and, 1615

infectious arthritis complicating, 496, 1487 sensitivity of the AIMS in, 844

VLA antigen in SF T cells in, 386

Rheumatic fever

acute, and coexistent acute glomerulonephritis, 230, 236

Rheumatism, desert (coccidioidomycosis), 1608

Rheumatoid arthritis (RA) AIMS in, 844, 1153

 α_1 -acid glycoprotein and infection in, 347

 α_2 -plasmin inhibitor-plasmin complex in, 1427 anemia in, recombinant human erythropoietin therapy of, 638

anticollagen in, 544, 1087 anticollagen antibodies in, 139 antigen specificity of SF in, 1371

antihistone antibodies in, 1319 antinuclear antibody (anti-RA33) in, 1515

antithymocyte globulin therapy in, 1494 arthroscopic synovectomy for chronic synovitis in, 10, 108 Rheumatoid arthritis (cont'd) articular index in. 531 auranofin in, and psoriatic arthritis, 158 azathioprine in, 837 bone changes in experimental inflammatory arthritis and, Clq in, 511, 544 C4AQ0 and C4B5 alleles in, 691 cartilage in, 1080 cell adhesion molecules in, 22 Center for Epidemiological Studies Depression Scale in, cervical spine in, 652 chondrocyte metabolism and insulin-like growth factors in. 66 class II major Listocompatibility gene sequences in, 251 classic, RF and HLA-DR4 in, 1221 collagen, type II, in, 1458 cost-effectiveness of inpatient and outpatient treatment of, C-reactive protein, RF, and immune complexes in, 117 cross-reactive antiidiotypic antibodies and RF in JRA and, cross-reactive idiotype (IdRO) in RF in, 134 cyclosporin A, T cells, and 1,25-dihydroxyvitamin D₃ in, 31 cytokines in, 1074 definite, RF and HLA-DR4 in, 1221 depression and disability in, 1100 detection of muramic acid in, 1268 DNA polymorphism of immunoglobulin k in, 634 effect of temperature and humidity on pain scores in, 1627 electron microscopic analysis of liver biopsy in, 1202 flare reactions of joint inflammation in mice and, 330 functional impairment and pain in, 851 y-IFN in, 964 hand radiographs in disability assessment in, 128, 1340 HIV infection in, 1453 HLA genes in, 15 HLA-DR in, 663, 682 HLA-DR4 in, 1365 IL-1 in, 279, 370, 1539 IL-1-inhibitory IgG in, 1528 immune complexes in, 117, 1521 immunoglobulin k genotype in, 1365 impotence after methotrexate in, 1341 infection in, 347, 1453 infectious arthritis complicating, 496, 1487 inhibition of neovascularization by methotrexate in, 1065 insulin-like growth factor and chondrocyte metabolism in, intractable, lymphoid irradiation in, 523 joint erosions and Clq in, 511 leukocyte adhesion molecules in synovial membranes in, lymphocytes in, 361, 1371 lymphoid irradiation in, 523 methotrexate in, 113, 114, 115, 121, 370, 378, 1065, 1160, monocytes in, HLA-DR expression on, 682 nonarticular cartilage in, 1080

Rheumatoid arthritis (cont'd) in nursing home residents, 1546 1,25-dihydroxyvitamin D3, cyclosporin A, and T cells in, 31 outcome measures in, 221, 1093 pain in, 851, 984, 1627 physical conditioning exercise in, 1396 poly(ADP-ribose) metabolism in SLE and, 1045 posterior tibial tendon in, 359, 1050 pregnancy in SSc and, 151 pristane-induced arthritis and, 1022 psychological factors in, 1100, 1611 radiologic assessment in, 221 refractory, 933, 1495 RF in, 117, 134, 505, 1221 seronegative, 1221 seropositive, 1221, 1453 SF in, 1371 Sjögren's syndrome in, 1453 sleep in, 974 Spanish language AIMS in, 1153 stress proteins, autoimmunity and, 1497 sulfasalazine in, 1160 suppression of synovial cells by dihomo-y-linolenic acid and, 1273 synovitis in, 10, 108 synovium in, 795 T cells in, 31, 116, 505, 795, 1381 T helper cells in synovium in, 795 vasculitis in, 1427 viscosity of hyaluronic acid and, 461 VLA antigen in, 386 Rheumatoid factor (RF) cross-reactive idiotypes in, 134, 265 in Felty's syndrome, 1319 HLA-DR4 and, in destructive arthritis, 1221 human, immunoglobulin VH genes and, 72 IgM, 361, 378, 1521 in JRA, 265 in pristane-induced arthritis, 1022 in RA, 117, 361, 505, 634, 1087, 1319, 1528 Rheumatoid joints, detection of muramic acid in, 1268 Rheumatoid vasculitis, anti-endothelial cell antibodies in, 1191 Rheumatology and rheumatologists Alphonsus of Ligouri, historical article, 807 assessment of disability and depression in RA and, 1100 participation of, in drug surveys, 1055 recognition of, as medical subspeciality, 1193 role of, in arthroscopic synovectomy, 108 Rheumatology research, patient education and, 1330 Ribosomal protein, antiribosomal S10 antibodies in SLE and, 1252 Ridging, in "neck sign" in scleroderma, 209 Ritchie articular index, lymphoid irradiation in intractable RA and, 523 RNA IL-1 gene expression in synovial fibroblasts and, 279 proto-oncogenes in SSc and, 430 retroviral transcripts in murine lupus and, 322

RNase, antinuclear antibody (anti-RA33) in RA and, 1515

RNP, nuclear, atrioventricular heart block and, in SLE, 1170 Ro (SS-A)

autoantibodies, 413, 1421

fine specificity of anti-Ro (SS-A), 1563 maternal, in childhood SLE, 1414

Ropes system, in clinical assessment of disease activity in SLE, 1107

Running, alterations to articular cartilage in dogs after, 1282

Sacroiliac involvement, in AS, 77

Sacroiliitis, in atlantoaxial subluxation in psoriatic arthritis,

Salicylates, chondrocytes and, in canine OA, 486

Salivary gland

lymphocytes, in Sjögren's syndrome, 859

sublabial, in immunohistologic diagnosis of Sjögren's syndrome, 1214

Salsalate, thyroid function tests and, 1344

Scl-70, and racial differences in scleroderma, 54

Scleroderma

avian, T cells in dermal lymphocytes in, 1031

bowel disease in, home central venous hyperalimentation and, 212

diffuse, 54, 430

immunosuppression with chlorambucil in, 584, 1631

"neck sign" in, 209

normotensive renal crisis in, 1128

prevalence of, in South Carolina, 998

procollagen gene restriction fragment length polymorphisms in, 1597

production of fibronectin by alveolar macrophages in, 577 racial differences in ANA in, 54

Self-assessment, in RA, 538, 1100, 1611

Self-care education, in arthritis, 706

Self-efficacy, development and evaluation of scale to measure, in arthritis, 37

Senile dementia, arthritis in nursing home residents and, 1546

Septic arthritis

acromioclavicular, osteomyelitis and, in AIDS, 1175 complicating RA, 496, 1487

Corynebacterium kutscheri, 1053

factitious, 352

herpes zoster and, 506

HIV infection and, 1615

Septic synovial fluid, detection of muramic acid in, 1268 Septicemia, after home central venous hyperalimentation in

scleroderma bowel disease, 212 Serine proteinase, glycosaminoglycan polysulfuric acid ester in canine OA and, 1300

Seronegative destruction arthritis, RF and HLA-DR4 in,

Seronegative JRA, RF cross-reactive idiotype in, 265

Seronegative psoriatic arthritis, auranofin in, 158

Seronegative RA

anticollagen in, 139, 1087 RF and HLA-DR4 in, 1221

Seronegative spondylarthropathy juvenile psoriatic arthritis and, 1007

T cell response to dendritic cells in, 1381

Seropositive inflammatory arthritis, pristane-induced, 1022 Seropositive RA

effect of temperature and humidity on pain in, 1627 anticollagen in, 139, 1087

RF and HLA-DR4 in, 1221

Serositis, in older-onset SLE, 1226

Serum amyloid P gene restriction fragment length polymorphism and reactive amyloidosis, 1325

Serum keratan sulfate in OA, 647, 1293

antigen-induced arthritis in C57Bl/10 mice and, 789

collagen arthritis in monkeys and, 748

male, maternal Ro (SS-A) in childhood SLE and, 1414 smoking in OA and, 166

Shigella flexneri, 2-Md plasmid from, in reactive arthritis, 937

Shoulder

coccidioidomycosis of bone and, 1608

joint, keratan sulfate, hvaluronate and, in canine OA, 312 pain in, after long-term peritoneal dialysis, 785 simplified articular index in RA and, 531

Sialadinitis, myoepithelial, salivary gland lymphocytes in

Sjögren's syndrome and, 859 Sibling studies, genetic and environmental factors in AS, 77

65K stress protein, arthritis, autoimmunity and, 1497

Sjögren's syndrome

anticollagen and C1q in, 544

anti-Ro (SS-A) in, 1563

EBV in, 811

HIV infection in, 1615

immunohistologic diagnostic criterion for, 1214

in older-onset SLE, 1226

primary, 413, 420

in RA, HIV infection in, 1453

salivary gland lymphocytes in, 859

thrombocytopenia in, 234

Skin

biopsy of, in hereditary amyloidosis, 1474

fibroblasts in, 247, 279

methotrexate toxicity in JRA and, 677

plasma infusion therapy of C2 deficiency in SLE and, 906 in SSc, 54, 151, 209, 1031

Skull, solitary plasmocytoma of, in immune complex vasculitis, 1470

Sleep, in RA, 974

Smoking, OA and, 166

Smooth endoplasmic reticulum, electron microscopy analysis of liver biopsy in RA and, 1202

Social factors

self-care education in arthritis and, 706 work disability in women with RA and, 538

Socioeconomic factors, in AIMS in English-Spanish format, 1153

Sodium salicylate

chondrocytes and, in canine OA, 486

mechanisms of action of, 1

Soft tissue, urate-mediated inflammation in nodal OA and,

SP-54 (pentosan polysulfate), cartilage degradation by, 608 Spinal stenosis and Paget's disease after etidronate disodium therapy, 776

Spine

cervical, in atlantoaxial subluxation in psoriatic arthritis,

in Paget's disease after etidronate disodium and, 776 radiography of, Alphonsus of Ligouri, historical article,

subaxial, in RA, 652

Spirochetes

Borrelia burgdorferi in reactive arthritis, 1057, 1182 Lyme disease, Reiter's syndrome and, 1057, 1182

fine specificity of anti-Ro (SS-A) and, 1563 methotrexate, IL-1 and, 370

retroviral transcripts in murine lupus and, 322 Spondylarthropathy

destructive, in chronic renal failure, 1492

seronegative, juvenile psoriatic arthritis and, 1007 Spondylitis, atlantoaxial subluxation in psoriatic arthritis and, 1338

Spontaneous abortion, HLA-DR5 in, 1572

Sports activity history, smoking in OA and, 166

Spouse assessment of disability and depression in RA, 1100 Staphylococcus aureus, septic acromioclavicular arthritis and osteomyelitis in AIDS and, 1175

Statistics, meta-analysis in older-onset SLE, 1226

Stenosis, spinal, and Paget's disease after etidronate disodium, 776

Steroid drugs

cartilage, osteophytes and, in Pond-Nuki dog model of OA, 181

in CNS vasculitis in Behçet's syndrome, 217

intraarticular injections of, and synovial mast cells in hydrarthrosis, 357

Stifle joint, after anterior cruciate ligament transection in dogs, 1142

Streptococcal infection in acute rheumatic fever and acute glomerulonephritis, 230, 236

Stress proteins, arthritis, autoimmunity and, 1497 Stromal interactions, cell adhesion molecules and, 22

Subacute cutaneous LE, during PUVA for psoriasis, 343 Subaxial spine, cervical spine in RA and, 652

Subchondral cysts of bone, in long-term peritoneal dialysis,

Subcutaneous cholesterol crystal deposition, tophus formation and, 1190

Sublabial salivary glands as immunohistologic diagnostic criterion for Sjögren's syndrome, 1214

Subluxation

atlantoaxial, in psoriatic arthritis, 1338

cervical spine in RA and, 652

Submandibular salivary gland, swelling of, in Sjögren's syndrome, 859

Sulfasalazine

Borrelia burgdorferi in reactive arthritis and, 1057, 1182 methotrexate and, in RA, 1160

Sulfated glycosaminoglycans

cartilage proteoglycans in antigen-induced arthritis and, 601

synthesis of human cytokines and, 173

Superior vena cava obstruction, after home central venous hyperalimentation in scleroderma bowel disease, 212

Suppressor/cytotoxic cells

synovial membrane lymphocyte infiltration in RA and, 361 in inflammatory myopathy and AIDS, 475

Suppressor/inducer cells

anti-CD4+2H4+ antilymphocyte antibodies in SLE and, 398

in RA, 116

Sural nerve vasculitis, 504

Surgery

in RA, 652, 1627

corticosteroids in Pond-Nuki dog model of OA and, 181

Survival

of infants of mothers with SSc. 151 methotrexate toxicity and, 1592

Swelling

cartilage, glycosaminoglycan polysulfuric acid in canine OA and, 759, 1300

in hydroxyapatite pseudopodagra, 741

salivary gland, in Sjögren's syndrome, 859

in RA, 531, 964

subcutaneous cholesterol crystal deposition, tophus formation and, 1190

Swimming, physical conditioning and, in RA and OA, 1396 Synovectomy, arthroscopic, in chronic knee synovitis, 10, 108

Synovial cells

mast, in intermittent hydrarthrosis, 357

suppression of, by dihomo-y-linolenic acid, 1273

Synovial cysts, in zygapophyseal joints, 660

Synovial fibroblasts

cell adhesion molecules and, 22

IL-1 and, 279, 1539

recombinant cytokines, glycosaminoglycan synthesis, cartilage and, 173

Synovial fluid (SF)

cytokines in chronic inflammatory arthritis and, 1074 dendritic cells and T cells in, 1381

examination of, after arthrocentesis, 271

IL-6 in, 1443

immune complexes in RA and, 1521

insulin-like growth factor, chondrocyte proteoglycan synthesis and, 66

keratan sulfate, hyaluronate and, in canine OA, 312

knee, proteoglycan fragments in, after injury, 1434

LE cells in drug-induced lupus and, 560

in OA, 312, 1434, 1458

phagocytes and type II collagen in, 1458

in RA, 116, 1080, 1458

septic, detection of muramic acid in, 1268

synovial mast cells in intermittent hydrarthrosis and, 357 T cells, 386, 1381

viscosity of hyaluronic acid and, 461

Synovial hyperplasia, in pristane-induced arthritis, 1022

Synovial inflammation

chondrolysis of hip joint in hemodialysis and, 1477 cross-reactive epitopes in AS and, 437

Synovial leukocytes, synovial analysis in drug-induced lupus and, 560

Synovial lining

cross-reactive epitopes in AS and, 437

hypertrophy of, HLA-DQ antigens in RA and, 955

Synovial membrane corticosteroids in Pond-Nuki dog model of OA and, 181 in RA, 361, 947, 955 Synovial tissue biopsy of, in polyarthritis in HTLV-I-associated myelopathy, 1342 cross-reactive epitopes in AS and, 437 IL-1 gene expression in synovial fibroblasts and, 279 inhibition of neovascularization by methotrexate and, 1065 in RA, 947, 1087 Synoviocytes IL-1 regulation of collagenase mRNA and, 1539 IL-6 production and, 1443 in RA, 947, 1087 Synovitis inflammatory, cell adhesion molecules in, 22 knee, chronic, arthroscopic synovectomy for, 10, 108 pyrophosphate, proteoglycans in knee joint and, 1434 rheumatoid, inhibition of neovascularization by methotrexate and, 1065 serum hyaluronate in experimental arthritis and, 306 Synovium biopsy of, in drug-induced lupus, 560 cytokines in chronic inflammatory arthritis and, 1074 effects of radiation on, 468 of hip, in dialysis, 785, 1477 in RA, 955, 1065 immunohistologic analysis of cell adhesion molecules and, 22 Systemic JRA 2-IFN in. 643 H1 and H5 antihistones in, 877 Systemic Lupus Activity Measure (SLAM) in clinical assessment of disease activity in SLE, 1107 Systemic lupus erythematosus (SLE) alopecia in, 1226 α₂-plasmin inhibitor-plasmin complex in, 1427 anticardiolipin antibodies in, 259, 1623 anticollagen and Clq in, 544 antihistone antibodies in RA and Felty's syndrome and, 1319 antihistones in, 406, 877 anti-La antibodies in, 1226 antilymphocyte antibodies against CD4+2H4+ cells in, antiribosomal S10 antibodies in, 1252 aplastic anemia and bone marrow proliferation in, 901, 924 atrioventricular heart block in, 1170 binding of dsDNA to glomeruli in rats and, 298 C2 deficiency in, plasma infusion therapy of, 906 childhood, 1414 complement activation in, 1406 CR1 in, 259, 393, 1465 disease activity in, 1107, 1406 disease heterogeneity model for, 826 DNA in, 406, 1243 early onset, 1243, 1414 erythrocytes in, 259 factor B activation in, 1406

fever in, 1226

Systemic lupus erythematosus (cont'd) gonadotropin-releasing hormone in, 1186 Hashimoto's thyroiditis and myasthenia gravis coexisting with, 119 HLA-DR antigen in, 1623 hypocomplementemia in, 1226 hypocomplementemic urticarial vasculitis syndrome and, 1119 iC3b neoantigen in, 1233 IgG antibodies, collagen and C1q in, 1601 IL-2 in, 552, 1356 immunoglobulin idiotypes in, 513 interstitial pulmonary disease in, 1226 Ki antigen in, 1554 La (SS-B) autoantibodies in, 413 lymphadenopathy in, 1226 major nucleolar phosphoprotein B23, anticardiolipin antibodies and, 1165 maternal Ro (SS-A) in, 1414 methyldopa-induced, 205 MX homologous protein in, 914 neonatal, 1414 neuropsychiatric involvement in, 1226 occlusive ocular vascular disease in, 1053 older-onset, meta-analysis in, 1226 photosensitivity rash and anti-Ro antibody in, 202 plasma infusion therapy of C2 deficiency in, 906 poly(ADP-ribose) metabolism in peripheral blood lymphocytes in, 1045 pregnancy in, 665 pulse intravenous methylprednisolone in, 717 Raynaud's phenomenon in, 1226, 1487 Ro (SS-A) in, 202, 413, 1414, 1563 serositis in, 1226 Sjögren's syndrome in, 1226 tumor necrosis factor in, 146 vasculitis in, 1427 Systemic necrotizing vasculitis, leg claudication and peripheral neuropathy in, 510 Systemic sclerosis (SSc) complement activation in, 1262 normotensive renal failure in, 1128 pathogenesis of, 817 pregnancy in, 151 prevalence of, in South Carolina, 998 production of fibronectin by alveolar macrophages in, 577 progressive, mutant fibronectin gene in skin fibroblasts in, 247 proto-oncogenes in, 430 Systemic vasculitis alpha-methyldopa-induced, Wegener's granulomatosis and, 356 in HIV infection, 569

T cells antigen-induced arthritis in C57Bl/10 mice and, 789 in avian scleroderma, 1031 Borrelia burgdorferi in reactive arthritis and, 1057, 1182 cell adhesions molecules and, 22 corticosteroids and, in temporal sateritis, 884

T cells (cont'd) dendritic cells and, 1381 in inflammatory myorathy and AIDS, 475 L3T4+, IL-6 in collagen arthritis in mice and, 594 MT4+, Lyt-2-, in induced murine arthritis flares, 330 in RA, 31, 116, 361, 505, 795, 955, 1087, 1371, 1381, 1495, 1528 in reactive arthritis, 955 receptor genes for, disease susceptibility and, 105 SF, VLA antigen in, 386 in Sjögren's syndrome, 420, 859 in SLE, 398, 552, 1356 in SSc, 430, 817 systemic vasculitis in HIV infection and, 569 Tarsal bones, in retinyl acetate-induced arthritis in mice, 625 "Technetium-DTPA analysis, "renal Raynaud's phenomenon" in SLE and, 1487 Temperature, effect of, on pain score in RA, 1627 Temporal arteritis aortic dissection in, 504 corticosteroids and cell subsets in, 884 mental status in, 1308 **Tendons** acute peritendinitis calcarea, 767 calcaneal spurs in, 338 posterior tibial, in RA, 359, 1050 in retinyl acetate-induced arthritis in mice, 625 Tetanus toxoid, antigen specificity in RA SF and, 1371 Tetradecanoyl-phorbol-acetate, IL-1 regulation of collagenase mRNA and, 1539 Tetrapeptide DNA, mutant fibronectin gene in progressive systemic sclerosis and, 247 Thrombocytopenia hepatic infarction, lupus anticoagulant and, 491 normotensive renal failure in SSc and, 1128 pregnancy in SLE and, 665 in RA, 1453 in Sjögren's syndrome, 234 Thrombocytopenia purpura, idiopathic, antilymphotoxin and tumor necrosis factor in, 1148 Thrombocytosis, in plasmocytoma of skull in immune com-

Toes, in "pencil-in-cup" deformities in Behçet's disease,

Tophi, in urate mediated inflammation in nodal OA, 86

scleroderma, 54 Toxicity of azathioprine in RA, 837 deoxyadenosine, in rabbit cartilage, 1014 methotrexate, 638, 671, 677, 770, 813, 1160, 1592 Tracheal cartilage, protein in RA and, 1080 Transaminase, methotrexate toxicity in JRA and, 677 Transferrin receptor, VLA antigen in SFT cells and, 386 Transforming growth factor β in pathogenesis of SSc, 817 proteoglycan metabolism in articular cartilage and, 1197 Trapezioscaphoid joint, radiographic grading scales for OA and, 1584 Trauma, proteoglycan fragments in knee joint after, 1434 Triamcinolone hexacetonide, intraarticular, in Pond-Nuki dog model of OA. 181 Trimethoprim/sulfamethoxazole, in Wegener's granulomato-Trypsin, MX homologous protein in mononuclear cells in SLE and, 914 Tumor necrosis factor antibodies to, in normal serum, 1148 effect of, on cartilage, prostaglandin E and caseinase. 780 human cytokines in glycosaminoglycan synthesis and, 173 IL-1 and, 279, 1528 pathogenesis of SSc and, 817 in SLE, 146 Tumoral calcinosis, 1484 Tumors salivary gland lymphocytes in Sjögren's syndrome and, toxic effects of azathioprine in RA and, 837 2-Md plasmid from Shigella flexneri, in reactive arthritis, 937 Tyramine, α-adrenergic responses in Raynaud's disease and,

ANA, histones and antigens in JRA and, 919

chronic anterior, in juvenile psoriatic arthritis, 1007

Topoisomerase I (Scl-70 antigen), and racial differences in

U U1 RNP antibodies and atrioventricular heart block in SLE, plex vasculitis, 1470 1170 **Thrombosis** Ultrasonography, in diagnosis of anserine bursal distention, arterial, after pyelography, anticardiolipin antibodies and, 1490 Unconventional remedies for arthritis, 1604 hepatic infarction, lupus anticoagulant and, 491 Unilateral anterior cruciate ligament, salicylates and chon-Thymocytes, IL-1-inhibitory IgG in RA and, 1528 drocytes in, in canine OA, 486 Thyroid function tests, salsalate and, 1344 University of Toronto SLE Disease Activity Index, in clin-Thymus, Ki antigen in SLE and, 1554 ical assessment of disease activity in SLE, 1107 Tibia Urate crystals, inflammation in nodal OA and, 86 alterations to cartilage in, after running in dogs, 1282 Uronic acid serum keratan sulfate in rabbit OA and, 1293 alterations to articular cartilage after running in dogs and, Tibial plateau, corticosteroids in Pond-Nuki dog model of in canine OA, 486, 647, 759, 1300 OA and, 181 Tibial tendon, posterior, in RA, 1050 Urticarial vasculitis syndrome, hypocomplementemic, IgG Tightening of skin, in "neck sign" in scleroderma, 209 anti-Clq in, 1119 Tissue destruction, IL-1, collagenase mRNA and, 1539 **Uveitis**

in AS, 77

Vascular disease, occlusive ocular, in SLE, 1053

Vascular endothelium

cell adhesion molecules and, 22

cross-reactive epitope in AS and, 437

inhibition of cell proliferation in, by methotrexate, 1065 Vascular occlusion, T cells in dermal lymphocytes in avian

scleroderma and, 1031

Vasculitis

 α_2 -plasmin inhibitor-plasmin complex in, 1427

cerebral, angiography of, 504

CNS, cytotoxic drugs in, in Behçet's syndrome, 217

CREST syndrome and, 661

cutaneous, factor B activation in SLE and, 1406

dementia in temporal arteritis in elderly and, 1308

hypocomplementemic urticarial, IgG anti-Clq in, 1119

immune complex, plasmocytoma of skull in, 1470

infectious complications of cyclophosphamide in, 45, 1626 leukocytoclastic, 1470, 1489

necrotizing, HIV infection and, 569, 1615

rheumatoid, anti-endothelial cell antibodies in, 119

sural nerve, 504

systemic

alpha-methyldopa-induced, Wegener's granulomatosis and, 356

HIV infection and, 569

necrotizing, leg claudication and peripheral neuropathy

Venous hyperalimentation in scleroderma bowel disease, 212

Vertebrae, lumbar, in Paget's disease, after etidronate diso-

dium treatment, 776 Very late activation (VLA) antigen, in SF T cells, 386

Viruses HIV infection, 569, 1453, 1615

HTLV-I-associated myelopathy, human, polyarthritis in,

influenza, MX protein in mononuclear cells in SLE and,

Newcastle disease-induced, IFN, in pristane-induced arthritis, 1022

Vision, loss of, in temporal arteritis in elderly and, 1308 Visual analog scale, disability and depression in RA and, 1100

folic acid and methotrexate in RA, 113 1,25-dihydroxyvitamin D₃, in RA, 31

Walking time

physical conditioning and, 1396

in RA, 523, 531

Water content of articular cartilage in canine OA, salicylate, chondrocytes and, 486

Wegener's granulomatosis

alpha-methyldopa-induced systemic vasculitis and, 356 infectious complications of cyclophosphamide in, 45, 1626 therapy of, 1050

trimethoprim/sulfamethoxazole in, 1052

Weight, smoking in OA and, 166

Wheelchairs, use of, by nursing home residents with arthritis, 1546

White blood cells

counts of, 523, 584, 1631

SF examination after arthrocentesis and, 271

Work disability, in women with RA, 538

World Health Organization (WHO), classes of lupus nephritis, iC3b neoantigen in SLE and, 1233

Wrist, simplified articular index in RA and, 531

Xenotropic gene expression, of retroviral transcripts in murine lupus, 322

Yersinia infection, in Behçet's disease, 1494

Yttrium 90

arthroscopic synovectomy for chronic synovitis after, 10,

effect of, on synovium and cartilage, 468

Z

Zinc-chelated pentosan polysulfate (DH-40J), cartilage degradation by, 608

Zygapophyseal joints, synovial cysts in, 660